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Directed differentiation of mouse embryonic stem cells into neocortical output neurons 
 
Abstract 
During development of the neocortex, many diverse projection neuron subtypes are 
generated under regulation of cell-extrinsic and cell-intrinsic controls. One broad projection 
neuron class, corticofugal projection neurons (CFuPN), is the primary output neuron population 
of the neocortex. CFuPN axons innervate sub-cortical targets including thalamus, striatum, 
brainstem, and spinal cord. 
The broad class of CFuPN includes multiple subtypes of projection neurons, residing 
and intermixed in distinct neocortical layers and areas, with distinct axonal targets. 
Corticospinal motor neurons (CSMN) are one clinically important corticofugal subtype; they 
reside in motor cortex layer V, and project axons to the spinal cord to control motor function. 
CSMN degenerate in amyotrophic lateral sclerosis (ALS), along with spinal motor neurons, and 
CSMN axonal damage after spinal cord injury (SCI) is central to ensuing loss of motor function. 
No effective therapies exist for ALS or SCI; the inability to produce CSMN (and CFuPN) in vitro 
is a significant roadblock to developing new treatments.  
Embryonic stem (ES) cells have theoretical potential to generate CFuPN in vitro. 
However, existing ES cell protocols are not directed toward generating specific classes, types, 
or subtypes of neocortical projection neurons. 
Work presented in this dissertation makes progress toward characterization and 
directed differentiation of CFuPN derived from mouse ES cells. First, I show that existing 
protocols produce heterogeneous, neocortical-like neurons that are immature and “stalled” at 
a stage resembling mid-embryonic differentiation in vivo. These analyses apply multiple criteria 
  iv 
derived from an emerging understanding of CFuPN developmental biology. Second, I build on 
that foundation to promote CFuPN-specific differentiation among these “stalled” neocortical-
like neurons, using recently-developed synthetic modified mRNA and high-content screening 
technologies. Finally, I enrich for ES-derived CFuPN by sequentially and transiently expressing 
critical forebrain, neocortex, and CFuPN-specific transcription factors; when micro-
transplanted into neonatal neocortex, these neurons appropriately innervate specific targets in 
the thalamus and midbrain. 
Together, biological and technical approaches presented in this dissertation both 
rigorously characterize ES-derived neuronal identity, and identify novel strategies to promote 
CFuPN differentiation. This work will enable further advances in the broader field of in vitro 
neurodegenerative disease modeling, particularly toward developing new treatments for ALS 
and SCI. 
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Chapter 1 
 
Introduction
2 
1.1 Overview 
 
The adult mammalian neocortex has the extraordinary capacity for higher-order 
cognitive functions and for orchestrating intricate motor behaviors, while continuously 
integrating feedback from major modalities of sensory input. In humans, the neocortex alone 
comprises over two-thirds the neuronal mass of the entire nervous system, and three-quarters 
of all synaptic connections (Rakic, 1988). Given the breadth of neocortical function and 
connectivity within the nervous system, it is not surprising that the neocortex is composed of 
hundreds of highly specialized neuronal subtypes with distinct connectivity, gene expression, 
and physiology (Molyneaux et al., 2007; Gord and Bernardo, 2011). 
The incredible neuronal diversity contained within the adult neocortex progressively 
emerges during an extended course of development (Woodworth et al., 2012; Custo Greig et 
al., in editorial revision, 2013). Neocortical projection neurons are among the very first neurons 
to populate the embryonic neocortex and are classified by their distinct axonal projections to 
multiple targets within or outside the neocortex (Figure 1.1). Collectively, these diverse 
projection neuron subtypes account for nearly all the excitatory neurons in the adult neocortex, 
roughly 85% of total neocortical neurons (Gord and Bernardo, 2011).  
One broad class of neocortical projection neurons, called corticofugal projection 
neurons (CFuPN; fugal ~ flight; Latin), constitutes the primary output neuron population of the 
neocortex. Distinct types and subtypes of these CFuPN are intermixed in the deep layers 
across all neocortical areas and have axons that exit the neocortex and selectively innervate 
distant targets in the central nervous system, including thalamus, striatum, brainstem, and 
spinal cord. Corticospinal motor neurons (CSMN) are one clinically important corticofugal 
subtype; they reside in motor cortex layer V, and project axons to the spinal cord to control 
motor function. CSMN specifically degenerate in amyotrophic lateral sclerosis (ALS / ”Lou 
3 
Gehrig's disease”), and CSMN axonal damage after spinal cord injury (SCI) is central to 
ensuing loss of motor function. 
Because there are no effective therapies for CSMN-specific and related CFuPN 
dysfunction, and because sufficient quantities of these neurons are not readily available for in 
vitro disease modeling and development of new treatments, I explored multiple approaches to 
generate these neurons from mouse embryonic stem (ES) cells. Although pluripotent ES cells 
have theoretical potential to generate large quantities of CFuPN in vitro, existing ES cell 
protocols are not directed toward generating specific classes, types, or subtypes of neocortical 
projection neurons (Hansen et al., 2011). 
In recent years, tremendous progress has been made to understand stepwise 
developmental molecular programs of distinct neocortical projection neuron classes, types, 
and subtypes in vivo (Molyneaux et al., 2007; Fame et al., 2011; Woodworth et al., 2012; 
MacDonald et al., in press; Custo Greig et al., in editorial revision, 2013). Importantly, the 
application of these advances to CFuPN-directed differentiation of ES cells forms the basis for 
all approaches and experimental findings discussed in my dissertation. This introductory 
chapter serves to delineate an emerging molecular understanding of CFuPN development, to 
provide perspectives on the development and limitations of existing protocols of ES cell 
directed differentiation, and, lastly, to broadly introduce my approaches to apply CFuPN 
developmental biology to the directed differentiation of mouse ES cells.  
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Figure 1.1. Classification of diverse neocortical projection neurons. Neocortical projection 
neurons can be subdivided into broad classes, types, and subtypes largely based on their 
axonal projections. Figure adapted from Custo Greig and colleagues (commissioned Nat Rev 
Neurosci manuscript in editorial revision, 2013). Illustrations are of the mouse brain. 
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1.2. Overview of sequential progenitor and post-mitotic CFuPN development 
 
 During development of the neocortex, many diverse projection neuron subtypes are 
generated under complex and seemingly precise regulation of cell-extrinsic and cell-intrinsic 
controls. Cell-extrinsic influences initially predominate during early development of the central 
nervous system (CNS), beginning with blastocyst formation at approximately three days 
following fertilization, in mice, and lasting until the start of neocortical neurogenesis 
approximately seven days later. Distinct extracellular molecules regulate the induction of both 
neural identity and region-specific patterning in the developing nervous system. Importantly, 
this cell-extrinsic patterning is executed and stabilized by cell-intrinsic transcriptional changes 
in order to molecularly delineate regions of the nervous system. Later, these cell-intrinsic 
transcriptional changes become disproportionately important during the transition to 
neocortical differentiation, and sequentially control the specification of distinct neocortical 
subtypes. Importantly, stage-specific functions of transcriptional regulators are “nested” within 
the emerging classes, types, and subtypes of projection neurons during neocortical 
differentiation (Woodworth et al., 2012; Custo Greig et al., in editorial revision, 2013). 
Replicating features of this process will be important for directed specification and 
differentiation of neocortical projection neurons, particularly CFuPN. These multiple cell-
extrinsic and cell-intrinsic controls over neocortical projection neuron differentiation will be 
reviewed and discussed from the perspective of pluripotent stem cell differentiation. 
 
Neural induction: the “default” specification of all neural progenitors 
At the earliest stages of mouse embryonic development, approximately embryonic day 
3.5 (E3.5), the pluripotent inner cell mass of blastocysts undergoes a process of “neural 
induction” to delineate the prospective progenitors of the entire CNS (Figure 1.2). Induction of 
6 
neural progenitor fate occurs largely by preventing the acquisition of alternative mesoderm and 
endoderm lineages signaled by distinct types of secreted molecules, collectively called 
morphogens. In the prospective neural region of the blastocyst, signaling pathways of bone 
morphogenic proteins (BMPs) must be repressed; this is initially accomplished by fibroblast 
growth factor (FGF) signaling, and later by chordin and noggin, which are secreted by the 
“node,” a primitive organizing center of the early embryo (Levine and Brivanlou, 2007). Many of 
these in vivo mechanisms of neural induction have been investigated using pluripotent mouse 
embryonic stem (ES) cells, and are largely replicable in vitro (Aubert et al., 2002; Ying et al., 
2003; Watanabe et al., 2005; Gaspard and Vanderhaeghen, 2010). 
Because the mere inhibition of alternate signaling pathways (e.g., BMP; activin/TGF-
beta, Wnt) is sufficient for neural induction, neural fate is seemingly the “default” path of 
embryonic differentiation (Jessell and Sanes, 2000; Rallu et al., 2002). For this reason, a 
number of protocols of ES cell differentiation induce neural differentiation by the removal of 
serum, which contains BMPs; within hours of serum removal, mouse ES cells express neural 
markers (Smukler et al., 2006). To improve the efficiency of this process in human pluripotent 
cells, “default” neural differentiation can be supported by BMP pathway inhibition using Noggin 
and a small molecule inhibitor of SMAD signaling (Chambers et al., 2009). Ultimately, multiple 
effectors of neural differentiation include transcriptional regulators, particularly Sox2, which 
reinforces cell-intrinsic neural differentiation (reviewed in Sarkar and Hochedlinger, 2013) by 
transcriptionally repressing alternate mesoderm and endoderm fates in the developing 
blastocyst and in human pluripotent stem cells (Keramari et al., 2010; Thomson et al., 2011). 
These potent transcriptional functions of Sox2 can be similarly exploited in the 
“reprogramming” of fibroblasts to neural progenitors (Ring et al., 2012; Lujan et al., 2012).  
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Figure 1.2. Cell-extrinsic and cell-intrinsic factors regulate the development of CFuPN 
within sequential, “nested” stages of differentiation.  
(A) “Default” neural and rostral differentiation occurs by the repression of alternate signaling 
pathways induced by multiple morphogens (e.g., Noggin inhibits BMP signaling during neural 
plate formation at ~E3.5-E6.5 in mice; telencephalic progenitors require low or absent 
expression of caudalizing retinoids (RA) and ventralizing Shh at ~E6.5-E8.5).  
(B) The dorsal aspect of the telencephalon is called the pallium, which gives rise to the 
neocortex. In contrast, the ventral telencephalon is called the subpallium. The delineation of 
these two telencephalic progenitor domains occurs between ~E8.5 and ~E10.5.  
(C) During corticogenesis, beginning at ~E10.5 in mice, multiple diverse neocortical projection 
neuron classes, types, and subtypes are sequentially generated from neocortical progenitors in 
the pallium. These projection neurons become refined with continued maturation through post-
natal ages. 
(D) Early stages of CFuPN differentiation are largely mediated by cell-extrinsic factors, whereas 
later stages of CFuPN differentiation are largely mediated by cell-intrinsic factors. 
(E) Following Shh-mediated dorsal-ventral patterning of the telencephalon, pallial and subpallial 
identities are reinforced by transcriptional regulation (Pax6 and Sox6 in the pallium; Gsh2 in the 
subpallium). 
(F) Pallial progenitors give rise to neocortical progenitors, which generate projection neuron 
subtypes during corticogenesis at ~E10.5. Early-born CFuPN populate the deep layers of the 
neocortex. Later-born CPN populate both deep and superficial layers of the neocortex. The 
molecular distinction of CPN and CFuPN occurs with continued maturation (represented by the 
transition from yellow, dual-marker expression to either red or green single-marker expression). 
(G) “Nested” expression of distinct transcriptional regulators at distinct developmental stages 
promotes stepwise CFuPN differentiation.
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Figure 1.2 (Continued)  
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Rostral and dorsal regional patterning of neocortical progenitors 
 Following neural induction, the prospective CNS continues to proliferate, and 
transitions from a “plate” at E6.5, in mice, to a closed “tube” containing two telencephalic 
protrusions at the rostral end at E8.5. During the course of these dynamic changes in 
morphology, distinct morphogen gradients along the rostral-caudal and dorsal-ventral axes 
pattern the prospective regions of the neural tube (e.g., Wnt and BMPs, rostrally/dorsally; FGFs 
and retinoids, caudally; Shh ventrally) (Monuki and Walsh, 2001; Rallu et al., 2002; Rash and 
Grove, 2006). Strikingly, the later roles of some morphogens (e.g., Wnts for rostral/dorsal 
patterning) greatly differ from their earlier roles in promoting non-neural lineages in the 
blastocyst. These temporally dynamic changes in Wnt signaling have been leveraged in 
protocols of ES cell differentiation; for example, Wnt inhibition for neural induction is followed 
by Wnt activation for subsequent dorsal patterning of ES-derived neural progenitors (Watanabe 
et al., 2005; Eiraku et al., 2008; Nasu et al., 2012). However, in vitro simplifications of a 
complex extracellular environment can sometimes result in markedly different outcomes of ES 
cell differentiation; for example, retinoid-independent ES cell differentiation in aggregate culture 
can generate either predominantly rostral (Watanabe et al., 2005; Eiraku et al., 2008) or 
predominantly caudal (Peljto et al., 2010; Patani et al., 2011) neural progenitors, depending on 
the modulation of Wnt signaling. Moreover, because much of this information has been 
consolidated and derived from studies in frogs and chicks, some of these discrepancies might 
pertain to species-specific differences (Jessell and Sanes, 2000; Levine and Brivanlou, 2007). 
In an analogous situation to “default” neural induction, the rostral specification of neural 
tube progenitors largely occurs in the absence of caudal-derived, spinal cord morphogens (e.g., 
FGFs and retinoids). Default rostral differentiation constitutes the first step of most protocols of 
telencephalic differentiation by ES cells (Gaspard and Vanderhaeghen, 2010; Hansen et al., 
2011). Importantly, the identity of rostral progenitor regions is reinforced by the cell-intrinsic 
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expression of transcriptional regulators, including Otx2, which demarcates the midbrain-
hindbrain boundary and is required for early specification of forebrain and midbrain (Acampora 
et al., 1999). Together, rostral “default” differentiation and transcriptional regulation (e.g. Otx2) 
maintain telencephalic identity. 
The dorsal telencephalon, called the pallium, ultimately gives rise to all neocortical 
projection neurons and contributes to the differentiation of other cortical structures, including 
the cingulate cortex and hippocampus. In contrast, the ventral telencephalon, called the 
subpallium, gives rise to all neocortical interneurons and inhibitory neurons of the basal ganglia, 
including striatum and globus pallidus (Schuurmans and Guillemot, 2002; Guillemot, 2005; 
Hébert and Fishell, 2008). 
Shh expression gradients (high ventral, low dorsal) are chiefly responsible for the early 
~E8.5 delineation of these pallial and subpallial progenitor domains in the telencephalon, 
occurring prior to neocortical differentiation in the pallium. Specification of the pallium (dorsal 
telencephalon) occurs in the absence of Shh signaling and in the presence of Wnts and BMPs 
(Rallu et al., 2002; Tiberi et al., 2012). Shh is secreted from the ventral mesoderm underlying 
the full extent of the neural tube, and Shh is important for the broad specification of ventral 
fates in the developing CNS, mediated by Shh repression of Gli family transcription factors. In 
contrast, in prospective dorsal regions, Gli3 delineates the early pallium in the absence of Shh 
signaling (Fuccillo et al., 2006; Hoch et al., 2009). Importantly, antagonism of Shh signaling can 
be exploited in the differentiation of mouse ES cells to dorsal, pallial fates (Gaspard et al., 
2008), although this step does not similarly enhance the generation of pallial progenitors by 
human pluripotent stem cells (Shi et al., 2012; Mariani et al., 2012; Espuny-Camacho et al., 
2013). In addition to blocking Shh signaling, pallial-promoting morphogens (e.g., Wnt) have 
been used for the dorsal patterning of ES-derived neural progenitors (Watanabe et al., 2005; 
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Eiraku et al., 2008; Nasu et al., 2012). In summary, dorsal patterning of the telencephalon is 
largely delineated by morphogens and reinforced by transcriptional regulation.  
During continued development of the pallium from E8.5-10.5, distinct mechanisms of 
cross-repressive transcriptional regulation, mediated by Pax6 and Sox6 in the pallium and by 
Gsh2 in the subpallium, establish the broad molecular identity of these progenitor domains. 
Pax6 is a well-studied and critical pallium-restricted transcription factor that promotes pallial 
fate in part by reciprocal and robust cross-repression of Gsh2, whose expression is restricted 
to the subpallium (Schuurmans and Guillemot, 2002). Importantly, dose-dependent Pax6 
expression is required for proper neocortical specification (Schedl et al., 1996; Manuel et al., 
2007). Moreover, misexpression of Pax6 in early postnatal cortical astroglia potently directs 
their conversion to glutamatergic neuronal fates (Berninger et al., 2007; Heins et al., 2002). 
Complementary to the role of Pax6, a second pallial transcription factor, Sox6, is also required 
for the proper specification of pallial progenitors; its absence results in misspecification of 
pallial progenitors, based on the ectopic expression of subpallial genes including Mash1 (Azim 
et al., 2009). At the same time, multiple other transcriptional regulators (e.g., Sox2 and Lhx2) 
contribute to increasingly precise pallial progenitor differentiation. In addition to its role at the 
E3.5 blastocyst stage, Sox2 is required by E8.5 for proper pallial differentiation (Aota et al., 
2003; Götz et al., 1998; reviewed in Georgala et al., 2011). Lhx2 is also required for proper 
neocortical progenitor development by E10.5 (Chou and O'Leary, 2013; Roy et al., 2013). Thus, 
multiple transcriptional regulators expressed in the pallium (Pax6, Sox6, Lhx2 and Sox2) 
ultimately enable the proper differentiation of neocortical progenitors by E10.5, which 
increasingly relies on cell-intrinsic mechanisms of neocortical development. 
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Potentially CFuPN fate-restricted neocortical progenitors  
 Beginning at E10.5, a neocortical subdomain of the pallium resolves into a molecularly 
diverse population of neocortical progenitors that are potentially fate-restricted to distinct 
projection neuron classes (Franco et al., 2012; Molyneaux et al., 2007; Custo Greig et al., in 
editorial revision, 2013). One subset of neocortical progenitors is fate-restricted to the broad 
class of commissural neocortical projection neurons: fate-mapping experiments have 
decisively shown that Cux2-expressing progenitors exclusively generate callosal projection 
neurons (CPN) (Franco et al., 2012). In addition, increasing evidence indicates the existence of 
a second subset of neocortical progenitors that is potentially fate-restricted to subcerebral 
projection neurons, SCPN, one type of CFuPN that projects to targets caudal to thalamus. This 
evidence includes heterogeneous, “salt-and-pepper” distribution of Fezf2 expression among 
pallial progenitors and mutant data confirming the requirement of Fezf2 for specification of 
SCPN (Molyneaux et al., 2005; Chen et al., 2005; Chen et al., 2008; Shim et al., 2012). Because 
Fezf2 is differentially expressed in all CFuPN, one leading hypothesis is that Fezf2-expressing 
progenitors give rise to the broad class of CFuPN, whose subsequent fate-restriction into 
distinct corticofugal types and subtypes is later controlled and modified by additional 
transcriptional regulators that are “nested” within these subtypes. This hypothetical 
“developmental logic” is consistent with recent findings in the field, and potentially explains the 
cell-intrinsic control of sequentially emerging classes, types, and subtypes of projection 
neurons during neocortical differentiation (reviewed in Molyneaux et al., 2007; Woodworth et 
al., 2012; Custo Greig et al., in editorial revision, 2013). 
 
Progressive transcriptional refinement of CFuPN identity 
During the process known as corticogenesis, neocortical progenitors sequentially 
generate many diverse classes, types, and subtypes of neocortical projection neurons that 
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populate the neocortex in an approximately inside-out manner from ~E10.5 until the end of 
embryonic development ~E18.5/E19.5 (Figure 1.2). Strikingly, this sequential generation of 
broad classes and types of neocortical projection neurons occurs in a largely cell-autonomous 
manner (Shen et al., 2006), although several cell-extrinsic factors are also important 
(Hashimoto-Torii et al., 2008; Rodriguez et al., 2012; Diaz-Alonso et al., 2012; Johansson et al., 
2013; reviewed in Tiberi et al., 2012).  
From ~E10.5 until ~E14.5 in mice, neocortical progenitors give rise to distinct types of 
Fezf2-expressing CFuPN, including corticothalamic projection neurons (CThPN), and SCPN 
(Figure 1.1). These early-born CFuPN types sequentially populate the deep layers of the 
neocortex: CThPN predominantly in layer VI and SCPN predominantly in layer V. Initially, these 
distinct CFuPN types share the expression of multiple transcriptional regulators, but co-
expression is then restricted in a subtype-specific manner later in differentiation (Lai et al., 
2008; Azim et al., 2009). Overall, multiple transcriptional regulators “nested” within the broad 
class of CFuPN promote the molecular distinction of SCPN versus CThPN.  
SCPN-specific specification, post-mitotic differentiation, axon guidance, and axon 
pruning are in large part collectively controlled by the transcriptional activities of Fezf2, Ctip2, 
and Otx1 (Molyneaux et al., 2005; Chen et al., 2005; Arlotta et al., 2005; Chen et al., 2008; Shim 
et al., 2012). Although these three transcription factors are initially expressed in both SCPN and 
CThPN, the dose and timing of their expression strongly indicates SCPN-specificity. Firstly, 
Fezf2 is required for the specification of SCPN, but not CThPN. In the absence of Fezf2, 
downstream Ctip2 transcription factor expression is lost, and prospective SCPN instead 
differentiate into two populations: commissural neurons, based on the appearance of axonal 
projections across the corpus callosum and anterior commissure; and CThPN, based on the 
ectopic expression of Tbr1 in layer V and the abundance of thalamic projections (Molyneaux et 
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al., 2005; Chen et al., 2005; Chen et al., 2008; Bedogni et al., 2010; McKenna et al., 2011). 
Secondly, Ctip2 is critical for the post-mitotic acquisition of SCPN identity, and, in its absence, 
SCPN do not project to the spinal cord, with additional defects in axon outgrowth, 
fasciculation, and guidance. Thirdly, Otx1 is specifically expressed in post-mitotic SCPN and 
directs pruning of SCPN axonal projections during late post-natal maturation (Weimann et al., 
1999). Together, Fezf2, Ctip2, and Otx1 are essential for the proper differentiation of SCPN. 
In contrast, the distinction of CThPN from later-born SCPN is, in large part, controlled 
by the interactions of transcriptional regulators that include Sox5 and Tbr1. Although these two 
transcription factors are initially expressed in both SCPN and CThPN, the dose and timing of 
their expression strongly indicates CThPN-specificity, where these factors repress Fezf2 
expression and SCPN identity (Lai et al., 2008; Shim et al., 2012; Bedogni et al., 2010; 
McKenna et al., 2011). In particular, Sox5 is expressed by two forebrain populations, 
neocortical post-mitotic CFuPN and subpallial progenitors (Lai et al., 2008). The deletion of 
Sox5 in CFuPN blurs the temporally distinct and sequential generation of CThPN followed by 
SCPN: some prospective CThPN that are Sox5-deficient alternately acquire SCPN-like axonal 
projections (Lai et al., 2008). Together, multiple type-specific transcriptional refinements (e.g., 
Fezf2/Ctip2 versus Sox5/Tbr1) contribute to the corticofugal class-specific distinction of 
CThPN and SCPN. 
 
Leveraging an emerging logic of CFuPN differentiation 
The overall biology of transcriptional regulation that is “nested” within distinct and 
increasingly fate-restricted classes, types, and subtypes during maturation is not limited to 
type-specific distinction of CThPN and SCPN within the class of CFuPN. In fact, inter-related 
processes of transcriptional refinements are shared by nearly all projection neuron classes, 
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including commissural projection neurons, and by subtypes distributed in multiple neocortical 
areas (Lai et al., 2008; Britanova et al., 2008; Alcamo et al., 2008; Chen et al., 2008; Azim et al., 
2009; Joshi et al., 2008; Cederquist et al., 2013). An emerging model of these molecular 
refinements encompasses an “n-dimensional subtype space” in which subtype distinction 
occurs on multiple axes of neocortical projection neuron identity (e.g., areas, layers, and 
hodological subtypes); this subtype-distinction is largely guided by the “nested” expression of 
distinct transcriptional regulators within these diverse subtypes (Custo Greig et al., in editorial 
revision, 2013).  
Pertinent to my approaches of directed differentiation of CFuPN, this emerging 
framework of neocortical development delineates distinct roles for transcriptional regulators 
that act at transient stages of differentiation, in specific combinations, at specific doses, and 
within specific classes of projection neurons. Because sequential transcriptional refinements 
appear essential to the precise specification of neocortical projection neuron subtypes, this 
transcriptional logic of neocortical differentiation forms the basis for my approaches to directed 
differentiation of ES cells into CFuPN. 
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1.3. Application of telencephalic development to ES cell differentiation 
 
Embryonic stem cells have potential to generate CFuPN 
 Mouse embryonic stem (ES) cells were first derived from the inner cell mass of 
blastocysts in 1981 (Evans and Kaufman, 1981; Martin, 1981). Because pluripotency is a 
normally transient embryonic state, ES cells immediately differentiate into more restricted cell 
lineages. However, in 1988, Austin Smith and colleagues established the first in vitro conditions 
for the stable, long-term maintenance of mouse ES cell pluripotency by the identification of 
leukemia inhibitory factor (Smith et al., 1988). This discovery was later followed by the 
derivation of human ES cells (Thomson et al., 1998), which are optimally cultured in the 
presence of bFGF to maintain their long-term pluripotency. Interestingly, the difference 
between mouse and human ES cell pluripotency requirements is largely attributable to the 
timing of derivation; mouse ES cells resemble an early, “ground” state of pluripotency at the 
blastocyst stage ~E3.5 (Ying et al., 2008), whereas human ES cells resemble a later, “primed” 
state of pluripotency derived from the late blastocyst (epiblast) stage ~E4.5 (Nichols and Smith, 
2009).  
Since their derivation, mouse ES cells have been touted for their proven ability to 
generate all tissue and cell types in vivo, and their theoretical ability to generate this repertoire 
of cell types in vitro (Smith, 2001). Given the vast potential of ES cells to acquire diverse 
cellular identities, Waddington’s ‘epigenetic landscape’ is a useful model for visualizing 
potential stochastic, cell-intrinsic, and cell-extrinsic mechanisms of sequential cell fate 
determination (Waddington, 1957; reviewed in Hochedlinger and Plath, 2009) (Figure 1.3). In 
the Waddington model, a ball rolling down a hilly landscape represents the trajectory and 
progressive restriction of cell fate determination. From this perspective of differentiation, a 
number of groups have successfully “directed” differentiation of ES cells along specific 
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trajectories of cell fate determination, by taking advantage of a combination of early cell-
extrinsic patterning (e.g., regional specification of the neural tube) followed by spontaneous 
subtype differentiation (Wichterle et al., 2002; Watanabe et al., 2005; Gaspard et al., 2008; 
Eiraku et al., 2008; Nasu et al., 2012; Espuny-Camacho et al., 2013). 
  
Strategies of morphogen-based “directed” differentiation  
The first successful example of “directed,” region-specific neuronal differentiation from 
ES cells (Wichterle et al., 2002) leveraged an understanding of two important aspects of in vivo 
spinal cord development: 1) distinct morphogen gradients along the rostral-caudal (e.g., 
retinoids) and dorsal-ventral (e.g., Shh) axes of the neural tube; 2) transcriptional profiling of 
spinal cord progenitor domains and post-mitotic neurons (Jessell, 2000; Briscoe et al., 2000; 
Shirasaki and Pfaff, 2002), including the identification of Hb9, an exclusive marker of spinal 
motor neurons (SMN) (Arber et al., 1999; Thaler et al., 1999). With this information, Wichterle 
and colleagues in the Jessell lab hypothesized that distinct concentrations of known 
morphogens could grossly induce caudal (spinal cord) and ventral (motor neuron) progenitor 
specification by ES cells in three steps, using previously-established protocols of embryoid 
body ES cell culture: 1) “default” rostral neural induction by removal of serum/BMP; 2) 
caudalization by retinoids; and 3) ventralization by Shh (Wichterle et al., 2002). Retinoid- and 
Shh-patterned, ES-derived ventral spinal cord progenitors spontaneously give rise to a small, 
molecularly heterogeneous population of neurons that include Hb9-expressing SMN in free-
floating embryoid body cell culture. This small population of ES-derived SMN has multiple 
characteristics of in vivo SMN axonal connectivity and physiology, particularly after intra-spinal 
transplantation in the developing chick (Wichterle et al., 2002; Peljto et al., 2010) or co-culture 
with chick myotubes (Miles et al., 2004). 
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Figure 1.3. The Waddington “epigenetic landscape” model depicts combined cell-
extrinsic, cell-intrinsic, and stochastic influences during differentiation, consistent with 
sequential, “nested” neocortical projection neuron development. Stepwise CFuPN 
development is consistent with the Waddington model of progressive fate restriction (reviewed 
in Hochedlinger and Plath, 2009) and contrasts with the hypothesis that single “transcriptional 
codes” might define and directly reprogram distinct neuronal subtypes (Ladewig et al., 2013). 
Fezf2 is a potent transcription factor that is specifically expressed by CFuPN in the neocortex, 
and is required for the specification of SCPN. Multiple lines of evidence suggest that Fezf2 
cannot directly promote SCPN identity; its actions are likely context-dependent (represented 
by the localized arrow at a bifurcation point in the selection of CFuPN versus CPN identity). 
This figure has been adapted from C. H. Waddington (1957).
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Multiple groups have adapted morphogen-based strategies to promote the regional 
specification of rostal and dorsal telencephalic progenitors by ES cells (Hansen et al., 2011). 
Similar to the example of ES-derived SMN, the first protocol of “directed” telencephalic 
regional differentiation from ES cells (Watanabe et al., 2005) used an understanding of in vivo 
telencephalic development, principally involving “default” rostral neural induction by removal of 
serum/BMP and direct Wnt and Nodal antagonism followed by Wnt activation. Telencephalic 
progenitors are identifiable by expression of an early telencephalon-restricted transcription 
factor, Foxg1 (Tao and Lai, 1992; Xuan et al., 1995). Building from this foundation, and using 
recently identified transcriptional controls over neocortical projection neuron differentiation to 
label in vitro neuronal populations (e.g., Ctip2, Arlotta et al., 2005; Satb2, Alcamo et al., 2008; 
Britanova et al., 2008; reviewed in Molyneaux et al., 2007), Eiraku and colleagues in the Sasai 
lab generated neocortical-like neurons within self-organized telencephalic embryoid body 
culture (Eiraku et al., 2008; Nasu et al., 2012; detailed protocol in Eiraku and Sasai, 2012). 
Interestingly, this embryoid body culture recapitulates some aspects of three-dimensional 
neocortical progenitor and neuron lamination, with heterogeneous neocortical neuron marker 
expression, grossly resembling early telencephalic differentiation.  
 
Development of monolayer protocols for neocortical-like differentiation  
Monolayer ES cell culture has multiple advantages over embryoid body culture that 
include easy visualization and access during the course of in vitro differentiation. Monolayer 
culture has recently been successfully applied to the regional specification of pallial-like 
progenitors by ES cells (Gaspard et al., 2008; Tiberi et al., 2012; Espuny-Camacho et al., 2013). 
The many advantages of monolayer culture have, for example, enabled the identification of 
largely intrinsic neocortical differentiation by individual progenitors isolated from E10.5 pallium 
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(Shen et al., 2006; reviewed in Okano and Temple, 2009). One of the first successful monolayer 
protocols of ES cell neural induction identified specific culture conditions that included the 
removal of serum and LIF (Ying et al., 2003).  
Building on these advances, Gaspard and colleagues in the Vanderhaeghen lab defined 
monolayer culture conditions of pallial-like progenitor specification by ES cells (Gaspard et al., 
2008; detailed protocol in Gaspard et al., 2009). This protocol was aided by the prior 
development of a protocol promoting telencephalic ES cell differentiation (Watanabe et al., 
2005) and by the recent identification of post-mitotic markers of distinct classes of neocortical 
projection neurons (e.g., Ctip2 and Satb2). The protocol by Gaspard and colleagues (2008, 
2009) makes use of “default” rostral differentiation, with the additional step of Shh antagonism 
by cyclopamine, to generate largely rostral and dorsal pallial-like differentiation. These ES-
derived pallial-like progenitors spontaneously generate heterogeneous neuronal populations 
that express individual characteristics of neocortical-like neurons, as well as the gross 
temporal order of marker expression in the developing neocortex. Considered a model of in 
vitro corticogenesis, this approach is now being successfully applied to in vitro investigations 
of neocortical biology by these ES-derived populations (Tiberi et al., 2012). Notably, 
adaptations of this monolayer protocol to human pluripotent stem cell culture have distinct 
differences in comparison to mouse ES cell culture: first, Shh antagonism is not necessary 
(Espuny-Camacho et al., 2013); second, pallial-like progenitor differentiation is enhanced by 
the late addition of retinoids (Shi et al., 2012; Mariani et al., 2012). This approach of monolayer 
ES cell differentiation is the starting point for my experimental approaches in this dissertation. 
 
Toward CFuPN-specific differentiation  
While the well-established monolayer protocol of ES cell differentiation is a substantial 
technical advance toward the directed differentiation of neocortical fates, the pallial-like 
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progenitors and neocortical-like neurons have not been assessed for their expression of stage-
specific transcriptional regulators. Moreover, because of its reliance on spontaneous 
differentiation, this protocol has not been directed toward differentiation of specific classes, 
types, or subtypes of neocortical projection neurons. 
To extend the principles of morphogen-directed differentiation from the generation of 
heterogeneous neocortical-like neurons to the specific generation of CFuPN, my approaches in 
this dissertation are largely based on the emerging understanding of neocortical projection 
neuron development (Molyneaux et al., 2007; Woodworth et al., 2012; Custo Greig et al., in 
editorial revision, 2013). This framework of neocortical development delineates distinct roles for 
transcriptional regulators that act in stage-specific combinations, at specific doses, and 
especially within specific classes of projection neurons. Moreover, stepwise transcriptional 
regulation is consistent with the Waddington epigenetic landscape model of progressive fate 
restriction (Hochedlinger and Plath, 2009) and contrasts with the hypothesis that single 
“transcriptional codes” might define and directly reprogram distinct neuronal subtypes 
(Ladewig et al., 2013). Additional evidence against a “transcriptional code” mechanism of 
neocortical development includes the argument that none of approximately 2,000 transcription 
factors expressed by mammalian genomes are specific to single neuronal subtypes in the 
nervous system. In fact, many transcriptional regulators described in this dissertation have 
critical roles in hematopoiesis, further supporting the exquisite context dependence of 
transcriptional regulation in neocortical differentiation. Overall, sequential transcriptional 
refinements appear essential to the specification of neocortical projection neuron subtypes, 
and this developmental framework forms the basis for my approaches to directed 
differentiation. 
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1.4 Dissertation overview 
In this dissertation, I introduce multiple approaches that apply an emerging 
understanding of neocortical and CFuPN development to both evaluate and direct mouse ES 
cell differentiation to CFuPN, the output neurons of the neocortex. Although ES cells have 
theoretical potential to generate CFuPN in vitro, existing ES cell differentiation protocols are 
not directed toward specific classes, types, or subtypes of neocortical projection neurons and 
instead rely on the spontaneous generation of neurons with neocortical-like characteristics.  
In Chapter 2, I first successfully replicate an established monolayer protocol of dorsal 
telencephalic differentiation that generates neurons with overall characteristics of neocortical 
differentiation (Gaspard et al., 2009). Using this protocol, I present experimental results 
strongly indicating that these spontaneously-generated, ES-derived neocortical-like neurons 
are heterogeneous, immature, and “stalled” at a stage roughly equivalent to mid-embryonic 
differentiation in vivo.  
In Chapter 3, I build on that foundation to promote CFuPN-specific differentiation 
among these “stalled” neocortical-like neurons using a combination of recently developed 
synthetic modified mRNA (modRNA) and high-content chemical screening technologies. These 
strategies address potential chromatin remodeling deficits during the spontaneous 
differentiation of neocortical-like neurons by ES cells. 
In Chapter 4, I take advantage of the framework of “nested” transcriptional regulation 
driving neocortical projection neuron differentiation, by sequentially expressing critical 
forebrain, neocortex, and CFuPN-specific transcription factors to direct differentiation of ES 
cells into CFuPN. When micro-transplanted into neonatal neocortex, CFuPN-directed ES-
derived neurons appropriately and relatively specifically innervate corticofugal targets in the 
thalamus and midbrain, in contrast to neurons generated by prior methods. Overall, my 
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experiments rigorously characterize and then successfully enhance the directed differentiation 
of mouse ES cells into CFuPN. 
Finally, in Chapter 5, I critically review my experimental findings and discuss topics of 
directed differentiation that have broad relevance to the field, including: 1) commonalities of 
maturation defects in many in vitro protocols of directed differentiation, potentially owing to 
“confusion” of molecular identity; 2) potential mechanisms causing immature or “confused” in 
vitro differentiation; and 3) future approaches for directed differentiation of clinically important 
subtypes (e.g. CSMN) within the broad class of CFuPN. Together, these topics delineate the 
broader challenges and long-term applications of my work for modeling CFuPN-specific 
neurodegenerative diseases and for developing new treatments for ALS and spinal cord injury. 
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Chapter 2 
 
An established monolayer protocol for 
differentiation of mouse embryonic stem cells 
generates heterogeneous, neocortical-like 
neurons that are stalled at a stage equivalent to 
mid-corticogenesis 
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2.1 Abstract 
 Neocortical projection neurons arise from discrete progenitor domains in the pallium, 
where the actions of specific molecular controls progressively refine their differentiation. Two 
existing and widely applied protocols of embryonic stem (ES) cell differentiation have been 
developed to enable in vitro generation of neurons resembling neocortical projection neurons in 
monolayer culture (Gaspard et al., 2008; Espuny-Camacho et al. 2013) and from embryoid 
bodies (Eiraku et al., 2008; Nasu et al., 2012); the monolayer approach offers advantages for 
detailed in vitro characterizations and potential mechanistic and therapeutic screening. 
 I asked whether mouse ES cells undergoing largely undirected neocortical 
differentiation in monolayer culture recapitulate progressive developmental programs of in vivo 
progenitor and post-mitotic differentiation, and whether they develop into specific neocortical 
subtypes, using rigorous criteria. I find that ES-derived mitotic cells that have been dorsalized 
by the Sonic hedgehog antagonist cyclopamine, and that express, as a total population, 
cardinal markers of telencephalic progenitors, are, in fact, molecularly heterogeneous. This 
finding is based on the largely non-overlapping expression of critical transcriptional controls 
over pallial progenitors, including Pax6 and Sox6. The absence of either of these transcription 
factors in vivo results in distinct deficits in neocortical differentiation. I next show that these 
progenitors subsequently generate small numbers of heterogeneous neocortical-like neurons 
that are “stalled” at an immature stage of differentiation, based on multiple developmental 
criteria: 1) sparse expression of mature neuronal markers (MAP2, NeuN); 2) immature and 
unresolved co-expression of molecular controls over multiple distinct classes and types of 
neocortical projection neurons; and 3) immature and unresolved expression of critical post-
mitotic transcription factors that progressively refine the neocortical area-specific 
differentiation of projection neuron subtypes.  
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 While some aspects of neocortical development are recapitulated by existing protocols 
of ES cell differentiation, these data indicate that mouse ES-derived neocortical progenitors are 
both more heterogeneous than their in vivo counterparts, and seemingly include many 
incorrectly specified progenitors. Further, these ES-derived progenitors spontaneously 
differentiate into sparse, incompletely and largely imprecisely differentiated, neocortical-like 
neurons that fail to adopt specific neuronal identities in vitro. These results provide both 
foundation and motivation for refining and enhancing directed differentiation of clinically 
important neocortical projection neuron subtypes. 
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2.2 Introduction 
 Neocortical neurons undergo distinct molecular refinements at progenitor (Molyneaux et 
al., 2005; Chen et al., 2005; Chen et al., 2008; Azim et al., 2009) and post-mitotic (Weimann et 
al., 1999; Arlotta et al., 2005; Alcamo et al., 2008; Britanova et al., 2008; Lai et al., 2008; Joshi 
et al., 2008; Azim et al., 2009; Tomassy et al., 2010; Cederquist et al., 2013) stages of 
development. These molecular refinements individually represent distinct developmental 
programs that, in sequential combinations, control neocortical development. In the absence of 
these critical transcription factors that control any of these stages, the precise molecular 
identity, laminar/area positioning, and/or projection patterns of neocortical projection neuron 
subtypes are disrupted in vivo. These transcriptional controls, therefore, are good candidates 
for rigorous characterization of in vitro neocortical-like neurons derived from embryonic stem 
(ES) cells. 
 Recent advances in mouse ES cell directed neocortical differentiation recapitulate 
some, but not all, aspects of corticogenesis (Gaspard et al., 2008; Eiraku et al., 2008; Nasu et 
al., 2012; Hansen et al., 2011). Importantly, populations of ES-derived neocortical-like neurons 
sequentially express single genes characteristic of neocortical neurons in vivo. However, many 
of these genes (e.g., Pax6, Ctip2, Satb2) are not specific only to the neocortex, but are 
expressed in other regions of the developing neural tube. For example, Pax6 is differentially 
expressed throughout the rostro-caudal extent of the neural tube ventricular zone (Ericson et 
al., 1997; Osumi et al., 1997; Briscoe et al., 2000; Alaynick et al., 2011), and Ctip2 is also 
expressed in striatum, olfactory bulb, and hippocampus (Leid et al., 2004; Arlotta et al., 2005; 
Arlotta et al., 2008).  
 With deeper analysis, using multiple markers, it is increasingly apparent that ES-derived 
neocortical-like neurons are incompletely specified in vitro. First, a substantial fraction of these 
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neurons express combinations of molecular markers that are not described in the neocortex in 
vivo (e.g., Reelin/Ctip2; Gaspard et al., 2008). Second, ES-derived neocortical neurons often 
display mixed subtype-specific molecular characteristics, such as co-expression of deep- and 
superficial-layer markers in individual hES-derived neurons (Mariani et al., 2012; Shi et al., 
2012. Finally, these neurons display skewed areal specification and projection patterns to 
visual and limbic targets (Gaspard et al., 2008; Espuny-Camacho et al., 2013). These subtle but 
distinct deficiencies in the differentiation of ES-derived neocortical neurons suggest incomplete 
differentiation, which might hinder neocortical subtype acquisition, and limit the interpretability 
of these in vitro models of corticogenesis. 
 More refined characterizations of in vitro neocortical differentiation are now possible, 
given recent advances in the study of neocortical development (Molyneaux et al., 2007; 
Woodworth et al., 2012; Custo Greig et al., in editorial revision, 2013). Pax6, often used to 
exclusively mark the pallium, is not a specific marker of the pallial tissue, given its expression 
throughout the neural tube (Alaynick et al., 2011). In the absence of positional information in 
vitro, characterization of Pax6-expressing “pallial” progenitors is incomplete without the 
presence of additional markers of pallial progenitors (e.g., Sox6; Azim et al., 2009; Otx2, 
Acampora et al., 1999), or the absence of other markers co-expressed with Pax6 outside of the 
pallium.  
 Sox6 is a transcription factor that controls the development of pallial progenitors 
independently from Pax6; its absence results in misspecification of pallial progenitors, by 
ectopic expression of subpallial genes (Azim et al., 2009). Like Pax6, Sox6 is not specific to the 
pallium, as it is also expressed by post-mitotic, subpallium-derived interneurons. However, 
when Sox6 is assessed in combination with Pax6, the presence of both markers greatly 
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increases the specificity for pallial progenitors. To date, this combination has not been used for 
the identification of pallial progenitors in vitro.  
 Post-mitotic neocortical neurons in vivo undergo a prolonged maturation process, 
during which gene expression becomes progressively restricted to particular subtypes (Lai et 
al., 2008; Britanova et al., 2008; Alcamo et al., 2008; Chen et al., 2008; Azim et al., 2009; Joshi 
et al., 2008; Woodworth et al., 2012; Cederquist et al., 2013; Custo Greig et al., in editorial 
revision, 2013). These neurons initially co-express transcriptional controls characteristic of 
multiple neocortical projection subtypes (e.g., Tbr1, Ctip2, Satb2, Ctip1) and multiple 
neocortical area identities (e.g., CoupTF1, Bhlhb5, Ctip1) before distinct subtype identities 
emerge. Together, this process of molecular refinement involves, at minimum, coordinated 
neuronal maturation, neocortical projection neuron class distinction, and neocortical area 
subtype distinction. These three stage-specific features of neocortical identity refinement form 
the basis for my approach to characterizing neocortical identity in vitro. 
 I assessed mouse ES cell-derived neocortical-like neurons at progenitor and post-
mitotic stages, and identified multiple characteristics consistent with stalled maturation. First, 
ES-derived neocortical-like progenitors are more heterogeneous than has been previously 
reported using single-marker analyses. Second, neocortical-like neurons are stalled at a 
maturation stage resembling mid-corticogenesis, as indicated by overlapping expression of 
multiple subtype-specific markers that do not resolve with time. Additionally, area-specific 
differentiation is abnormal, as ES-derived neocortical neurons are deficient in the rostral 
regulator of neocortical development, Bhlhb5. Overall, this approach rigorously investigates the 
refinement of ES-derived neocortical differentiation and indicates directions for refining 
directed differentiation of clinically important neocortical projection neurons. 
 31 
2.3 Results 
 To begin characterizing ES-derived neocortical-like cells, I cultured mouse ES cells, and 
directed their differentiation to neocortical fates using an established monolayer cell culture 
protocol (Gaspard et al., 2009). This protocol enables rostral and dorsal differentiation by 
plating ES cells at low-density, removing serum and retinoids, and antagonizing residual Shh 
morphogen signaling with cyclopamine. I replicated this protocol, and generated sequential 
waves of broad neural populations (neural progenitors, immature neurons, and astroglia) from 
E14Tg2a mouse ES cells over the course of 28 days (Figure 2.1). After two weeks in culture, 
approximately 60% of ES-derived cells express Nestin, an intermediate filament protein, 
broadly marking neural progenitors. Similar results were obtained using Nagy G4 mouse ES 
cells (data not shown). These results show that both the timing of neural induction, and 
sequential generation of neural progenitors, neurons, and astroglia, are nearly identical to 
previously published results (Gaspard et al., 2008). 
 
Distinct subsets of pallial progenitors are generated from ES cells 
 I first assessed the proportion of rostral, dorsal, pallial-like differentiation by ES-derived 
Nestin-expressing neural progenitors at in vitro day 14. Approximately half of Nestin-
expressing progenitors are pallial-like, based on co-expression of Pax6 (Figure 2.2A). All Pax6-
expressing cells co-express Nestin, and Pax6 is not expressed by any TuJ1 (beta tubulin III)-
expressing immature neurons (data not shown). Together, these data suggest that Pax6 
expression is restricted to about half of ES-derived neural progenitors. 
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Figure 2.1. Sequential generation of neural progenitors, neurons, and astroglia in an 
established monolayer ES cell protocol is reproducible. (A, B) Nestin expression decreases, 
as a proportion of total cells, from day in vitro (DIV) 14 to DIV 21. (C, D) TuJ1 expression 
increases, as a proportion of total cells, from day 14 to day 21. (E, F) GFAP expression begins 
by day 28. (G) Quantification of Nestin, TuJ1, GFAP expression over the course of 28 days. 
Data are represented as mean +/- s.e.m. (N = 3).
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Figure 2.2. Pallial-like progenitors generated by ES-derived progenitors are molecularly 
heterogeneous. (A, B) Half of Nestin-expressing progenitors co-express Pax6 (A) or Sox6 (B). 
(C) ~20% of progenitors express both Pax6 and Sox6. (D, E) The majority of Pax6 (D) and Sox6 
(E) pallial progenitors co-express Otx2. (F) Ngn2 is expressed in some Pax6 low/negative 
progenitors. (G) Mash1/Nestin subpallial-like progenitors represent ~10% of cells. (H-J) 
Ventralized ES cells lose Pax6 expression (H), and increase subpallial Nkx2.1 (I) and Gsh2 (J). 
(K, L) Pax6/Mash1 (K) and Sox6/Mash1 (L) cellular subsets are mostly distinct. 
 
 
 34 
 
Figure 2.2 (Continued)
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 I next asked whether these Pax6-expressing neural progenitors at in vitro day 14 
display other characteristics of pallial progenitors. I hypothesized that correctly-specified pallial 
progenitors will co-express Sox6 (Azim et al., 2009). Similar to the proportion of Pax6-
expressing progenitors, I find that approximately half of Nestin-expressing progenitors also 
express Sox6 (Figure 2.2B). However, Pax6 and Sox6 are co-expressed by only approximately 
20% of progenitors (Figure 2.2C), which is strikingly dissimilar to their highly overlapping 
expression in vivo (Azim et al., 2009). Overall, the combined distribution of Pax6 and Sox6 
expression accounts for the majority of Nestin-expressing progenitors at day 14, but these 
pallial transcription factor controls are largely not expressed by the same cells. 
 Since most Pax6-expressing cells do not co-express Sox6, I hypothesized that some 
Pax6-expressing cells might possess identities characteristic of a position in the neural tube 
caudal to the telencephalon. Otx2, expressed throughout the ventricular zone of the neural 
tube rostral to the hindbrain, demarcates the midbrain-hindbrain boundary, and is required for 
early specification of forebrain and midbrain (Acampora et al., 1999). I find that the majority of 
Pax6-expressing pallial-like progenitors co-express Otx2, consistent with a forebrain 
progenitor identity (Figure 2.2D). Otx2 is also co-expressed by most Sox6-expressing 
progenitors (Figure 2.2E). While these data suggest that many Pax6- and Sox6-expressing 
progenitors resemble forebrain pallial progenitors, the absence of Otx2 co-expression in many 
progenitors indicates further heterogeneity not observed in vivo. 
 To assess whether downstream pallial molecular programs are intact in cells 
differentiating under these conditions, I assessed expression of Ngn2 in these ES-derived 
pallial-like progenitors. In the developing pallium, Pax6 and Sox6 are both upstream of Ngn2, a 
pro-neurogenic transcription factor that has cell cycle dependent expression in progenitors 
undergoing neurogenesis (Azim et al., 2009; Kageyama et al., 2008; Ma et al., 2008; 
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Schuurmans et al., 2004). I find that Ngn2 is highly expressed by cells with low Pax6 
expression, suggesting that ES-derived pallial-like progenitors are undergoing neurogenesis 
with dynamic regulation of Pax6 and Ngn2 (Figure 2.2F). 
 To investigate whether pallial-like progenitors appropriately exclude markers of 
subpallial identity, I tested for molecular markers of these populations at in vitro day 14. 
Mash1, also called Ascl1, is a transcription factor expressed in the subpallium (both lateral and 
medial ganglionic eminences) and at the adjacent pallial-subpallial boundary; in concert with 
Dlx1/2, it is essential for the proper specification of subpallium-derived neurons (Long et al., 
2009). I find that Mash1 is co-expressed by approximately 10% of Nestin-expressing ES-
derived progenitors (Figure 2.2G).  
 To investigate whether Mash1-expressing progenitors display other characteristics of 
subpallial progenitors, I assessed their co-expression with Gsh2 and/or Nkx2.1. Gsh2 is a 
transcription factor expressed by early progenitors of the lateral ganglionic eminence, and, to a 
lesser extent, the medial ganglionic eminence; Gsh2 functions upstream of Mash1 activation, 
and represses Pax6 transcription (Corbin et al., 2003; Wang et al., 2009; Pei et al., 2011; Azim 
et al., 2009; Batista-Brito et al., 2009). Nkx2.1 is another subpallial control, expressed in the 
medial ganglionic eminence (Butt et al., 2008). Gsh2 and Nkx2.1 are individually co-expressed 
with Mash1 in the subpallium, in distinct compartments; I hypothesized that some Mash1-
expressing progenitors might co-express one or both these subpallial transcription factors. 
However, I find that Gsh2 and Nkx2.1 expression is absent in ES-derived progenitors (data not 
shown). 
 To determine whether this protocol is competent to generate cells with appropriate 
subpallial characteristics, I directed the ventralization of ES-derived neural progenitors with 
Shh agonism. In the presence of the Shh agonist Ag1.3, Pax6 expression is appropriately lost 
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(Figure 2.2H), while expression of Nkx2.1 and Gsh2, individually, is increased (Figure 2.2I,J). 
Mash1 expression was not affected (data not shown). These data provide a positive control for 
the absence of Gsh2 and Nkx2.1 expression with cyclopamine-mediated dorsal differentiation, 
confirming that subpallial gene expression by ES-derived progenitors is Shh-dependent, as 
expected in vivo. In contrast, Mash1 expression by a subpopulation of these cells appears to 
be independent of subpallial specification. 
 I next asked whether Mash1-expressing progenitors are instead pallial-like, given 
previous reports of cells with Mash1 expression in the dorsal pallium and at the pallial-
subpallial boundary in vivo (Britz et al., 2006; Ge et al., 2006). While pallial progenitors 
expressing Pax6 (Figure 2.2K) or Sox6 (Figure 2.2L) are mostly distinct from Mash1-
expressing progenitors, I find that approximately 15% of Pax6-expressing progenitors co-
express Mash1 (Figure 2.2K). These findings suggest that many Mash1-expressing ES-derived 
progenitors are potentially pallial. This interpretation is consistent with the broad dorsalization 
induced by cyclopamine in ES cell differentiation, but again highlights a high degree of 
heterogeneity within ES-derived pallial-like progenitors by day 14. 
 
A small subset of ES-derived neurons is neocortical, based on multiple markers  
 At 21 days of differentiation, approximately 30% of cells express TuJ1, and can be 
considered immature neurons, although this proportion is highly variable (Figure 2.3). Previous 
reports using this protocol have indicated that a higher proportion of ES-derived neurons are 
generated (Gaspard et al., 2008; Gaspard et al., 2009), which raises specific methodological 
points that might explain the quantitative differences I observe. First, the ES-derived cells 
produced by this monolayer protocol do not remain a monolayer after greater than seven days 
of differentiation; at later times, I observe cell overgrowth and “clumping” of cells with 
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heterogeneous morphologies. I use confocal imaging to more precisely localize TuJ1 staining 
near areas of dense cell over-growth at day 21. Counting total nuclei within aggregates of cells 
has not proved reliable, and I therefore excluded neurons found within these dense 
aggregates. Second, I maintained strict criteria for counting TuJ1-expressing neurons: TuJ1 
staining must minimally encompass a hemi-circle around the nucleus, and display a polarized, 
neuron-like morphology. Third, because TuJ1 expression is not entirely specific to neurons 
(e.g., TuJ1 is expressed in fibroblasts; Vierbuchen et al., 2010), I excluded non-neuronal TuJ1-
expressing cells based on multiple exclusion criteria: comparatively lower intensity of TuJ1 
expression, fibroblast-like morphology, or any nuclei surrounded by an exceedingly high 
density of neurites from adjacent neurons, which can sometimes incorrectly resemble distinct 
neurons. Finally, TuJ1 expression is not distributed uniformly in vitro across a coverslip, and all 
characterizations were performed on selected imaging fields containing substantial numbers of 
neurons. 
 To investigate the potentially neocortical identity of these ES-derived neurons at day 21, 
I performed immunostaining for multiple neuronal markers. I first assessed the expression of 
Tbr1, which is expressed briefly by all post-mitotic pyramidal neurons generated in the 
developing pallium, before its expression becomes restricted to corticothalamic projection 
neurons (CThPN) and callosal projection neurons (CPN) in layer VI (Englund et al., 2005; Hevner 
et al., 2001). Tbr1 is expressed in few brain areas other than neocortex, and Tbr1-expressing 
neurons are glutamatergic (Hevner et al., 2001; Bedogni et al., 2010; McKenna et al., 2011). 
Approximately 10-20% of TuJ1-expressing neurons in vitro also express Tbr1 (Figure 2.3A). 
Given the low percentage of ES-derived neurons expressing Tbr1, I imaged selected fields 
containing relatively high concentrations of Tbr1-expressing neurons for further subtype 
characterization.  
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Figure 2.3. ES-derived, Ctip2-expressing neurons are neocortical-like. (A) Tbr1-expressing 
neurons co-express TuJ1. (B) Ctip2-expressing neurons co-express TuJ1. (C) Ctip2-expressing 
neurons co-express Tbr1. (D) Ctip2-expressing cells are distinct from GAD67-expressing cells; 
Er81 is co-expressed in Ctip2 neurons (filled arrowheads: Ctip2/Er81; empty arrowheads: 
GAD67). 
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Figure 2.3 (Continued) 
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To identify cells with properties of early neocortical neurons, and potentially of specific 
deep-layer subtypes, I focused on expression of Ctip2. Like Tbr1, Ctip2 is a critical 
transcription factor expressed at distinct levels (off, low, high) by multiple newly post-mitotic 
neocortical subtypes; later in development, Ctip2 controls corticofugal projection neuron 
(CFuPN) axon outgrowth and fasciculation, with refined laminar expression specific to deep 
layers – low level by CThPN in layer VI, and high level by SCPN in layer V (Arlotta et al., 2005). 
Expression of Ctip2 by immature CPN, and therefore co-expression with CPN marker Satb2, is 
lost by late embryogenesis (Alcamo et al., 2008; Britanova et al., 2008; Chen et al., 2008). 
Importantly, Ctip2 is highly expressed in brain regions other than the neocortex, most highly by 
medium-sized spiny neurons in the striatum (Leid et al., 2004; Arlotta et al., 2005; Arlotta et al., 
2008). 
I find that Ctip2, similarly to Tbr1, is expressed by a small fraction of TuJ1-expressing 
neurons (approximately 10-20% of neurons in selected fields containing positive Ctip2 staining) 
(Figure 2.3B). If these Ctip2-expressing neurons are neocortical-like, I hypothesized that most 
should also express Tbr1. Consistent with this prediction, Ctip2 and Tbr1 display nearly 
complete co-expression after 21 days in culture (Figure 2.3C). These data suggest that this 
sparse population of ES-derived Ctip2-expressing neurons is glutamatergic, and most closely 
resembles immature deep-layer projection neurons. 
 To rigorously test whether these Ctip2 and Tbr1 co-expressing neurons represent non-
neocortical neurons, I performed co-expression analysis of Ctip2 with Er81 and GAD67. Er81 is 
expressed in neocortical deep layers, olfactory bulb (interneurons), amygdala, thalamus, but 
not in striatum (Stenman et al., 2003; Yoneshima et al., 2006); the intersection of Er81 and 
Ctip2 expression is fairly exclusive to neocortex. I find that Ctip2-expressing neurons co-
express Er81 in the cytoplasm (Figure 2.3D), which indicates that they are not striatal. Many 
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important striatal genes, such as Darpp32, Foxp1, and Foxp2, are expressed both in cortex 
and in striatum, and we therefore examined expression of GAD67, which is expressed only by 
GABAergic inhibitory populations, such as medium-sized spiny neurons and subpallium-
derived cortical interneurons (reviewed in Gord and Bernardo, 2011). I find that the ES-derived 
neurons expressing Ctip2 do not co-express GAD67, and, therefore, are not GABAergic 
(Figure 2.3D). Together, the co-expression of Ctip2, Er81, and Tbr1, and the absence of 
GAD67, strongly support the interpretation that a small proportion of ES-derived neurons under 
these relatively undirected conditions adopt properties of immature neocortical neurons in 
vitro. 
 
Neocortical neurons are relatively immature  
 To investigate whether neocortical-like Ctip2-expressing neurons display appropriate 
features of stage-specific differentiation, I first assessed basic markers of neuronal maturation. 
Nearly all CNS neurons activate common programs of neuronal maturation, as marked by 
TuJ1, Map2, and NeuN/Fox-3 (Kim et al., 2009). Very few mature neurons in the CNS lack 
NeuN expression, most notably Purkinje neurons and gamma spinal motor neurons (Friese et 
al., 2009). 
 I find that these ES-derived neurons are relatively immature, based on the low 
abundance of NeuN expression after 21 or 28 days (approximately 5-10% of TuJ1-positive 
neurons co-express NeuN, assessed in selected fields in vitro). Given the importance of 
neuronal maturation for the timing of post-mitotic neocortical subtype refinement, I asked 
whether the small population of neocortical-like neurons that co-express Ctip2, Tbr1, and Er81 
is mature or immature. I find that all Ctip2-expressing neurons co-express TuJ1 (Figure 2.3B). 
Approximately one third of these neurons express both Map2 and NeuN (Figure 2.4A). These 
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neurons are not uniformly or completely mature, but some display crucial hallmarks of at least 
early maturation. 
 I next investigated whether the extent of NeuN expression might indicate an equivalent 
stage in development. In vivo at E16.5-E18.5, NeuN is expressed by approximately one-third of 
of Ctip2-expressing neocortical neurons (Figure 2.4B,C). Later, at P6, all Ctip2-expressing 
neocortical neurons also express NeuN (Figure 2.4D). Between E16.5 and P6, Ctip2-
expressing cortical neurons in vivo extend axons to their targets in the midbrain, brainstem, 
and spinal cord, and begin the process of pruning collateral connections (Arlotta et al., 2005; 
Stanfield, 1992). In contrast, ES-derived neocortical neurons in culture develop to a relatively 
immature state most highly resembling mid-corticogenesis.  
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Figure 2.4. ES-derived, Ctip2-expressing neurons are immature, consistent with NeuN 
expression at mid-corticogenesis in vivo. (A) Approximately one third of ES-derived, Ctip2-
expressing neurons co-express Map2 and NeuN in vitro (arrows: Ctip2/Map2/NeuN) (B,C) In 
vivo, NeuN is normally expressed in one third of (B) E16.5 and (C) E18.5 Ctip2-high neurons. 
(D) By P6, in vivo, all retrograde-labeled SCPN co-express Ctip2 and NeuN, indicating 
completion of a next stage of progressive maturation.
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Impaired subtype distinction of immature ES-derived CFuPN 
 I next assessed whether ES-derived, Ctip2-expressing, immature neurons are 
appropriately molecularly distinct from other subtypes. During mid-corticogenesis, in vivo, 
when only a small percentage of neurons express NeuN, neocortical projection neurons co-
express markers characteristic of multiple subtypes. By the first week of postnatal neocortical 
development, this molecular co-expression resolves into a refined, subtype-specific molecular 
identity, termed “subtype refinement” (Lai et al., 2008; Joshi et al., 2008; Azim et al., 2009; 
Cederquist et al., 2013; Lickiss et al., 2012). One example transcription factor, Satb2, is 
transiently expressed by early-stage CFuPN, but is later restricted to specific expression by 
CPN and other associative neocortical neurons (Alcamo et al., 2008; Britanova et al., 2008; 
Lickiss et al., 2012). To specifically investigate this subtype refinement of Ctip2 and Satb2 in 
vivo, for comparison to the events in culture, I assessed E16.5 neocortex and find significant 
Ctip2/Satb2 co-expression in layer V; these immature Ctip2/Satb2 co-expressing post-mitotic 
neurons consistently do not express NeuN (Figure 2.5A).  
 As a further, direct comparison, I next assessed post-mitotic subtype refinement by 
primary developing neocortical neurons in vitro using dissociated E12.5 neocortical cells 
cultured under the same conditions as day 14-21 ES-derived neocortical neurons. I find that 
these primary neurons reduce their initially high levels of Ctip2 and Satb2 co-expression, and 
increase the intensity of either Ctip2 or Satb2 over the course of four days in vitro (Figure 
2.5B-D), confirming that primary neurons are capable of subtype-specific transcription factor 
refinement during maturation in vitro.  
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Figure 2.5. ES-derived, Ctip2-expressing neurons do not resolve immature projection 
neuron marker expression over one week in vitro. (A) At E16.5 in vivo, Ctip2 and Satb2 co-
expressing neurons are relatively immature neurons, indicated by the absence of NeuN co-
labeling. (B, C, D) Dissociated primary E15.5 neocortical cells initially co-express Ctip2 and 
Satb2, but this immature expression resolves during the course of four days in vitro (DIV). (E, F) 
Under the same culture conditions, ES-derived neocortical-like neurons co-express Ctip2 and 
Satb2 at 21 days (E) and this co-expression persists at 28 days (F). (G) ES-derived neocortical-
like neurons also co-express Ctip2 and Ctip1 at 28 days. 
  
 47 
 
 
 
Figure 2.5 (Continued) 
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 I then asked whether the small population of ES-derived, Ctip2-expressing, immature 
neocortical neurons similarly display molecular profiles consistent with mid-corticogenesis, and 
whether this molecular identity refines to subtype specificity over time. I find that most Ctip2-
expressing neurons continue to co-express Satb2 at 21 days (one week after the onset of in 
vitro neurogenesis) (Figure 2.5E). Strikingly, Ctip2/Satb2 co-expression is still maintained by 
28 days of post-mitotic differentiation (Figure 2.5F), in contrast to primary dissociated E15.5 
neocortical neurons cultured for only four days under the same conditions in vitro (Figure 
2.4B-D). Moreover, these ES-derived neocortical-like neurons express a continuum of low, 
medium, and high expression levels of Ctip2 and Satb2, in contrast to primary dissociated 
E15.5 neocortical neurons, which have distinctly high, low, or absent expression levels of Ctip2 
or Satb2, when cultured under the same conditions in vitro.  
 To exclude the possibility of an isolated Ctip2/Satb2-specific molecular deficit, I asked 
whether the refinement of another subtype-specific transcription factor pair is also impaired. 
Ctip1 is a transcription factor that regulates both subtype- and area-specific identity; it is 
initially co-expressed with Ctip2 but is excluded from SCPN later in development (Woodworth 
et al., unpublished data, 2013). Importantly, I find that Ctip1 is co-expressed by most Ctip2-
expressing neurons at day 28 (Figure 2.5G), consistent with a broader impairment of subtype-
specific molecular refinement. These data suggest that the small population of ES-derived 
neocortical neurons, with overlapping expression of multiple post-mitotic neocortical markers 
(Ctip2, Tbr1, Er81, Satb2, and Ctip1), recapitulates a stage resembling mid-corticogenesis. 
 
Incomplete molecular area refinement of ES-derived CFuPN 
 It has been previously reported that some ES cell-derived neurons, when grafted in the 
white matter tracts ventral to the neocortex of P0/P1 mice, project axons to intra-cortical and 
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subcerebral (mostly visual) targets after one month (Gaspard et al., 2008). The expression of a 
single caudal neocortex marker, CoupTF1, was used to explain these biased projection 
patterns. Since the time of that publication, multiple transcription factors (e.g., Bhlhb5, 
CoupTF1, Lmo4, and Ctip1) have been characterized as important post-mitotic controls over 
neocortical area specification in vivo (Joshi et al., 2008; Armentano et al., 2007; Tomassy et al., 
2010; Huang et al., 2009; Cederquist et al., 2013; Woodworth et al., unpublished data, 2013; 
Custo Greig et al., unpublished data, 2013). In striking parallel to initially broad expression of 
genes that refine over time to define precise subtype identity, these post-mitotic area controls 
are initially co-expressed broadly in all neocortical areas, then become refined in expression 
during the first postnatal week (Woodworth et al., 2012; Custo Greig et al., in editorial revision, 
2013). To investigate whether immature ES-derived CFuPN might have area-specific molecular 
identity, I assessed putative CFuPN marked by high Ctip2 expression. I find that nearly all ES 
cell-derived Ctip2-expressing neurons co-express CoupTF1 (Figure 2.6A), which is consistent 
with in vivo broad expression (caudal-high to rostral-low gradient) in the neocortex at mid-
corticogenesis. In addition, Ctip2-expressing neurons also co-express Ctip1 (Figure 2.6G). In 
striking contrast, Ctip2-expressing neurons do not co-express Bhlhb5 (Figure 2.6B), although 
Bhlhb5 is expressed by other ES-derived neurons (Figure 2.6C). These data indicate that the 
absence of Bhlhb5 co-expression is inappropriate for the same stage of development in vivo 
and might represent deficits in area-specific differentiation by ES-derived neocortical neurons. 
 
 50 
 
 
 
 
 
 
Figure 2.6. ES-derived, Ctip2-expressing neurons do not complete post-mitotic area 
refinements. (A) All ES-derived Ctip2-expressing neurons co-express CoupTF1. (B) All ES-
derived Ctip2-expressing neurons cells exclude Bhlhb5. (C) Bhlhb5 is expressed by other ES-
derived neurons (N=4; approximately 1,000 neurons were screened). 
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2.4 Discussion  
 The experiments presented here are the first to deeply investigate the differentiation of 
neocortical-like neurons derived from ES cells, using the current and rapidly advancing 
knowledge in the field, and the results identify maturation deficits of these neurons. I 
demonstrate the utility of coordinating markers of neuronal maturation with markers of 
neocortical subtypes to assess the stage and extent of neocortical differentiation. Previous 
reports of ES-derived neocortical neuronal subtypes have assessed the presence of individual 
markers or, less commonly, combinations of very limited and relatively broad markers to 
identify neocortical subtypes (Gaspard et al., 2008; Eiraku et al., 2008; Nasu et al., 2012; 
Ideguchi et al., 2010; Mariani et al., 2012; Shi et al., 2012; Espuny-Camacho et al., 2013). 
However, most neocortical subtype-specific markers are only truly specific during transient 
developmental stages, in defined anatomical locations, and are not individually specific to the 
neocortex (Molyneaux et al., 2007; Woodworth et al., 2012; Custo Greig et al., in editorial 
revision, 2013).  
 Developmental stage-specific characterizations of ES-derived neocortical-like neurons 
in vitro suggest that these neurons most resemble in vivo neocortical neurons at mid-
corticogenesis. This conclusion is based on three distinct developmental criteria. First, less 
than one third of TuJ1-expressing neocortical-like neurons express mature neuronal markers 
(MAP2, NeuN), consistent with the proportion of neocortical neurons that express NeuN in vivo 
at approximately E16.5-E18.5 (Figure 2.4). These data provide a metric for comparison to a 
similar developmental stage in vivo; I use this information to interpret the stage-specific 
expression of subtype markers. Second, neocortical-like neurons co-express multiple subtype-
specific transcription factors (e.g., Tbr1, Ctip2, Satb2, Ctip1) in a continuum of low, medium, 
and high expression levels consistent with in vivo co-expression of these genes during early- to 
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mid-corticogenesis, but which is in striking contrast to the more mature expression of these 
transcription factors by primary, dissociated E15.5 neocortical neurons cultured under the 
same conditions in vitro (Figure 2.3; Figure 2.5). Third, neocortical-like neurons appropriately 
co-express some, but not all, post-mitotic controls over area-specific differentiation (e.g., 
CoupTF1, Bhlhb5, Ctip1; Figure 2.6); while this expression profile is most consistent with 
caudal fates, it does not reflect the broad patterns of area-specific markers during mid-
corticogenesis.  
Neocortical projection neurons are not the only population that displays increasingly 
restricted expression of subtype-specific transcription factors during maturation; indeed, spinal 
motor neurons (SMN) follow a similar process of refinement and diversity generation in vivo 
(Jessell, 2000; Dasen and Jessell, 2009; Alaynick et al., 2011). Initially, early post-mitotic SMN 
express the transcription factors Hb9, Islet1, and Lhx3 (Sharma et. al., 1998), and with 
continued maturation and position-dependent differentiation (Sürmeli et al., 2011), expression 
of each transcription factor becomes progressively restricted to distinct SMN subtype 
identities, including medial, lateral, and hypaxial motor column subtypes. However, in vitro 
subtype-specific molecular refinements by heterogeneous ES-derived SMN are not distinct at 
early, immature stages of differentiation (Wichterle et al., 2002; Soundararajan et al., 2006; 
Peljto and Wichterle, 2011). My findings, though directed toward characterizing neocortical 
neuronal identities, also reveal unresolved, immature subtype refinement in vitro. 
Though ES-derived neocortical-like neurons recapitulate some aspects of immature 
neocortical development specific to a stage approximating mid-corticogenesis, these data also 
indicate that these neurons are “stalled” in maturation in vitro. This conclusion is based on the 
comparison of subtype refinement by primary dissociated neocortical cells and ES-derived 
neocortical neurons under the same culture conditions (Figure 2.5). The immature subtype 
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marker profiles in ES-derived neurons do not resolve over the course of two weeks in vitro, in 
contrast to the timing observed in vivo, or to primary neurons cultured with the same 
conditions in vitro. The conclusion that ES-derived neocortical-like neurons are stalled in 
differentiation, rather than permanently mis-specified, is supported by evidence of continued 
neuronal maturation, based on the extension of long-range axons to forebrain and midbrain 
targets but not by resolution of subtype-specific molecular markers, following transplantation 
into early post-natal mice (Gaspard et al., 2008). 
 Increasingly, more refined analyses of ES-derived neuron physiology and subtype 
identity indicates stalled or incomplete neuronal differentiation following directed differentiation 
in vitro. For example, in one protocol of SMN generation from mouse ES cells, in vitro 
maturation is limited; only after five days of myotube co-culture do ES-derived SMN express 
more mature physiologic properties of post-natal spinal motor neurons (Miles et al., 2004). 
Recently, more detailed analyses of ES-derived photoreceptor neurons (Eiraku and Sasai), 
midbrain-like dopaminergic neurons (Kriks et al., 2011), and spinal nociceptor neurons 
(Chambers et al., 2012), similarly suggest variability and limitations in the extent of neuronal 
subtype maturation in vitro, and following grafting in vivo. 
 I speculate that the maturation deficits in ES-derived neocortical neurons are the result 
of both intrinsic and extrinsic deficits. First, recent mouse studies demonstrate that the 
absence of specific intrinsic factors might accelerate, delay, or interrupt mature laminar or area 
positioning (e.g., Sox5 in Lai et al., 2008; FoxG1 in Miyoshi and Fishell, 2012; Bhlhb5 in Joshi 
et al., 2008; CoupTF1 in Tomassy et al., 2010, and Alfano et al., 2011; Ctip1 in Woodworth et 
al., unpublished data, 2013). The finding that Bhlhb5 is absent in ES-derived neocortical-like 
neurons at mid-corticogenesis is consistent with at least one intrinsic deficit in area-specific 
transcriptional refinement. Second, simplified growth and media conditions in vitro might 
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exclude extrinsic factors necessary for neocortical subtype distinction (reviewed in Tiberi et al., 
2012). Co-culturing with astrocytes might be beneficial, particularly for synaptic maturation and 
other refinements that occur later in postnatal development (Johnson et al., 2007; Foo et al., 
2011), although the deficits of subtype-specific molecular refinement by ES-derived neocortical 
neurons occur prior to the stage that coincides with post-natal gliogenesis. Third, the absence 
of cell-cell interactions in adherent cell culture might impede subtype-specific refinements; 
strikingly, subtype marker overlap does not appear to be as severe in aggregate-based 
protocols of ES-derived neocortical differentiation, possibly indicating the utility of cell-cell 
interactions within self-organized ES-derived aggregates (Eiraku et al., 2008; Nasu et al., 2012). 
Similarly, subtype-specific maturation of ES-derived neocortical-like neurons might occur when 
transplanted as individually isolated neurons in vivo, into embryonic or post-natal neocortex, 
although such subtype characterizations have not been performed in situ (Gaspard et al., 
2008). Finally, intrinsic deficits in the chromatin landscape might contribute to the stalled 
maturation of ES-derived neocortical-like neurons; recent studies suggest that chromatin 
remodeling is important at multiple stages of corticogenesis (MacDonald and Roskams, 2009; 
Tiberi et al., 2012; Baranek et al., 2012). I speculate that some of these deficits might 
contribute to the insufficiency of ES-derived progenitors, by multiple protocols, to generate 
distinct superficial-layer neuron subtypes (Hansen et al., 2011). 
 Early deficits in pallial progenitor specification might explain the sparse enrichment and 
stalled maturation of post-mitotic neocortical neurons. My data presented here describe 
heterogeneity of pallial and forebrain markers (e.g., Pax6, Sox6, Otx2, and Mash1) and 
absence of subpallial markers in ES-derived progenitors (Figure 2.2). While these data suggest 
that dorsalization of ES-derived progenitors is highly efficient, the heterogeneity and minimally 
overlapping expression of multiple pallial markers (e.g. Pax6 and Sox6) strongly indicate an 
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incomplete extent of pallial differentiation by most ES-derived progenitors. In particular, the 
strikingly low efficiency of neocortical-like neuron generation (at most 20% of ES-derived 
neurons express Tbr1, Ctip2, Satb2, or Ctip1) supports the interpretation that most ES-derived 
pallial-like progenitors are incompletely specified. I speculate that the small population of Pax6 
and Sox6 co-expressing progenitors (~20% of total progenitors; Figure 2.2C) most closely 
resembles true pallial progenitors and likely accounts for the small population of neocortical-
like neurons; the prospective isolation of these ES-derived pallial-like progenitors might enable 
further study of neocortical subtype specification in future studies. Together, these data 
suggest that deficits in neocortical-like neuron subtype specification might originate with 
incomplete pallial progenitor specification. 
 Judging from the typically exceptional specificity of neocortical neuronal subtype 
involvement with specific neurodegenerative diseases (e.g., CSMN and spinal motor neurons in 
ALS; cortico-striatal projection neurons in Huntington’s disease), the utility of directed 
differentiation for studying neocortical biology, pathologic mechanisms, and potential therapies 
hinges on its close approximation to in vivo development. While the results presented in this 
chapter suggest caution in utilizing ES-derived neocortical cells as a model for cortical 
development, with further refinements these protocols might be substantially improved. For 
example, the same protocol of ES-derived neocortical directed differentiation was recently 
used as a model system to identify Bcl6 as a regulator of neocortical progenitors, and this 
pathway was verified in vivo (Tiberi et al., 2012). Absent a mechanistic understanding of the 
deficits of ES-derived neocortical neuron differentiation, these data indicate specific directions 
for the continued refinement of directed differentiation to more closely approximate neocortical 
development. For example, deficits in the transcriptional state or chromatin landscape of ES-
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derived neurons might be targeted for manipulation to enhance neocortical differentiation 
(Juliandi et al., 2012; Chapter 3).  
 Taken together, the data from these experiments and from prior work by other groups 
indicate that ES-derived neocortical differentiation is limited in vitro, with multiple maturation 
deficits not consistent with in vivo development. The stage-specific, multiple-marker 
methodology presented here promises to be increasingly useful for the characterization of 
neocortical subtypes and for potentially directing the differentiation of refined subtypes. These 
results provide both foundation and motivation for refining, enhancing, and enriching for 
directed differentiation of clinically important CFuPN as a class and of distinct CFuPN 
subtypes. 
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2.5 Experimental Procedures 
 
Cell culture and differentiation 
 Murine embryonic stem cells: Nagy ES cell line G4 (MMRRC stock# 011987-MU) or 
feeder-free E14Tg2a (Baygenomics) mouse embryonic stem cells were propagated using 
standard procedures (Ying et al., 2003) on gelatin-coated (0.1% gelatin, StemCell 
Technologies) cell culture treated plastic dishes. Nagy ES cells were cultured on mouse 
embryonic fibroblast feeder cells (Millipore EmbryoMax PMEF-N). Mouse embryonic stem cell 
media is GMEM (Invitrogen) supplemented with 10% ESC-certified fetal bovine serum (vol/vol, 
Invitrogen), 0.1 mM nonessential amino acids (Invitrogen), 1mM sodium pyruvate (Invitrogen), 
0.1mM β-mercaptoethanol (Sigma), 50 U/mL penicillin/streptomycin and 1000 U/mL leukemia 
inhibitor factor (ESGRO).  
 For differentiation, Nagy G4 and E14Tg2a ES cells were plated at low density (5,000 
cells/cm2) on gelatin-coated plastic dishes in ES cell medium, and cultured as described 
(Gaspard et al., 2009). Briefly, ESCs were trypsinized, dissociated, and plated on gelatin-
coated cell culture plates. Medium was changed to DDM after one day. DDM consists of 
DMEM/F12 (Invitrogen-Gibco) supplemented with N2 supplement (N2 supplement consists of 
8.61uM insulin, 1mM transferrin, 2uM progesterone, 10mM putrescine and 3uM selenite; 
Invitrogen-Gibco), 2mM glutamine, 0.1 mM nonessential amino acids, 1mM sodium pyruvate, 
0.5 mg/ml bovine serum albumin fraction V (all from Invitrogen-Gibco), and 0.1mM β-
mercaptoethanol (Sigma).  
 Cyclopamine (Calbiochem) or Ag1.3 (gift from Lee Rubin, Harvard University) was 
added from day 2 to day 10 in the differentiation medium at a final concentration of 1uM. After 
10 to 14 days of differentiation, cells were trypsinized, dissociated and plated on poly-
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lysine/laminin (Becton-Dickinson) coated glass coverslips and allowed to grow for 4–14 days in 
N2B27 medium. N2B27 medium consists of a 1:1 mixture of DDM and Neurobasal that is 
supplemented with B27 (without vitamin A; Invitrogen-Gibco) and 2 mM glutamine. 
Immunocytochemistry 
 Cells were fixed in 4% paraformaldehyde (wt/vol) for 30 min, and washed three times in 
phosphate-buffered saline (PBS). For primary antibodies, I used rabbit antibody to Pax6 
(Covance), rabbit antibody to Sox6 (1:500, Abcam), mouse antibody to Mash1 (1:500, BD), 
rabbit antibody to Gsh2 (1:500, Abcam), mouse antibody to Nkx2.1/TTF1 (1:5,000 BioPat), 
rabbit antibody to Tbr1 (1:500, Abcam), rat antibody to Ctip2 (1:500, Abcam), mouse antibody 
to Satb2 (1:200, Abcam), rabbit antibody to Er81 (1:100, Abcam), mouse antibody to GAD67 
(1:1000, Chemicon), rabbit antibody to TuJ (1:1000, Sigma), mouse antibody to TuJ (1:1000, 
Covance), mouse or rabbit antibody to Map2 (1:500, Sigma), mouse antibody to NeuN 
(Chemicon or Millipore), mouse antibody to Ctip1 (1:250, Abcam), goat antibody to Bhlhb5 
(1:300, Santa Cruz), rabbit antibody to CoupTF1 (1:500, gift of M. Studer lab). Secondary 
antibodies were from the Invitrogen Molecular Probes Alexa series. Nuclei were stained with 
Hoechst#33342 (1:3,000, Sigma). 
 Wide-field image acquisition was performed using a Nikon 90i epifluorescence 
microscope with a Clara DR-328G cooled CCD digital camera (Andor Technology, Belfast, 
Northern Ireland). Confocal imaging was performed with a BioRad Radiance 2100 Rainbow 
laser-scanning confocal microscope based on a Nikon E800 microscope. Images were 
assembled in Adobe Photoshop and Illustrator (CS3, CS5), with adjustments for contrast, 
brightness, and color balance to obtain optimal visual reproduction of data. 
 
Mice 
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 All mouse studies were approved by the Massachusetts General Hospital and/or 
Harvard University IACUCs, and were performed in accordance with institutional and federal 
guidelines. The date of vaginal plug detection was designated E0.5, and the day of birth as P0. 
Wild-type CD1 mice were used in all experiments (Charles River Laboratories). 
 Brains were fixed using standard methods (Fricker-Gates et al., 2002; Arlotta et al., 
2005). Briefly, brains were fixed by trans-cardial perfusion with PBS– heparin (10 U/ml), 
followed by 4% paraformaldehyde, and post-fixed overnight at 4°C in 4% paraformaldehyde. 
Brains were sectioned coronally at 50 um on a vibrating microtome (Leica). Coverslips or 
floating sections were blocked in 1% BSA (Sigma) and 0.1% Triton X-100 (Sigma) for 20min at 
room temperature, before incubation in primary antibody. 
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Chapter 3 
 
Sirt1 inhibition promotes refinement of 
subcerebral projection neuron identity among 
heterogeneous neocortical-like neurons 
generated from mouse embryonic stem cells 
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3.1 Abstract 
Corticofugal projection neurons (CFuPN) are the broad class of neocortical projection 
neurons that send their axons to sub-cortical targets including the thalamus, striatum, 
brainstem, and spinal cord. Among the many types of CFuPN, subcerebral projection neurons 
(SCPN) specifically send their axons to sub-cerebral targets in the brainstem and spinal cord. 
Importantly, the expression of a single transcription factor, Fezf2, is both required and 
sufficient for SCPN specification from neocortical progenitors in vivo. In contrast, callosal 
projection neurons (CPN) comprise a second broad class of projection neurons that differ from 
CFuPN (and thus, SCPN), in that they send inter-hemispheric axons within the neocortex and 
do not express Fezf2.  
During late embryonic development of the neocortex, these distinct broad classes of 
projection neurons initially express overlapping molecular controls that later refine to specific 
classes and subtypes as increasingly diverse neurons mature. Such molecular refinements are 
largely absent in heterogeneous neocortical-like neurons spontaneously generated by an 
established protocol of embryonic stem (ES) cell differentiation (Chapter 2). Given probable 
deficiencies in chromatin remodeling during maturation of ES-derived neocortical-like neurons, 
I investigated whether distinct chromatin modifiers might promote SCPN-specific 
differentiation among heterogeneous, maturation-stalled neocortical-like neurons 
spontaneously generated from ES cells. 
Using a combination of “high content” screening technologies, and recently developed 
synthetic modified mRNA (modRNA; pioneered by the Derrick Rossi laboratory at Harvard; 
Warren et al., 2010), I investigated whether chromatin remodeling might enhance Fezf2-
mediated SCPN specification among ES-derived neocortical-like neurons. I screened a library 
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of eighty small molecules that target known chromatin remodeling enzymes for SCPN 
differentiation, in the context of transient Fezf2 expression.  
The data show that the inhibition of a specific histone deacetylase, Sirtuin 1 (Sirt1), 
enhances the refinement of SCPN identity, as assessed by positive and negative molecular 
markers of SCPN identity in individual cells. Using expression analysis in vivo during mouse 
cortical development, I find that this effect of Sirt1 inhibition in promoting ES-derived SCPN 
differentiation is consistent with specific absence of Sirt1 expression by SCPN during their late 
embryonic and post-natal differentiation in vivo. Moreover, Sirt1 inhibition by small molecules 
or siRNA knockdown enhances SCPN subtype refinement by primary dissociated E12.5 
neocortical cells, reinforcing the biological relevance of the work with ES-derived neurons. 
Together, these data provide the first report of subtype-specific expression and 
function of a chromatin-remodeling enzyme in the mouse neocortex, applicable to directing ES 
cell differentiation. Moreover, these findings indicate that histone modifications contribute to 
the molecular refinement of neuronal subtype identity during neocortical development. 
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3.2 Introduction 
 Corticofugal projection neurons (CFuPN) are the broad class of neocortical neurons that 
send axonal projections from the neocortex to distal targets in the thalamus, midbrain, 
hindbrain, and spinal cord (Molyneaux et al., 2007; Woodworth et al., 2012). A defining 
molecular feature of CFuPN is the early and temporally dynamic expression of Fezf2, a 
required transcription factor that specifies their anatomical and molecular identity (Molyneaux 
et al., 2005; Chen et al., 2005; Chen et al., 2008; Shim et al., 2012). The expression of Fezf2 is 
highest in neocortical subcerebral projection neurons (SCPN), which are a subset of CFuPN 
with axonal projections to targets that are more caudal to the thalamus, beyond the cerebral 
peduncle (Molyneaux et al., 2005). 
Although Fezf2-expressing SCPN are among the first neurons generated in the 
neocortex, they undergo progressive transcriptional refinements that continue for multiple 
weeks prior to the acquisition of a stable molecular identity (Azim et al., 2009; Cederquist et al., 
2013). SCPN identity is initially masked by the co-expression of multiple subtype-specific 
markers of inter-hemispheric callosal projection neurons (CPN), including Satb2 (Alcamo et al., 
2008; Britanova et al., 2008; Azim et al., 2009; Woodworth et al., 2012; Chapter 2). Following 
continued maturation, Fezf2-expressing SCPN stably repress the expression of Satb2 and 
other markers of CPN identity. SCPN further resolve into distinct subtypes of projection 
neurons with laminar- and area-specific properties (Woodworth et al., 2012; Custo Greig et al., 
in editorial revision, 2013). While multiple molecular controls over the post-mitotic regulation of 
neocortical subtype refinement have been identified (Joshi et al., 2008; Lai et al., 2008; 
Tomassy et al., 2010; Miyoshi and Fishell, 2012; Cederquist et al., 2013), it is currently unclear 
how these subtype-specific post-mitotic refinements are regulated.  
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Multiple epigenetic mechanisms might help generate diverse neocortical subtypes and 
enable their refinement and maturation (Kishi and Macklis, 2004; MacDonald and Roskams, 
2008, 2009; Kishi et al., 2012; Yip et al., 2012). Importantly, neocortical subtype-specific 
mechanisms have been recently identified and are being investigated. First, Satb2, a required 
transcriptional control over callosal projection neuron (CPN) development, is a CPN-specific 
matrix-attachment region (MAR) binding protein with punctate intra-nuclear localization 
consistent with specific chromatin binding (Britanova et al., 2005; Gyorgy et al., 2008; Alcamo 
et al., 2008; Britanova et al., 2008); MAR binding proteins, such as Satb2, can mediate long-
range interactions of enhancer sites with promoters (Yasui et al., 2002; Cai et al., 2003; 
Dobreva et al., 2003). Second, Ski, a subtype non-specific transcriptional cofactor, binds Satb2 
in CPN and recruits the nucleosome remodeling and histone deacetylase (NuRD) complex 
(Baranek et al., 2012). Additionally, studies in non-neocortical cells have suggested epigenetic 
mechanisms for transcriptional regulators with roles in neocortical subtype-specific 
differentiation. The transcription factors Ctip2 and Ctip1 are differentially expressed in the 
neocortex, with specific roles in directing the precision of SCPN and CPN differentiation (Leid 
et al., 2004; Arlotta et al., 2005; Woodworth et al., unpublished data, 2013). These transcription 
factors have been demonstrated to interact with the NuRD complex (Topark-Ngarm et al., 
2006; Cismasiu et al., 2005) and Sirt1 (Senawong et al., 2003; Senawong et al., 2005) to 
mediate chromatin remodeling in non-neocortical cells. Together, these reports suggest that 
chromatin remodeling might contribute to the post-mitotic refinement of neocortical projection 
neuron subtypes, particularly in the refinement of Ctip2-expressing SCPN from Satb2-
expressing CPN. 
Embryonic stem (ES) cell-based models of neocortical differentiation are emerging as a 
useful tool to study the roles of chromatin modifications in neocortical development. For 
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example, in a recent genetic screen of ES-derived neocortical cells, Bcl6 was identified as a 
pro-neurogenic transcription factor that recruits the histone deacetylase Sirtuin1 within 
neocortical progenitors (Tiberi et al., 2012). In a related protocol of neocortical directed 
differentiation from ES cells, a broad histone deacetylase inhibitor, valproic acid, was shown to 
increase the population of neurons expressing Cux1, which, as a single marker in vitro, is 
potentially indicative of CPN identity (Juliandi et al., 2012). These studies suggest that ES-
derived neocortical cells can potentially identify epigenetic mechanisms of post-mitotic 
differentiation to bias differentiation toward specific post-mitotic fates. 
To specifically study SCPN post-mitotic refinement, I first hypothesized that the 
appropriately timed induction of Fezf2 in ES-derived neocortical progenitors might bias these 
cells toward SCPN fate. Fezf2 mis-expression by non-SCPN forebrain cell types (e.g., 
superficial layer neocortical progenitors, callosal projection neurons, or striatal medium spiny 
neurons) induces SCPN molecular identity within these cells and redirects their axonal 
projections to targets in the midbrain and hindbrain (Molyneaux et al., 2005; Chen et al., 2008; 
Rouaux and Arlotta, 2010; Rouaux and Arlotta, 2013; De la Rossa et al., 2013).  
Although Fezf2 is a versatile transcriptional regulator that can act in numerous forebrain 
subtypes, its potency is dependent on molecular context and timing. The expression of Fezf2 
is critically regulated by multiple Sox family transcription factors on upstream enhancer sites 
(Lai et al., 2008; Shim et al., 2012), and its transcriptional activity is likely regulated by specific 
cofactors in the molecular context of forebrain development. In the absence of these forebrain-
specific factors, Fezf2 mis-expression at early stages of ES cell differentiation does not drive 
SCPN molecular identity (Wang et al., 2011; Sadegh, unpublished data, 2011). By extension, 
incompletely specified ES-derived forebrain-like cells might not express the context-dependent 
factors needed for Fezf2-mediated fate specification.  
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While protocols for directing neocortical differentiation from ES cells have succeeded in 
replicating some of the molecular characteristics of neocortical development (Eiraku et al., 
2008; Gaspard et al., 2008), the enrichment and mature refinement of neocortical subtypes is 
incomplete (Chapter 2). These data suggest that ES-derived neocortical cells are unlikely to 
have a sufficiently permissive molecular context for Fezf2-directed differentiation of SCPN. 
I hypothesized that chromatin remodeling by incompletely specified ES-derived 
neocortical progenitors might promote a permissive molecular context for Fezf2 induction and 
directed SCPN subtype refinement. This concept of “epigenetic priming” (term coined by 
Scandura et al., 2011) is increasingly accepted as a strategy of partially reversing an 
epigenetically-repressed transcriptional state, as demonstrated by the neuronal reprogramming 
of germ cells in C. elegans (Tursun et al., 2011; Patel et al., 2012) and by the promotion of 
induced pluripotent stem (iPS) cell reprogramming (Papp and Plath, 2013). 
To identify candidate chromatin remodeling enzymes, I conducted a high-content 
screening experiment on ES-derived neocortical cells, using a library of small molecules that 
modulate known epigenetic enzymes. Importantly, I developed an assay to identify molecular 
refinement of distinct post-mitotic subtypes. 
From this screen, I identify the histone deacetylase Sirtuin1 (Sirt1) as a repressor of 
Fezf2-mediated SCPN refinements. Small molecule inhibitors of Sirt1 (e.g., EX-527, CHIC-35) 
help refine the identity of Ctip2-expressing SCPN from Ctip2/Satb2 co-expressing immature 
neocortical neurons in vitro. Moreover, I verify in vivo Sirt1 subtype specificity in post-mitotic 
neocortical projection neuron subtypes during late embryonic and early post-natal 
development. Together, these data implicate differential chromatin remodeling as an important 
epigenetic mechanism of neocortical subtype refinement both in vivo and for in vitro directed 
differentiation. 
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3.3 Results 
Synthetic modified mRNA induces transient and dose-dependent gene expression in ES-
derived neocortical-like cells 
 Synthetic modified mRNA (modRNA) enables precision over gene dosage and timing in 
a variety of mouse and human cell types (Warren et al., 2010). Because modRNA does not 
integrate into the genome and has a limited duration of expression (approximately 2 days), 
modRNA enables transient induction of genes with minimal disruption of ES-derived cells. This 
technology was powerfully demonstrated to reprogram fibroblasts to induced pluripotent stem 
(iPS) cells, and to direct the differentiation of myotubes from these iPS cells (Warren et al., 
2010). Other related modRNA technologies have also successfully generated dose- and time-
limited expression of proteins in vitro and in vivo (Angel and Yanik, 2010; Kormann et al., 2011; 
Petsch et al., 2012; Mays et al., 2013). 
 I investigated whether modRNA transfection results in time- and dose-sensitive protein 
expression by differentiating feeder-free E14Tg2a mouse embryonic stem (ES) cells in an 
established monolayer protocol that generates heterogeneous, maturation-limited, neocortical-
like neurons (Gaspard et al., 2008; Gaspard et al., 2009; Chapter 2). In agreement with the 
prior literature, I find a dose-dependent intensity of GFP expression after modRNA transfection 
of ES-derived cells at the peak of pallial-like differentiation at day 14; modRNA-induced GFP 
expression peaks between 12-24 hours, with sharp reduction of expression by 48hrs (Figure 
3.1A,B). I also find that modRNA transfection is not biased to a specific neural population; 
modRNA transfects Nestin-expressing neural progenitors, TuJ1-expressing neurons, and other 
cells (Figure 3.2). Overall, these data indicate that modRNA technology enables unbiased, 
dose- and time-dependent gene expression in ES-derived cells, including progenitors and 
neurons. 
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Figure 3.1. Synthetic modified RNA (modRNA) enables precision over gene dosage and 
timing in ES cell-derived populations, and is functional when expressed in vivo. (A) Native 
GFP expression is detected in 25-50% of cells after 24hrs; the intensity of expression is dose-
dependent, over the range of 0, 2, 4 ug modRNA transfection. (B) GFP mod-RNA expression is 
time-dependent over 48hrs. (C) In the brain of a viable mouse embryo within the uterus, GFP 
modRNA is injected into the forebrain lateral ventricles (cross-section is shown) and is 
directionally electroporated (five 50ms square-wave pulses at 30 V) into the pallium (positive 
paddle above dark blue colored tissue). (D) Following GFP modRNA in utero electroporation, 
GFP is expressed after eight hours, and is restricted to Ki67-expressing progenitors of the 
pallium. (E) Sagittal section of an E17.5 Fezf2-null mouse, following E12.5 in utero 
electroporation of Fezf2 modRNA (0.8ug/uL) and tdTomato plasmid (1ug/uL), shows targeted 
tdTomato fluorescence appropriately restricted to the rostral pallium. (F) Zoom showing 
tdTomato expression in the cortical plate. (G) As expected in the Fezf2-null mouse, many 
tdTomato axons project across the cerebral commissures, including anterior commissure 
(depicted) and corpus callosum in (E). (H) Strikingly, some tdTomato axons project caudal to 
the thalamus, indicating rescue of E12.5 SCPN. (I) A smaller subset of these tdTomato axons 
reaches the cerebral peduncle (N = 3).  
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Figure 3.1 (Continued)
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Figure 3.2: modRNA transfection is not biased to a specific neural population. (A) After 
24hrs, GFP modRNA transfects progenitors (Nestin-expressing, empty arrows), neurons (TuJ1-
expressing, filled arrows), and other cells. (B) GFP modRNA is expressed in Nestin-positive 
cells after three hours. (C) mCherry and GFP mod-RNA are co-expressed in the same cells. 
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Transient Fezf2 expression rescues SCPN in vivo within a stage-specific molecular 
context 
Prior to investigating the expression of Fezf2 in ES-derived neurons, I first asked 
whether in vivo Fezf2 expression by modRNA is functionally comparable to established 
protocols of Fezf2 expression by plasmid vectors. Specifically, with a single induction at a 
relatively low dose, I asked at what age of development is a transient pulse of Fezf2 sufficient 
to drive SCPN specification in vivo. To address this question, I hypothesized that transient 
Fezf2 modRNA expression by Fezf2-null neocortical progenitors rescues Fezf2-dependent 
SCPN differentiation. In Fezf2-null mice, E12.5 post-mitotic neurons do not differentiate into 
SCPN, and instead are re-specified to CPN; Fezf2-deficient neocortical neurons do not project 
axons caudal to thalamus. Fezf2 expression by plasmid electroporation in Fezf2 null mice at 
E12.5 can rescue normal SCPN specification and their projections to the distal hindbrain (Azim, 
2009, Dissertation). At E13.5, E15.5, and later ages, Fezf2 mis-expression by plasmid 
electroporation can redirect commissural neurons to SCPN targets in the hindbrain (Molyneaux 
et al., 2005; Chen et al., 2008; Rouaux and Arlotta, 2010; Rouaux and Arlotta, 2013; De la 
Rossa et al., 2013). 
I first assessed the extent of modRNA electroporation in vivo, and found that in utero 
electroporation of GFP modRNA into the pallium (Figure 3.1C) is limited to the mitotic (Ki67-
expressing) ventricular zone (Figure 3.1D). Next, in Fezf2 null mice at E12.5, I found that in 
utero electroporation of Fezf2 modRNA (with tdTomato plasmid for long-term visualization of 
axons; Figure 3.1E,F,G) rescues a subset of SCPN that project beyond the thalamus to the 
cerebral peduncle (Figure 3.1H,I), comparable to plasmid-mediated Fezf2 expression after the 
same number of days. In contrast, in utero electroporation of Fezf2 modRNA does not induce 
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SCPN at E15.5 (data not shown), possibly due to lower modRNA dosage (0.8ug/uL) or duration 
of expression (approximately 48hrs) as compared to Fezf2 plasmid electroporation. 
These data indicate that Fezf2 modRNA is functional within the molecular context of 
e12.5 neocortical progenitors. Importantly, a single transient dose of Fezf2 is sufficient to 
rescue Fezf2-null SCPN at E12.5; at later ages, a higher dose or duration of expression (as 
provided by a plasmid vector) is required for re-specifying alternate neocortical subtypes 
(Molyneaux et al., 2005; Chen et al., 2008; Rouaux and Arlotta, 2010; Rouaux and Arlotta, 
2013; De la Rossa et al., 2013). 
 
Transient Fezf2 expression alone minimally refines SCPN differentiation within ES-
derived neocortical-like neurons 
I next asked whether Fezf2 modRNA alone can induce SCPN-specific differentiation of 
ES-derived neocortical cells. I hypothesized that Fezf2-directed SCPN differentiation would be 
limited to the sparse population of ES-derived cells with an appropriate forebrain-specific 
molecular context. To assess the small population of ES-derived Ctip2- and Satb2-expressing 
neocortical-like neurons, I used randomized, automated imaging (at 20x magnification, on 
approximately 40 fields per well; ~5,000 cells), to count sufficient numbers of neocortical-like 
neurons for these analyses. A high threshold for positive antibody staining was manually 
established (compared to baseline staining without primary antibody) because populations of 
ES-derived neurons expressed a continuum of transcription factor staining intensities, in 
contrast to populations of primary dissociated E15.5 neocortical neurons, which displayed 
typically bimodal staining (low, high). Using this methodology, I found that 48hrs after Fezf2 
modRNA transfection in ES-derived neocortical cells at in vitro day 18, between time points of 
peak Nestin and TuJ1 expression, overall numbers of Ctip2- or Satb2-expressing neocortical 
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neurons are not increased (Figure 3.3A). Normally, Ctip2 expression occurs within 48hrs of 
Fezf2 expression (data not shown). Given the low dose and transient expression of Fezf2 
modRNA, the absence of statistically significant Ctip2 enrichment by a largely heterogeneous, 
immature, and incompletely specified population of ES-derived neurons (Chapter 2) is not 
surprising. 
I next hypothesized that transient Fezf2 modRNA expression biases subtype refinement 
toward SCPN among the relatively small fraction of pre-existing immature neocortical-like 
neurons, which are the cells most likely to have a permissive molecular context to respond to 
Fezf2. Specifically, I asked whether Fezf2 modRNA transfection increases Ctip2 expression at 
the expense of Satb2. Using the refinement of Ctip2 expression (ratio of Ctip2-only expressing 
cells to Ctip2/Satb2 dual expressing cells) as an indication of SCPN identity refinement, I found 
that Fezf2 + GFP promotes SCPN subtype refinement compared to GFP alone, though not 
with statistical significance (Figure 3.3A). Among Ctip2/Satb2 dual-expressing neocortical-like 
neurons transfected with Fezf2 and GFP, the average intensity of Ctip2 expression increases 
(though not with statistical significance), while average Satb2 expression is unchanged, 
compared to GFP alone (Figure 3.3B). These data suggest that a single, transient dose of 
Fezf2 is not sufficient to refine SCPN identity by ES-derived neurons with an immature 
neocortical-like molecular context. These data are consistent with the inability of a single Fezf2 
transfection to redirect E15.5 CPN axons to subcerebral targets in vivo (data not shown, see 
also Figure 3.1C-I). Therefore, the absence of statistically significant Fezf2 modRNA-mediated 
enhancement of SCPN differentiation within heterogeneous, maturation-stalled, ES-derived, 
neocortical-like neurons suggests that additional, potentially complementary manipulations are 
needed to more completely direct SCPN differentiation. 
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Figure 3.3. Fezf2 induction in ES-derived neurons does not significantly increase subtype 
distinction. (A) At 21 days in vitro (21DIV), the ratio of Ctip2 (Satb2 negative) neurons to 
Ctip2/Satb2 dual expressing neurons is increased by approximately 20% (though not with 
statistical significance) 48hrs after Fezf2 and GFP co-transfection (dark grey) relative to GFP 
transfection alone (light gray). Total number of Ctip2-expressing neurons is largely unaffected, 
whereas total Satb2-expressing and Ctip2/Satb2 dual expressing neurons decrease in number 
(though not with statistical significance). (B) The intensity of Ctip2 expression within Fezf2+GFP 
modRNA-treated neurons increases relative to GFP modRNA controls. Data are presented as 
mean +/- s.e.m. (N=3; approximately 5,000 cells per condition, from 40 randomly sampled 
fields at 20x magnification). 
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Small molecule screening of ES-derived neocortical-like neurons identifies Sirt1 
I next asked whether remodeling the epigenetic state might enable a higher proportion 
of neocortical-like neurons to respond to Fezf2-induced SCPN subtype refinement. To address 
this question, I designed a combined small molecule screening / Fezf2 induction approach: 
directed differentiation to day 14 neocortical progenitors; small molecule library addition to 
media for four days; Fezf2 modRNA transfection, followed by fixation after 48hrs (Figure 3.4A). 
I designed a custom library of eighty small molecules modulating known epigenetic enzymes, 
with targets including histone deacetylases, methyltransferases, and kinases (Figure 3.4B). 
Using automated imaging and threshold analyses, I quantified the expression of Ctip2 and 
Satb2 within individual neurons (Figure 3.4C,D). 
 I used multiple selection criteria to identify candidates. In the first assay, I found that 
multiple Sirtuin modulators enhanced or inhibited Fezf2-mediated subtype refinement, as 
indicated by the ratio of Ctip2(+)/Satb2(-) neurons to Ctip(+)/Satb2(+) neurons (Figure 3.5A). 
Focusing on the small molecules that enhanced Fezf2-mediated refinement of Ctip2(+)/Satb2(-) 
expression, I then asked which small molecules increased the number of Ctip2 expressing 
neurons, relative to Fezf2 induction alone (Figure 3.5B). Lastly, selecting for compounds that 
showed higher numbers of Ctip2-expressing cells, I asked which compounds maintained or 
decreased the number of Satb2 expressing neurons dependent on Fezf2 induction alone 
(Figure 3.5C). With these multiple criteria, the Sirt1 inhibitor EX-527 emerged as a top 
candidate regarding induction of molecular characteristics of SCPN. As an internal control, I 
compared the activity of EX-527 to other sirtuin inhibitors and activators. Non-specific sirtuin 
inhibitors (nicotinamide, forskolin, and tenovin-6) did not increase SCPN refinement. 
Conversely, the Sirt1-specific activator (CAY10591) displayed antagonism to SCPN refinement.   
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Figure 3.4: Design of high throughput screening protocol to assess subtype refinement 
within neurons. (A) Schematic of screening strategy in 96-well plates. Monolayer ES cell 
differentiation to telencephalic progenitors is followed by the addition of a custom small 
molecule library; composition of this library is described in (B). After small molecule incubation 
for six days, each well is transfected with Fezf2 modRNA. Two days later, cells are fixed and 
immunostained for Ctip2, Satb2, and Ctip1. Automated imaging and fluorescence intensity 
thresholding algorithms distinguish and count neurons; example of this in (C). 
(B) The composition of a custom set of 80 chemicals affecting histone deacetylases, 
methyltransferases, and kinases is depicted in this pie chart. 
(C) Automated imaging and counting algorithms identify Ctip2 and Satb2 expression levels. 
Manually determined thresholds distinguish [Ctip2(+) / Satb2(-)] neurons (pseudo-colored 
green) from dual expressing [Ctip2(+) / Satb2(+)] neurons (pseudo-colored yellow). 
(D) Thresholds for nucleus area and mean staining intensity were manually set using Columbus 
software (PerkinElmer). Examples are shown for the gating of high Ctip2 and low Satb2 
expression, with screenshots from the software. 
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Figure 3.4 (Continued)  
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Figure 3.4 (Continued) 
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Figure 3.5. High-content screen of SCPN molecular refinement by ES-derived neurons 
identifies candidate small molecules, including Sirt1 inhibitor EX-527.  
(A) Each well of a 96-well plate containing ES-derived neurons at 15 days was incubated with a 
distinct small molecule from the library (Figure 3.4B) for 96hrs, followed by transfection with 
GFP or Fezf2 modRNA, incubated for 48hrs, and finally fixed at 21 days in vitro (21DIV). 
Distinct small molecules enhanced or inhibited Fezf2-mediated SCPN subtype refinement, as 
indicated by the ratio of Ctip2(+)/Satb2(-) neurons to Ctip(+)/Satb2(+) neurons.  
(B) Some candidate small molecules, from marked box in (A), increase the number of Ctip2-
expressing neurons relative to Fezf2 induction alone.  
(C) Fewer candidate small molecules, from marked box in (B), decrease the number of Satb2-
expressing neurons relative to Fezf2 induction alone; these include Sirt1 inhibitor EX-527. 
Asterisks represent small molecules that modify HDAC Class III (Sirtuin). Black arrowheads 
represent GFP and Fezf2 transfection conditions, for comparison. Red arrowhead represents 
EX-527, a specific Sirt1 inhibitor. Data from this pilot experiment (N=1) are represented as a 
normalized ratio (approximately 1,000 cells per condition, from 40 randomly sampled fields at 
20x magnification). 
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Figure 3.5 (Continued)  
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Based on these data, using multiple subtype markers and selection criteria, I selected Sirt1 as 
a target for subsequent analysis. 
 
Sirt1 expression in vivo is CPN-subtype specific 
Because in vitro ES-derived neocortical-like neurons are incompletely specified and 
maturation-stalled (Chapter 2), I next asked whether in vivo Sirt1 expression is consistent with 
the results of the screening approach in ES-derived neurons. I used immunocytochemistry to 
assess Sirt1 protein localization in the developing neocortex. While Sirt1 expression is broadly 
distributed in the brain, as previously reported (Hasegawa and Yoshikawa, 2008; Michan and 
Sinclair, 2007; Qin et al., 2006), I hypothesized that its expression varies in distinct neocortical 
subtypes. Strikingly, I found that Sirt1 is differentially expressed in CPN and SCPN neocortical 
subtypes in vivo (Figure 3.6). Using wide-field fluorescence imaging on brain sections at P4, I 
found that Sirt1 is expressed throughout the rostro-caudal extent of the neocortex, in layers 
2/3, 6, and subplate (Figure 3.6A). Using confocal imaging, I found that, as early as E18.5, 
Sirt1 expression is subtype-specific, with near-complete co-localization with Satb2-expressing 
CPN and relative exclusion by Ctip2-expressing SCPN in layer V (Figure 3.6B). Again at P4, 
confocal imaging shows that Sirt1 expression is excluded from increasingly mature SCPN 
(Figure 3.6C). 
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Figure 3.6. Sirt1 is differentially expressed by CPN and SCPN in vivo. (A) At P4, immuno-
labeling indicates that Sirt1 is expressed along the entire rostral-caudal extent of the 
neocortex, in layers II/III, VI, and subplate (50um coronal section, wide-field fluorescence 
imaging). (B) At E18.5, Sirt1 expression in deep layers of motor cortex is mostly restricted to 
Satb2-expressing neurons and is absent or relatively low in Ctip2-expressing neurons (50um 
coronal section, confocal fluorescence imaging). (C) At P4, Sirt1 expression in deep layers of 
motor cortex is almost completely restricted to Satb2-expressing neurons (50um coronal 
section, confocal fluorescence imaging) 
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Figure 3.6 (Continued)  
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Figure 3.7: Sirt1 mRNA expression is CPN-specific in the neocortex at late embryonic and 
post-natal ages. (A) Sirt1 expression is higher in CPN (red lines) than in CSMN (blue lines) at 
E18.5, P3, P6, and P14; these populations were retrogradely labeled and isolated for 
comparative gene expression analysis at each time-point (data from Arlotta et al., 2005). (B) 
Other HDACs (e.g., HDAC1 and HDAC2) are not differentially expressed at all ages, using the 
same array data. 
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 I next asked whether Sirt1 is differentially transcribed in pure populations of retrograde-
labeled CPN versus corticospinal motor neurons (CSMN: a subtype of SCPN in layer V that 
project their axons to the spinal cord). The Macklis laboratory previously published microarray-
based comparative gene expression analysis of retrograde-labeled CPN and CSMN 
(Molyneaux et al., 2005). Using these data, I find that Sirt1 is the only differentially expressed 
histone deacetylase (HDAC) throughout post-mitotic neocortical differentiation at E18.5, P3, 
P6, and P14, with highest expression by CPN at all ages (Figure 3.7). Combined with the 
protein expression data in Figure 3.6, these findings show that Sirt1 protein and mRNA are 
specifically and highly expressed by Satb2-expressing CPN subtypes during corticogenesis, 
and are expressed at markedly lower levels by Ctip2-expressing SCPN, coinciding with all 
stages of subtype identity refinement. These in vivo findings support the CFuPN-specificity of 
Sirt1 from the screening approach in ES-derived neurons. 
 
Sirt1 inhibition refines E12.5 SCPN subtype identity 
Because ES-derived neocortical-like neurons have specific deficits in differentiation, 
and do not fully resemble primary neocortical neurons (Chapter 2), I next asked whether Sirt1 
inhibition also promotes SCPN subtype distinction within bonafide primary neocortical 
neurons. In this experiment, Fezf2 was not induced with modRNA, because Fezf2 is already 
highly expressed by primary SCPN progenitors. Dissociated E12.5 neocortical neurons were 
treated with small molecule inhibitors of Sirt1 for six days (compounds were dissolved in 
DMSO; importantly, experimental control samples were treated with matched volumes of 
DMSO, considering its reported enhancement of terminal differentiation in vitro in Chetty et al., 
2013). I again identify EX-527, and a more specific Sirt1 inhibitor, CHIC-35, as potent factors 
that increase Ctip2/Satb2 subtype distinction (Figure 3.8A). CHIC-35 is Sirt1-specific with a 
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binding site within the Sirt1 catalytic cleft that blocks substrate binding (Napper et al., 2005; 
Zhao et al., 2013). Compared to non-specific inhibitors, both EX-527 and CHIC-35 show highly 
selective enhancement of Ctip2 refinement (Figure 3.8A). 
To help determine whether Sirt1 inhibition broadly regulates SCPN subtype identity 
rather than only reducing Satb2 expression, I asked whether other subtype-specific 
refinements occur. Ctip1 is a transcription factor that regulates both subtype- and area-
specific identity. Despite its close homology to Ctip2, Ctip1 is initially co-expressed with Ctip2, 
but its expression later becomes restricted to CPN (Woodworth et al., unpublished data, 2013). 
Importantly, I find that Sirt1 small molecule inhibition promotes Ctip2/Ctip1 subtype distinction 
(Figure 3.8B). Based on both Ctip2/Satb2 and Ctip2/Ctip1 subtype distinction in the context of 
Fezf2 expression, these data indicate that Sirt1 inhibition refines neocortical subtype identity 
toward SCPN.  
Given the roles of Sirt1 in neural progenitor differentiation and neuronal survival 
(Prozorovski et al., 2008; Li et al., 2008; Tiberi et al., 2012; Hisahara et al., 2008), I next tested 
an alternative hypothesis that Sirt1 inhibition potentially alters the proportions of progenitors 
and neurons, giving an impression of post-mitotic subtype distinction while instead acting at 
the progenitor level. To the contrary, I find that the increase in proportion of Ctip2-expressing 
neurons is nearly completely compensated by the loss of Ctip2/Satb2 dual-expressing neurons 
(Figure 3.8A,B). Because the combined fraction of Ctip2- and Satb2-expressing neurons 
remains constant, it is unlikely that the subtype refinement phenotype is attributable to 
changes in the proliferation of neocortical progenitors. 
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Figure 3.8. Sirt1 inhibition in dissociated E12.5 neocortical neurons enhances CFuPN 
subtype refinement, increasing the number of Ctip2-expressing neurons at the expense 
of Ctip2/Satb2 dual expressing neurons. (A) EX-527 and a more specific Sirt1 inhibitor, 
CHIC-35, increase Ctip2/Satb2 subtype distinction relative to DMSO-only controls (0.5uM and 
5uM).  (B) The same trend holds for Ctip2/Ctip1 subtype distinction. (C) Although the relative 
proportions to DMSO control of total Ctip2- and total Satb2-expressing neurons do not change 
following the CHIC-35 Sirt1 inhibition, the relative proportion of Ctip2/Satb2 dual-expressing 
neurons decreases. In contrast, the relative proportion of [Ctip2(+)/Satb2(-)] neurons increases.  
(D) Pie chart schematics depict the relative proportions to total nuclei of Ctip2-only neurons, 
Satb2-only neurons, Ctip2/Satb2-dual neurons, and unlabeled cells derived from E12.5 
neocortical cells in the DMSO control versus CHIC-35 Sirt1 inhibition treatment conditions. 
Data are presented as mean +/- s.e.m. (N=3; >10,000 nuclei screened per condition from 60 
randomly sampled fields at 20x magnification).) *P < 0.05; **P < 0.01 (unpaired t-test). 
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 Although EX-527 and CHIC-35 are highly specific small molecule inhibitors of Sirt1 
(Zhao et al., 2013), to increase confidence that Sirt1 is the main target of repression, I pursued 
Sirt1-specific molecular knockdown with siRNA. I find that Sirt1 knockdown recapitulates the 
effect of small molecule inhibition of Sirt1, increasing both Ctip2/Satb2 and Ctip2/Ctip1 
subtype specific refinement (Figure 3.9). These results further support the conclusion that Sirt1 
inhibition enhances subtype specification toward SCPN.  
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Figure 3.9: siRNA knockdown of Sirt1 recapitulates the effect of small molecule inhibition 
of Sirt1. (A) Ctip2/Satb2 refinement increases with Sirt1 knockdown. (B) Consistent with 
multiple molecular refinements during neocortical projection neuron subtype distinction, 
Ctip2/Ctip1 refinement also increases with Sirt1 knockdown. Data are presented as mean +/- 
s.e.m. (N=3; >10,000 nuclei screened per condition, from 60 randomly sampled fields at 20x 
magnification).) *P < 0.05 (unpaired t-test).
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3.4 Discussion 
I identify Sirt1 as the first chromatin-remodeling enzyme that is differentially expressed 
by two neocortical projection neuron subtypes: low in subcerebral projection neurons (SCPN), 
and high in inter-hemispheric callosal projection neurons (CPN). Sirt1 is a widely expressed 
NAD-dependent histone deacetylase (HDAC) with context-dependent roles in multiple cell 
types (Michan and Sinclair, 2007; Haigis and Sinclair, 2010; Gräff and Tsai, 2013). Although 
previous studies have shown a layer-specific Sirt1 expression pattern in the neocortex at E14.5 
and adult ages (10 months post-natal), specific neocortical subtypes were not assessed 
(Hasegawa and Yoshikawa, 2008; Michan and Sinclair, 2007; Qin et al., 2006). Using multiple 
markers of neocortical subtypes in vivo, I find that neocortical SCPN specifically exclude Sirt1 
expression in mid- to late-corticogenesis, whereas Sirt1 is highly expressed by both deep and 
superficial layer CPN (Figure 3.6). This protein localization is verified by differential Sirt1 mRNA 
transcription in retrograde-labeled CSMN and CPN at post-mitotic stages of subtype identity 
refinement (Figure 3.7; Molyneaux et al., 2005). In contrast, multiple other HDAC enzymes do 
not show projection neuron subtype specificity in the neocortex (Figure 3.7; Molyneaux et al., 
2005; MacDonald and Roskams, 2008). 
The experimental screening approach used to identify Sirt1 was based on the 
hypothesis that early chromatin remodeling might enable Fezf2-mediated induction of SCPN 
identity within incompletely specified ES-derived neocortical progenitors. In support of this 
approach of “epigenetic priming” (Tursun et al., 2011; Patel et al., 2012; Gräff and Tsai, 2013; 
Papp and Plath, 2013), multiple lines of evidence indicate that Fezf2-mediated SCPN identity 
refinement (in vivo and in ES-derived neurons) requires a permissive molecular context during 
differentiation. First, transient Fezf2 expression is sufficient to generate SCPN in Fezf2-null 
mice at E12.5, and not at E15.5 (Figure 3.1). At later ages (E13.5 through P7), a higher dose or 
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duration of Fezf2 expression can re-specify alternate neocortical subtypes to SCPN identity 
(Molyneaux et al., 2005; Chen et al., 2008; Rouaux and Arlotta, 2013; De la Rossa et al., 2013). 
However, after E15.5, the mis-expression of Fezf2 does not induce Ctip2 expression in most 
neurons (Chen et al., 2008; Rouaux and Arlotta, 2013; De la Rossa et al., 2013), and does not 
repress Satb2 expression (Chen et al., 2008; De la Rossa et al., 2013). Together, these findings 
indicate that an optimal molecular context exists for the Fezf2-mediated specification of SCPN, 
induction of Ctip2 expression, and stable epigenetic silencing of Satb2 at approximately E12.5.  
These in vivo data emphasize the required specificity in the timing of Fezf2 expression 
and the importance of an optimal neocortical molecular context in vitro for Fezf2 to direct 
differentiation of ES-derived neurons. Fezf2 induction prior to neocortical differentiation among 
non-neocortical-like neurons does not induce SCPN identity (Wang et al., 2011; Sadegh, 
unpublished data, 2011). Moreover, when Fezf2 modRNA is induced at a time approximating 
E12.5 neocortical differentiation, it does not significantly increase SCPN subtype-specific 
transcription factor expression within ES-derived neocortical cells (Figure 3.3). These in vitro 
data indicate that, although timing is important, it is not sufficient to enable complete Fezf2-
mediated SCPN differentiation; incompletely specified and maturation-stalled ES-derived 
neocortical neurons are not an optimal molecular context (Chapter 2). Therefore, to enhance 
the context of Fezf2-directed differentiation, I pursued a high content screening approach to 
identify small molecule modifiers of chromatin structure. 
To identify a specific chromatin-remodeling enzyme that can enable Fezf2-mediated 
SCPN differentiation within maturation-stalled ES-derived neocortical cells, I screened diverse 
types of epigenetic modifiers (Figure 3.4). I then induced ES-derived cells with Fezf2 and 
assessed the extent of neocortical subtype identity refinement with multiple markers. From the 
initial pilot screening experiment (Figure 3.5), I find that the inhibition of Sirt1 preceding Fezf2 
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induction enhances SCPN identity refinement in ES-derived neocortical neurons. Within 
primary neocortical cells, I show that direct Sirt1 inhibition, by either small molecule or 
knockdown approaches in primary neocortical neurons, promotes mature molecular refinement 
of Fezf2-mediated SCPN identity (Figure 3.8, 3.9). These findings are consistent with SCPN 
subtype-specific Sirt1 exclusion (Figure 3.6), which temporally correlates with heightened 
post-mitotic Fezf2 expression. The data presented support the interpretation that Sirt1 down-
regulation is functionally important for the refinement of SCPN identity in vivo and useful for the 
refinement of ES-derived SCPN in vitro.  
  Although Sirt1-null mice have not yet been assessed for subtype-specific deficits in the 
neocortex, their gross neocortical anatomy (e.g. intact corpus callosum, absence of Probst 
bundles) appears intact (Cheng et al., 2003; McBurney et al., 2003; Michán et al., 2010), 
suggesting that Sirt1 is not required for CPN specification. Given that subtle subtype identity 
deficits might exist in Sirt1-null mice, any interpretations must take into account the multiple 
known functions of Sirt1 in neocortical differentiation. At a stage prior to subtype refinement, 
Sirt1 regulates neurogenesis within neocortical progenitors; Sirt1 is recruited to repress the 
Notch-Hes pathway to irreversibly promote neurogenesis despite persistent Notch signaling 
(Tiberi et al., 2012; Hisahara et al., 2008). Moreover, other critical chromatin modifiers 
theoretically required for CPN differentiation might compensate for Sirt1 loss of function by 
modifying the global chromatin state. 
 CPN are an evolutionarily more recent and diversified subtype of neocortical neurons, 
and likely employ multiple sequential epigenetic mechanisms in their specification, molecular 
refinement, and maturation (Molyneaux et al., 2009; MacDonald and Roskams, 2009; Kishi and 
Macklis, 2010; Fame et al., 2011). At late stages of maturation of layer 2/3 CPN (e.g. eight 
postnatal weeks), the widely expressed methyl binding protein MeCP2 is required for the 
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development and/or maintenance of dendritic complexity and soma size (Kishi and Macklis, 
2004, 2010). At earlier stages of CPN development, Satb2 is a required CPN-specific 
transcription factor that indirectly guides chromatin remodeling by binding to matrix 
attachment regions (MAR) and recruiting HDAC enzymes through a binding partner, Ski 
(Britanova et al., 2005; Britanova et al., 2008; Alcamo et al., 2008; Gyorgy et al., 2008; Baranek 
et al., 2012). Together, with varying extents of CPN-specificity, Sirt1, Satb2/Ski, and MeCP2 
might coordinate chromatin remodeling in CPN at distinct stages of development.  
The subtype-specificity of Sirt1 expression in the neocortex is also interesting because 
Sirt1 is implicated in the oxidative stress response and survival of neurons (Li et al., 2008; 
Prozorovski et al., 2008). This suggests that Sirt1-expressing CPN might be resistant to 
metabolic insults; conversely, it raises the possibility that reduced Sirt1 expression might 
increase SCPN sensitivity to metabolic stress and oxidizing conditions. SCPN and the 
subpopulation of corticospinal motor neurons are the neocortical neurons that selectively 
degenerate in amyotrophic lateral sclerosis (ALS; Ozdinler and Macklis, 2006; Zang and 
Cheema, 2002). In fact, Sirt1 over-expression has been shown to promote short-term neuronal 
survival in dissociated neocortical cells mis-expressing ALS associated mutant SOD1 (Kim et 
al., 2007). More broadly, non-specific HDAC inhibitors show neuro-protective properties in 
mouse models of ALS (Petri et al., 2006; Rouaux et al., 2007). Although highly speculative, 
these findings are consistent with SCPN vulnerability to metabolic stress. Given the multiple 
roles of Sirt1 in other cell populations, the full implications of its subtype specificity in the 
neocortex remain to be explored. 
Together, these findings strongly suggest a stage-specific role for Sirt1 in the 
differential molecular refinement of neocortical SCPN and CPN subtype identity. Despite 
widespread expression of Sirt1, these data implicate a subtype-specific mechanism of 
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regulation in neocortical projection neurons. Importantly, these findings demonstrate the utility 
of combining epigenetic priming with subtype-specific transcription factor induction in ES cell 
directed differentiation. This strategy provides a specific enhancement to protocols of directed 
SCPN differentiation. 
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3.5 Experimental Procedures 
 
Cell culture and differentiation 
 Murine embryonic stem cells: Feeder-free E14Tg2a (Baygenomics) mouse embryonic 
stem cells were propagated using standard procedures (Ying et al., 2003) on gelatin-coated 
(0.1% gelatin, StemCell Technologies) cell culture treated plastic dishes. Mouse embryonic 
stem cell media is GMEM (Invitrogen) supplemented with 10% ESC-certified fetal bovine 
serum (vol/vol, Invitrogen), 0.1 mM nonessential amino acids (Invitrogen), 1mM sodium 
pyruvate (Invitrogen), 0.1mM β-mercaptoethanol (Sigma), 50 U/mL penicillin/streptomycin and 
1000 U/mL leukemia inhibitor factor (ESGRO).  
 For differentiation, ES cells were plated at low density (5,000 cells/cm2) on gelatin-
coated plastic dishes in ES cell medium, and cultured as described (Gaspard et al., 2009). 
Briefly, ESCs were trypsinized, dissociated, and plated on gelatin-coated cell culture plates. 
Medium was changed to DDM after one day. DDM consists of DMEM/F12 (Invitrogen-Gibco) 
supplemented with N2 supplement (N2 supplement consists of 8.61uM insulin, 1mM 
transferrin, 2uM progesterone, 10mM putrescine and 3uM selenite; Invitrogen-Gibco), 2mM 
glutamine, 0.1 mM nonessential amino acids, 1mM sodium pyruvate, 0.5 mg/ml bovine serum 
albumin fraction V (all from Invitrogen-Gibco), and 0.1mM β-mercaptoethanol (Sigma).  
 Cyclopamine (Calbiochem) was added from day 2 to day 10 in the differentiation 
medium at a final concentration of 1uM. After 10 to 14 days of differentiation, cells were 
trypsinized, dissociated and plated on poly-lysine/laminin (Becton-Dickinson) coated glass 
coverslips and allowed to grow for 4–14 days in N2B27 medium. N2B27 medium consists of a 
1:1 mixture of DDM and Neurobasal that is supplemented with B27 (without vitamin A; 
Invitrogen-Gibco) and 2 mM glutamine. 
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Mice 
 All mice used in these experiments were handled according to guidelines of the 
National Institutes of Health (NIH), and all procedures were conducted with approval of the 
Institutional Animal Care and Use Committee (IACUC) of Harvard University. The date of 
vaginal plug detection was designated E0.5, and the day of birth as P0. Fezf2-null mice were 
the generous gift of S. McConnell (Chen et al., 2005). Wild-type CD1 mice were used in all 
other experiments (Charles River Laboratories). 
 
Immunocytochemistry 
 Mice were deeply anesthetized with a lethal dose of anesthetic (Avertin) or hypothermia, 
and perfused trans-cardially with phosphate-buffered saline (PBS), followed by 4% 
paraformaldehyde. Brains were removed, post-fixed overnight in 4% paraformaldehyde, rinsed 
with PBS, and sectioned coronally with 50µm thickness on a vibrating microtome (Leica). 
Sections were blocked in 1% BSA (Sigma), and 0.3% Triton X-100 (Sigma) for 1hr at room 
temperature before incubation with primary antibodies overnight at 4°C. Primary antibodies 
and dilutions used were: rat antibody to Ctip2 (1:500, Abcam), mouse antibody to Satb2 
(1:200, Abcam), rabbit antibody to Sirt1 (1:250, Millipore), rabbit antibody to Ctip1 (1:500, 
Abcam), rabbit antibody to GFP (1:500, Invitrogen), chicken antibody to Nestin (1:500, Novus 
Biologicals), mouse antibody to TuJ (1:500, Covance), mouse antibody to Map2 (1:500, Sigma), 
and mouse antibody to NeuN (1:250, Millipore). Alexa fluorophore conjugated secondary 
antibodies from Invitrogen were used at a dilution of 1:1000. Hoechst 33342 counterstain was 
used to visualize nuclei (1:3,000, Invitrogen). 
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Visualization and Analysis 
 Wide-field image acquisition was performed using a Nikon 90i epifluorescence 
microscope with a Clara DR-328G cooled CCD digital camera (Andor Technology, Belfast, 
Northern Ireland). Confocal imaging was performed with a BioRad Radiance 2100 Rainbow 
laser-scanning confocal microscope based on a Nikon E800 microscope. Images were 
assembled in Adobe Photoshop and Illustrator (CS3, CS5), with adjustments for contrast, 
brightness, and color balance to obtain optimal visual reproduction of data. 
 
High-content small molecule screening  
 High content screening protocol was adapted from (Makhortova et al., 2011). Briefly, ES 
cells were seeded at 5,000 cells per well in 96-well plates and treated in duplicate at 10 μM, 1 
μM and 0.1 μM with individual compounds from the screening library, a custom set of 80 
chemicals affecting histone deacetylases, methyltransferases, and kinases (Figure 3.4). These 
compounds were curated from the following chemical libraries: LOPAC1280 Collection (Sigma-
Aldrich), Spectrum Collection (Microsource Discovery Systems), Prestwick Chemical Library. 
EX-527 (Sigma), CHIC-35 (Sigma), and nicotinamide (Sigma) were re-suspended in DMSO, 
according to the manufacturer’s instructions.  
 Following immunostaining, 96-well plates were scanned by an automated confocal 
microscope (PerkinElmer Opera) at 20X magnification with separate fluorescence exposures 
from a UV light source and 488, 546, 647nM lasers. Image analysis was done using Columbus 
software (version 2.3.0; PerkinElmer; see also Figure 3.4C,D), which automatically set the 
boundaries of cell nuclei based on Hoechst staining. These boundaries were optimized by 
manual inspection to exclude nuclear fragments or adjacent double nuclei based on the total 
area and staining intensity of Hoechst-positive nuclei. Next, the intensity of antibody staining 
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for each distinct transcription factor in each nucleus was quantified. A high threshold for 
positive antibody staining was manually established compared to baseline staining without 
primary antibody, for Ctip2, Satb2, and Ctip1. Relatively high thresholds of positivity were 
established because populations of ES-derived neurons expressed a continuum of 
transcription factor staining intensities, in contrast to populations of primary dissociated E15.5 
neocortical neurons, which displayed typically bimodal staining (low, high).  
 
RNA synthesis and transfection 
 ModRNA was generated as per Warren et al. (2010). Briefly, RNA was synthesized with 
the MEGAscript T7 kit (Ambion, Austin, TX). A custom ribonucleoside blend was used 
comprising 6 mM 5’ cap analog (New England Biolabs), 7.5 mM adenosine triphosphate and 
1.5 mM guanosine triphosphate (USB, Cleveland, OH), 7.5 mM 5-methylcytidine triphosphate 
and 7.5 mM pseudo-uridine triphosphate (TriLink Biotechnologies, San Diego, CA). Reactions 
were incubated 3–6 hr at 37°C and DNase treated as directed by the manufacturer. RNA was 
purified with Ambion MEGAclear spin columns, then treated with Antarctic Phosphatase (New 
England Biolabs) for 30 min at 37°C to remove residual 5’ triphosphates. Treated RNA was re-
purified, quantitated by Nano-drop (Thermo), and adjusted to 100ng/mL working concentration 
by addition of Tris-EDTA (pH 7.0). Transfections of modRNA and multiple siRNA targeted 
against Sirt1 and Satb2 (both from Santa Cruz) were carried out with RNAiMAX (Invitrogen), as 
per the manufacturer’s instructions. 
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4.1 Abstract 
During development of the neocortex, many diverse projection neuron subtypes are 
generated under the relatively precise regulation of sequentially and transiently expressed 
molecular controls, centrally including transcriptional regulators. One major class of projection 
neurons, corticofugal projection neurons (CFuPN), sends axons to sub-cortical targets 
including thalamus, striatum, brainstem, and spinal cord. In recent years, a growing number of 
stage-specific transcriptional regulators that act sequentially to direct the progressive 
specification and differentiation of CFuPN have been identified. 
Existing protocols to generate neocortical-like neurons from embryonic stem (ES) cells 
are not directed toward the generation of specific classes, types, or subtypes of projection 
neurons; instead, an established monolayer protocol of ES cell differentiation relies on 
spontaneous generation of neocortical-like neurons, which I have shown to be heterogeneous 
and maturation-stalled (Chapter 2). 
By comparison to in vivo CFuPN development, I investigated whether the sequential 
and transient expression of “nested” forebrain, neocortex, and CFuPN-specific transcriptional 
regulators can progressively direct ES cells to acquire CFuPN identity in vitro. We applied 
synthetic modified mRNAs (modRNA), which are in vitro transcribed messenger RNAs with 
specific nucleotide substitutions to avoid innate cellular immune responses to foreign single-
strand RNA; modRNA have been demonstrated to powerfully function with a transient temporal 
course and controllable dosage of expression (Warren et al., 2010). 
Using modRNA to mimic the timing and dosage of gene expression during 
development, I show that sequential expression of twelve progressively CFuPN-specific 
transcription factors accelerates neurogenesis toward CFuPN phenotype in vitro. When micro-
transplanted into postnatal neocortex, these ES-derived, CFuPN-directed neurons 
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appropriately project their axons to ipsilateral thalamic and midbrain targets, and avoid 
inappropriate projections to the contralateral hemisphere. I tested rigorously for cell fusion with 
host CFuPN and find no evidence for it, based on numerous criteria, including: 1) progressive 
axon extension over the course of six days; 2) the corticofugal specificity of axonal projections; 
and 3) the relatively superficial position of transplanted neurons relative to host CFuPN. 
Together, these data provide evidence that developmentally informed molecular 
“programming” of ES-derived progenitors can direct and enhance their differentiation into 
desired neocortical neuron classes and subtypes. 
These results demonstrate the feasibility of sequentially and transiently expressing 
“nested” molecular controls over CFuPN development to direct the differentiation of one broad 
class of neocortical projection neurons. Refinements of this initial approach might enable 
increasingly specific directed differentiation of other classes, types, and subtypes of 
neocortical neurons. 
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4.2 Introduction 
Corticofugal projection neurons (CFuPN) are a broad class of neocortical neurons that 
send axonal projections from the neocortex to distal targets in the thalamus, midbrain, 
hindbrain, and spinal cord (Molyneaux et al., 2007). The recent delineation of progressive 
stages of neocortical and CFuPN subtype differentiation (Azim et al., 2009; Woodworth et al., 
2012) now makes it possible to raise the question of whether a simplified sequence of “nested” 
transcriptional regulators (Custo Greig et al., in editorial revision, 2013) might be sufficient to 
direct the differentiation of embryonic stem (ES) cells into CFuPN.  
As first exemplified by the generation of ES-derived spinal motor neurons (SMN), 
replicating appropriate levels of key morphogens associated with defined rostral-caudal and 
dorsal-ventral domains in vivo can be used to direct ES cell differentiation (Wichterle et al., 
2002). These regionally-specified ES-derived ventral spinal cord progenitors spontaneously 
give rise to heterogeneous motor column subclasses of SMN (Peljto and Wichterle, 2011).  
Multiple related protocols have modified this morphogen-based approach to instead 
direct rostral and dorsal differentiation to generate progenitors with pallial telencephalic 
characteristics; these ES-derived, pallial-like progenitors spontaneously generate highly 
heterogeneous neocortical-like neurons in vitro (Gaspard et al., 2008; Eiraku et al., 2008; 
Mariani et al., 2012; Shi et al., 2012; Nasu et al., 2012; Espuny-Camacho et al., 2013; Chapter 
2), potentially including mixed populations of sub-cortical CFuPN and inter-hemispheric 
callosal projection neurons (CPN), as assessed by bulk transplantation experiments (Gaspard 
et al., 2008; Espuny-Camacho et al., 2013).  
The spontaneous differentiation of ES-derived pallial progenitors recapitulates some, 
but not all, aspects of corticogenesis (Hansen et al., 2011). In particular, ES-derived neocortical 
progenitors and neurons, including CFuPN-like neurons (e.g., Ctip2 positive / Satb2 negative), 
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are incompletely specified and maturation-stalled (Chapter 2). These deficits pose distinct 
challenges to the generation of fully specified CFuPN. 
Several transcription factors are known to direct specification of CFuPN identity in vivo, 
but the expression of these controls in vitro has proved ineffective for CFuPN enrichment by 
ES-derived progenitors. For example, overexpression of CFuPN transcriptional regulators (e.g., 
Fezf2, (Molyneaux et al., 2005); Ctip2, (Chen et al., 2008); and Fezf1, (Eckler et al., 2011) can 
induce sub-cortical CFuPN specification in neocortical progenitors in vivo. The most potent of 
these genes, Fezf2, can additionally reprogram striatal medium spiny neurons, post-mitotic 
layer IV neurons, and post-mitotic callosal projection neurons to acquire multiple 
characteristics of CFuPN in vivo (Rouaux and Arlotta, 2010; Rouaux and Arlotta, 2013; De la 
Rossa et al., 2013). In striking contrast to in vivo misexpression, Fezf2 does not direct CFuPN 
specification when expressed early in ES cell differentiation protocols (Wang et al., 2011). 
However, I find that Fezf2, when expressed at later time points of ES cell differentiation, directs 
more mature CFuPN differentiation without increasing overall numbers of CFuPN (Chapter 3). 
Because many of the deficits I have identified among spontaneously-generated 
neocortical-like neurons, from an established protocol of ES cell differentiation, precede the 
generation of neurons and occur at the progenitor level (Chapter 2), my data collectively 
suggest the need for a more comprehensive approach to faithfully direct differentiation of ES 
cells into CFuPN, beginning at earlier progenitor stages of differentiation. I hypothesized that 
closely approximating multiple stages of CFuPN development, including neural induction, 
pallial specification, and post-mitotic subtype identity refinement, might more effectively direct 
mouse ES cells toward CFuPN identity.  
An emerging understanding of CFuPN differentiation by neocortical progenitors 
(Molyneaux et al., 2005; Chen et al., 2005; Azim et al., 2009; Shim et al., 2012) and post-mitotic 
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neocortical neurons (Weimann et al., 1999; Arlotta et al., 2005; Lai et al., 2008; Joshi et al., 
2008; Azim et al., 2009; Bedogni et al., 2010; McKenna et al., 2011) indicate a sequence of 
“nested” transcriptional regulators that might act synergistically to promote CFuPN 
differentiation (Woodworth et al., 2012; Custo Greig et al., unpublished data, 2013). 
Importantly, most of these developmental regulators are expressed transiently, sequentially, 
and with dose-dependence; these genes are only rarely maintained at later stages of 
development (e.g., Fezf2 is expressed in adult mouse neocortex, (Inoue et al., 2004; Molyneaux 
et al., 2005; Ozdinler et al., 2011).  
To best approximate the transient and sequential nature of CFuPN molecular 
development, I decided to express critical developmental transcriptional regulators using 
synthetic modified mRNA (modRNA; Warren et al., 2010). modRNA technology is especially 
well-suited for directed differentiation, as it enables greater precision for controlling the timing 
and dosage of critical transcriptional regulators; its transient and non-integrating 
characteristics make it suitable for short-duration, combinatorial, and stage-specific 
manipulations in a variety of cell types. In Chapter 3, I have previously demonstrated that Fezf2 
expression by modRNA can direct CFuPN differentiation both in vivo and in vitro (Chapter 3).  
In this chapter, I show that transient modRNA-based expression of twelve critical 
CFuPN transcription factors provided at five time points in vitro accelerates ES-derived 
neocortical neurogenesis, and directs differentiation of ES cells into CFuPN. When micro-
transplanted into the neocortical parenchyma, these ES-derived neurons send ipsilateral 
axonal projections to thalamic and midbrain targets, and appropriately do not innervate the 
contralateral hemisphere, indicating that they have acquired corticofugal identity. 
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4.3 Results 
Synthetic, modified mRNA enables time- and dose-dependent protein expression 
 Synthetic modified mRNAs (modRNA) are in vitro transcribed messenger RNAs with 
specific nucleotide substitutions to avoid innate cellular immune responses to foreign single-
strand RNA (Warren et al., 2010). The modRNA and expressed proteins are transient, normally 
degrading over 24-48hrs; sustained expression can be achieved with repeated daily 
transfection of cells, and expression levels are correlated with the dosage of transfected 
modRNA. 
 To investigate whether modRNA enables precise control over gene dosage and kinetics 
of expression in feeder-free E14Tg2a ES cell-derived neocortical-like progenitors, I first tested 
the transient expression of modRNA coding for GFP. Following cationic lipid-based modRNA 
transfection, GFP is expressed by 40-50% of total cells, and the intensity of native GFP 
expression is dose-dependent (0, 2, 4, 8ug modRNA; Figure 3.1). modRNA-induced GFP 
expression is also time-dependent, beginning expression as early as 3hrs, plateauing after 
24hrs, and decreasing in intensity by 48hrs, consistent with the published time course (Figure 
3.1). 
 To investigate whether modRNA transfection has cell type-specific tropism within 
feeder-free E14Tg2a ES cell-derived populations, I tested the expression of GFP modRNA 
specifically within progenitors or immature neurons. After 24hrs, GFP modRNA is expressed in 
both progenitors and neurons, as well as in other cells, without a discernible bias (Figure 3.2). 
Multiple modRNA are consistently expressed in the same cells (observed following co-
transfection of GFP and mCherry modRNA; Figure 3.2). 
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Sequential expression of modRNA-encoded developmental transcriptional regulators 
enriches for ES-derived neurons 
In order to pursue the strategy of directed differentiation by sequential and transient 
gene expression, we generated modRNA for each of twelve transcription factors selected on 
the basis of their critical functions during development (Table 4.1). Tau::GFP mouse ES cells 
(Wernig et al., 2002) were dissociated at low density on gelatin-coated plastic dishes following 
a well-characterized adherent cell culture protocol for generating neocortical neurons, as 
previously described (Gaspard et al., 2009; Chapter 2). Starting 24hr after initial plating, 
termed day 0, ES cells were given serum-free, defined differentiation medium (DDM) containing 
N2. These day 0 ES cells were immediately transfected with the first set of modRNA (Sox2, 
Lhx2, Pax6) to promote neural induction and pallial progenitor specification. 
The transcription factors Sox2, Lhx2, and Pax6 were selected for the earliest 
expression in ES cell culture because of their well-established roles in neural, pallial, and 
neocortical specification. At the earliest stage of embryonic development, Sox2 acts to 
suppress mesendoderm fates in the mouse blastocyst and human pluripotent stem cells 
(Keramari et al., 2010; Thomson et al., 2011; Sarkar and Hochedlinger, 2013); Sox2 can also 
induce neural stem cell-like identity in fibroblasts (Ring et al., 2012; Lujan et al., 2012). Sox2 
expression at E8.5 is required for proper pallial differentiation (Aota et al., 2003; Götz et al., 
1998; reviewed in Georgala et al., 2011). Lhx2 is also required for proper neocortical progenitor 
development at approximately E10, and, importantly, activates the expression of Hes1 in 
neocortical progenitors (Chou and O'Leary, 2013; Roy et al., 2013).  
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On day 2, prior to the addition of cyclopamine to the medium for dorsalization, I 
transiently expressed two pro-neurogenic pallial transcription factors, Ngn2 and NeuroD4. 
During neocortical development, Ngn2 is critical for induction of neurogenesis (Fode et al., 
2000; Schuurmans et al., 2004). NeuroD4 is a pallial-restricted Ngn2 transcriptional target and 
cofactor that accelerates transcription of Ngn2 target genes (Mattar et al., 2008). 
During the remainder of this protocol of directed differentiation, I sequentially 
expressed, at two-day intervals, sets of transcription factors corresponding to progenitor, 
immature post-mitotic, and mature post-mitotic stages of CFuPN development. The first set of 
transcription factors (Sox11, Sox4, and Fezf2), expressed on day 4, promotes CFuPN 
progenitor specification. Fezf2 is required for the specification of sub-cerebral CFuPN 
(Molyneaux et al., 2005; Chen et al., 2005). Sox11 and Sox4 are required for neocortex-specific 
expression of Fezf2 (Shim et al., 2012). The second set replicates immature post-mitotic 
CFuPN differentiation with co-expression of Ctip2, Tbr1, and Sox5; these transcription factors 
regulate the differentiation of distinct CFuPN subtypes. Subcerebral projection neurons (SCPN) 
express Fezf2 and Ctip2 more highly than Tbr1 and Sox5. Conversely, corticothalamic 
projection neurons (CThPN) express Tbr1 and Sox5 more highly; both of these transcription 
factors repress Fezf2 and SCPN identity (Tbr1, Bedogni et al., 2010; McKenna et al., 2011; 
Sox5, Lai et al., 2008; Shim et al., 2012). Although these transcription factors are co-expressed 
at early developmental time points, their expression refines to distinct subtypes during late 
corticogenesis (Azim et al., 2009; Woodworth et al., 2012; Custo Greig et al., in editorial 
revision, 2013). Our final, third set of transcription factors biases toward SCPN subtype 
specification by reinforcing the sustained expression of Fezf2 and Ctip2, with the additional 
expression of Otx1, which directs pruning of SCPN axonal projections (Weimann et al., 1999). 
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At the peak expression of Nestin-expressing neural progenitors, on day 14, these 
modRNA-treated, ES-derived cells were assessed for neuronal induction on the basis of 
Tau::GFP expression (Figure 4.1). ES-derived cells sequentially transfected with modRNA 
coding for all transcription factors (“12-mod”) show a large enrichment of Tau-expressing 
neurons relative to the untreated cells.  
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Figure 4.1. Sequential and transient induction of twelve transcription factors using 
modRNA enriches proportion of Tau-expressing, ES-derived neurons. (A) Tau::GFP mouse 
ES cells were differentiated for 14 days using an established monolayer protocol that 
generates pallial-like progenitors (Gaspard et al., 2009). (B) Following sequential transfections, 
totaling twelve modRNAs coding for forebrain, neocortex, and CFuPN transcription factors 
(Table 4.1), Tau::GFP mouse ES cells generate enriched numbers of GFP-expressing neurons 
(N = 4).  
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The complete sequence of twelve transcription factors optimally improves directed 
generation of ES-derived corticofugal neurons 
To further isolate which factors were essential for neuronal enrichment in our modRNA-
directed differentiation protocol, I selectively removed individual transcription factors and 
assessed the impact on the generation of neurons (data not shown). I find that early pro-
neural factors (especially Sox2, Ngn2, NeuroD4) are essential for a substantial fraction of the 
neuronal enrichment. Strikingly, removing the expression of late sets of transcription factors 
also diminished the neuronal enrichment, suggesting that the overall sequence could not be 
simplified to a smaller set of factors without compromising the quality of directed 
differentiation.  
Given that each transfection step does not target all cells, I asked whether neuronal 
enrichment might be improved with the fully penetrant delivery of all factors in all cells. To test 
this hypothesis, I devised an alternate positive-selection protocol to enrich for cells that 
received all twelve transcription factors. I first cloned puromycin resistance (PuroR) modRNA. 
Next, I assessed whether PuroR acutely and transiently protects transfected ES-derived cells 
during the application of puromycin antibtiotic (Figure 4.2). I find that PuroR lasts 
approximately 48hrs, consistent with the kinetics of most modRNA-expressed genes. These 
kinetics suggest that PuroR modRNA can be effectively used for positive selection of 
transfected cells. Addition of PuroR modRNA at each stage of the modRNA directed 
differentiation protocol would ensure that only cells that have received each set of transcription 
factors during progressive rounds of modRNA transfection will survive selection with 
puromycin. However, we find that this approach generates neurons at a similar density as we 
had previously observed, and could not be distinguished from neurons undergoing the original 
protocol (data not shown).  
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Figure 4.2. Transient expression of puromycin resistance gene acutely selects for 
transfected ES-derived cells following puromycin treatment. Wild-type mouse ES cells 
were differentiated using an established monolayer protocol that generates pallial-like 
progenitors (Gaspard et al., 2009). On the fourth day of differentiation, these cells were 
transfected with modRNA encoding GFP and/or Puromycin resistance (PuroR). Twelve hours 
following transfection, puromycin antibiotic was added to the medium. On the sixth day of 
differentiation, cells were fixed and immunolabeled for GFP. Panel on the left demonstrates 
puromycin-mediated cell death and loss of viable GFP-transfected cells, in the absence of 
PuroR. Panel on the right shows viability and puromycin-mediated selection of GFP / PuroR 
co-expressing cells following PuroR co-transfection.
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Micro-transplanted ES-derived project axons specifically to corticofugal targets 
 To assess whether “12-mod” treated ES-derived neurons have acquired corticofugal 
projection neuron class identity, I directly micro-transplanted the heterogeneous mix of ES-
derived neurons and other cells obtained at the end of our modRNA directed differentiation 
protocol into early postnatal mouse neocortex. These micro-transplantation experiments differ 
from previously published studies in two important respects. First, I micro-transplanted only 2-
3,000 cells in a total volume of ~50nL. In contrast, other groups injected a 100-fold larger 
number of ES-derived cells (Gaspard et al., 2008; Espuny-Camacho et al., 2013), which 
potentially obscures cell autonomous projection decisions by causing clumping and 
sequestration from the in vivo microenvironment. Because of the high enrichment of neurons in 
our differentiation protocol (Figure 4.2), there are enough neurons to observe axon outgrowth 
without FACS enrichment.  
Second, the depth of a single stereotactic injection was limited to the neocortical 
parenchyma. Avoiding the subcortical white matter and striatum enables transplanted neurons 
to project according to their intrinsic identity, rather than fasciculating with and following host 
projections, as occurs when embryonic neocortical cells are transplanted into the deep white 
matter (Fricker-Gates et al., 2002; Wuttke and Macklis, unpublished data, 2013). If transplanted 
more deeply into the dorsal striatum, the axonal projections of transplanted neurons become 
even more distributed, following multiple non-specific projection patterns (Magavi and Lois, 
2008). I defined strict a priori exclusion criteria, rejecting samples containing injections in the 
white matter (or deeper) from further analysis.  
 I first assessed non-modRNA-treated ES-derived neocortical cells as a control, and find 
that there are no projections in the pyramidal tract, though a few stray axons were found in the 
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midbrain (Figure 4.3). The differences between my current results and the original report 
showing specific visual/limbic axonal projections from large transplants of heterogeneous, ES-
derived neocortical-like neurons (Gaspard et al., 2008) include: 1) my protocol of 
transplantation avoids non-cell autonomous axon fasciculation; 2) my analyses were done 
within one week of micro-transplantation, rather than after 28 days in alternate protocols, 
which could have incorporated the continued neurogenesis of Tau::GFP-negative ES-derived 
progenitors or allowed potential axonal pruning.  
I next assessed the transplantation of “12-mod”-treated ES-derived neurons. Within 
three days of micro-transplantation into the postnatal neocortex, these modRNA-directed ES-
derived Tau::GFP neurons send numerous projections specifically toward the internal capsule, 
while axons in the corpus callosum are rare (Figure 4.4). By six days post-transplantation, the 
axonal processes of ES-derived transplanted neurons have continued along the pyramidal 
tract, reaching the midbrain (Figure 4.5). Strikingly few axon terminals are present in 
contralateral cortex. 
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Figure 4.3. Untreated, ES-derived neurons micro-transplanted in post-natal neocortical 
parenchyma do not project their axons along the pyramidal tract. Tau::GFP mouse ES 
cells were differentiated for 14 days using an established monolayer protocol that generates 
pallial-like progenitors and neocortical-like neurons (Gaspard et al., 2009). Six days following 
micro-transplantation into P0 neocortical parenchyma, I assessed the axonal projections of 
transplanted, ES-derived neurons. (A) Rare, ES-derived, Tau::GFP axons are identified in the 
striatum at P6. (B) Rare, ES-derived, Tau::GFP axons in caudal sections are not located in the 
cerebral peduncle at P6 (N=2 littermates). 
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Figure 4.3 (Continued)
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Figure 4.4. “12-mod”-treated, ES-derived neurons project their axons into the dorsal 
aspect of the internal capsule, three days following micro-transplantation in post-natal 
neocortical parenchyma. Tau::GFP mouse ES cells were sequentially transfected with a total 
of twelve distinct transcription factors (Table 4.1) over 14 days of differentiation, using an 
established monolayer protocol that generates pallial-like progenitors and neocortical-like 
neurons (Gaspard et al., 2009). Three days following micro-transplantation into P0 neocortical 
parenchyma, I assessed the axonal projections of transplanted, ES-derived neurons. (A) Large 
numbers of ES-derived, Tau::GFP axons are identified in the striatum at P3. (B) The somata of 
ES-derived, Tau::GFP neurons are locally-dispersed and largely restricted to Ctip2-negative 
upper layers. (C) The majority of ES-derived, Tau::GFP axons are fasciculated and enter the 
internal capsule, whereas rare axons are found in the corpus callosum and contralateral 
neocortex. (N=2 littermates) 
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Figure 4.4 (Continued)
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Figure 4.5. “12-mod”-treated, ES-derived neurons project their axons along the 
pyramidal tract and enter the cerebral peduncle, six days following micro-transplantation 
in post-natal neocortical parenchyma. Tau::GFP mouse ES cells were sequentially 
transfected with a total of twelve distinct transcription factors (Table 4.1) over 14 days of 
differentiation, using an established monolayer protocol that generates pallial-like progenitors 
and neocortical-like neurons (Gaspard et al., 2009). Six days following micro-transplantation 
into P0 neocortical parenchyma, I assessed the axonal projections of transplanted, Tau::GFP 
ES-derived neurons. (A) Whole-mount immunofluorescence shows a single transplantation site 
in the neocortex. (B) Coronal section at the transplantation site reveals large numbers of ES-
derived, Tau::GFP axons entering the internal capsule; only rare axons enter the contralateral 
neocortex. (C) 160um caudal to injection site, Tau::GFP axons are present in the dorsal internal 
capsule and avoid the contralateral cortex. (D) Caudal section shows Tau::GFP axons in the 
pyramidal tract, innervating thalamus. (E) Tau::GFP axons are localized within the pyramidal 
tract of the cerebral peduncle. (N=2 littermates)
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Figure 4.5 (Continued) 
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Micro-transplanted ES-derived neurons do not fuse with endogenous CFuPN 
 Early-stage ES-derived cells and ES cells themselves have been shown to fuse with 
primary neurons under specific conditions in vitro and in vivo (Ying et al., 2002; Cusulin et al., 
2012). Similarly, fusion reportedly occurs between CNS-derived multi-potent neural progenitor 
cells (NPCs) in vitro (Chen et al., 2006) and between NPCs and host neocortical neurons in vivo 
(Brilli et al., 2012). In contrast, this phenomenon has not been observed after the 
transplantation of more mature, dissociated embryonic neocortical neurons into mouse 
neocortex or striatum (Fricker-Gates et al., 2002; Gaillard et al., 2007; Magavi and Lois, 2008; 
Wuttke and Macklis, unpublished data, 2013). 
I investigated this theoretical possibility rigorously, and find that fusion is highly unlikely 
in my transplantation experiments, for the following reasons. First, the relative abundance of 
axons in the internal capsule compared to the corpus callosum; projection patterns would be 
expected to more closely resemble those of host neurons in the event of fusion, and two to 
three times as many host neurons project across the corpus callosum than in the internal 
capsule (Figure 4.4, Figure 4.5). Second, differentiation of ES-derived neurons progressively 
unfolds over the course of six days; if fusion had occurred, gradual growth of axons along the 
pyramidal tract would not have been observed. Third, the position of micro-transplanted 
neurons was mostly in the upper layers, so the bias toward corticofugal neurons cannot be 
explained by fusion with neurons at the transplantation location. Fourth, expression of Ctip2 is 
detectable only in rare cells; many more ES-derived neurons would be expected to be Ctip2-
positive if fusion had occurred (Figure 4.6). 
To more rigorously exclude the possibility of cell fusion, I conducted a two-color 
transplantation experiment in which Tau::GFP ES-derived neurons were transplanted into a 
Rosa26::tdTomato mouse. I find that none of the transplanted neurons acquire expression of 
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tdTomato (data not shown). While these experiments do not completely rule out the possibility 
of rare fusion events, such low frequency events could not account for the corticofugal 
projections from ES-derived neurons.  
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Figure 4.6. Ctip2 is not expressed by most “12-mod”-treated, ES-derived neurons, six 
days following micro-transplantation in post-natal neocortical parenchyma. Tau::GFP 
mouse ES cells were sequentially transfected with a total of twelve distinct transcription factors 
(Table 4.1) over 14 days of differentiation, using an established monolayer protocol that 
generates pallial-like progenitors and neocortical-like neurons (Gaspard et al., 2009). Six days 
following micro-transplantation into P0 neocortical parenchyma, I assessed the expression of 
Ctip2 and Satb2 by transplanted, ES-derived neurons, and show one Tau-expressing neuron 
with a corticofugal axon that co-expresses Ctip2 and does not co-express Satb2; all other 
neurons were negative for both Ctip2 and Satb2 (N = 25 isolated intraparenchymal neurons).
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4.4 Discussion 
 I have assessed whether the sequential and transient expression of multiple 
transcriptional regulators over CFuPN development can direct the differentiation of mouse ES 
cells into CFuPN. My results show that this approach accelerates neurogenesis in a previously 
established monolayer protocol of heterogeneous, neocortical-like differentiation (Gaspard et 
al., 2008; Chapter 2; Figure 4.2). When micro-transplanted into neocortical parenchyma, a 
significant proportion of these modRNA-treated neurons are CFuPN-like, specifically directing 
their axonal projections to distinct targets in the thalamus, striatum, and pyramidal tract 
consistent with at least two types of CFuPN: corticothalamic and subcerebral projection 
neurons (Figure 4.5). 
My findings indicate the first substantial enrichment of a single broad neocortical class 
(CFuPN) derived from mouse ES cells, as assessed by micro-transplantation. Refinements of 
this initial approach might enable increasingly specific directed differentiation of other classes, 
types, and subtypes of neocortical neurons. In contrast, prior reports using the monolayer 
protocols of morphogen-based pallial-like progenitor specification have generated 
heterogeneous populations expressing characteristics of neocortical-like neurons (Gaspard et 
al., 2008; Mariani et al., 2012; Shi et al., 2012; Espuny-Camacho et al., 2013; Chapter 2).  
Previous efforts to generate CFuPN have focused on the transcription factor Fezf2, a 
“master” regulator of sub-cortical CFuPN (SCPN) specification (Molyneaux et al., 2005; Chen 
et al., 2005; Chen et al., 2008; Shim et al., 2012). However, increasing evidence suggests that 
Fezf2 requires a specific molecular context to fully activate CFuPN molecular identity 
(including, but not limited to, Ctip2 expression) and to fully repress CPN molecular identity 
(e.g., Satb2), both in vivo (Chen et al., 2008; Rouaux and Arlotta, 2013; De la Rossa et al., 2013) 
and in vitro (Chapter 3; Wang et al., 2011). I have previously shown that the molecular identity 
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of ES-derived neocortical-like neurons is incompletely specified, resulting in stalled neocortical 
maturation (Chapter 2). I have also shown that Fezf2 expression, when preceded by CFuPN-
specific epigenetic priming (Sirt1 inhibition), helps refine CFuPN molecular identity, but cannot 
enrich its quantity (Chapter 3). 
Because deficits in early neocortical differentiation are observed using previously 
published morphogen-based protocols (Chapter 2), my novel modRNA-based approach 
begins at the earliest stages of ES cell differentiation and neural induction, in order to promote 
more uniform progenitor differentiation. The major molecular pathways chosen for this 
approach recapitulate a schematized progression through major milestones of CFuPN 
development (Molyneaux et al., 2007; Woodworth et al., 2012) (Table 4.1). 
Synthetic modified mRNA (modRNA) technology enables greater precision over 
transient gene dosing than is available with similar methods such as transfection (Warren et al., 
2010; Chapter 2). In contrast to alternate methods of gene expression, this modRNA-based 
approach has several advantages. First, transient expression enables the expression of a 
temporally restricted sequence of transcription factors normally active during neural tube 
differentiation. Second, the co-expression of multiple modRNAs permits stoichiometric gene 
dosing, which can be used to further optimize this protocol in the future. Third, the kinetics of 
modRNA expression and degradation are consistent with near-physiological ranges and 
oscillations of gene dosing. For example, multiple regulators of neocortical differentiation are 
expressed in a cyclical or cell cycle-dependent manner (e.g., Notch/Hes, Ngn2, and Nestin; 
Kageyama et al., 2008; Sunabori et al., 2008). Additionally, several transcription factor controls 
are known to regulate differentiation in a dose-dependent manner (e.g., Pax6, Sox2, and 
Otx1/2; Schedl et al., 1996; Manuel et al., 2007; Georgala et al., 2011; Kopp et al., 2008; 
Acampora et al., 1999). Fezf2, Sox5, Ctip2, and Tbr1 are likely also dose-sensitive during 
 130 
neocortical development, on the basis of expression analysis (Molyneaux et al., 2005; Lai et al., 
2008; Arlotta et al., 2005; Bedogni et al., 2010; McKenna et al., 2011), and on the basis of 
observed phenotypic abnormalities in heterozygous mice, particularly for Ctip2 and Fezf2 
(Arlotta et al., 2005; Galazo and Macklis, unpublished data, 2013). Finally, for reasons that are 
still unclear, in comparison to virus-mediated reprogramming, modRNA more quickly and 
efficiently induces reprogramming (Warren et al., 2010); I speculate that this might result from 
near-physiologic gene dosing. 
Moreover, transient gene dosing might promote stable and high fidelity subtype identity 
acquisition. Neurons that are already committed to alternate fates are unlikely to be 
reprogrammed by transient gene expression; multiple lines of evidence suggest that above-
physiological transgene levels are required to override a stable transcriptional network 
(Hochedlinger and Plath, 2009; Ladewig et al., 2013). The constitutive misexpression of 
normally transiently expressed transcription factors frequently generates hybrid cell types, 
owing to residual epigenetic marks from the original cell type (reviewed in Vierbuchen and 
Wernig, 2012, 2011). For example, hepatocytes converted to neuron-like cells by constitutive 
expression of Mash1, Brn2, and Myt1l maintain residual expression of hepatocyte-specific 
genes (Marro et al., 2011); fibroblasts converted to dopaminergic neuron-like cells, by 
constitutive expression of Mash1, Nurr1, and Lmx1a also maintain numerous transcriptional 
differences when compared to authentic midbrain dopaminergic neurons (Caiazzo et al., 2011). 
I speculate that ES cells at a transitional developmental stage might be most appropriately 
biased toward an endogenously stabilized neuronal identity with transient gene dosing.  
This modRNA approach does not target all cells; since the penetrance of transfection is 
approximately 40-50% (lower than the reported 80-90% within fibroblasts; Warren et al., 2010), 
most cells receive an incomplete complement of factors (Figure 4.1). This likely explains why 
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all factors appear to contribute to the enrichment of neurons (Figure 4.3). However, the 
incomplete expression of factors likely does not inhibit the enrichment of neurons. When ES-
derived cells that receive all factors are selected by sequential puromycin dosing (Figure 4.4), 
the proportion of Tau-expression is comparable to the unselected condition (Figure 4.4). 
In addition to this novel strategy of directed differentiation, I utilize micro-
transplantation as a highly rigorous approach for assessment of ES-derived neocortical axonal 
projection subtype identity (adapted from (Wuttke and Macklis, unpublished data, 2013). In 
contrast to prior protocols of transplantation into postnatal animals that examined the 
transplantation of many cells into the neocortical white matter, I injected very small numbers of 
neurons into relatively superficial neocortical parenchyma. I made these protocol changes 
because large clumps of cells can mask neuronal identity by enabling non-specific axonal 
projections along nearby white matter tracts (Gaspard et al., 2008; Espuny-Camacho et al., 
2013). In addition, even small numbers of transplanted cells placed in the deeper subcortical 
white matter and the striatum result in exuberant, non-specific projections within the white 
matter (Magavi and Lois, 2008). This micro-transplantation approach provides substantially 
refined phenotypic and functional analysis of ES-derived neurons. 
Fusion does not account for the neuronal projection patterns of ES-derived 
transplanted neurons. First, micro-transplanted neurons robustly projected axons only as far as 
the dorsal aspect of the internal capsule after 3 days, and the number of axons entering the 
midbrain at 6 days was similar. This growth pattern is most consistent with transplant-derived 
axon extension. Second, GFP-positive axons in the corticofugal tract were more abundant, 
relative to innervation of contralateral cortex. Given that contralateral cortical innervation is 
significantly more abundant by native cortical neurons, these data are most consistent with 
transplant-derived axons preferentially projecting to corticofugal targets. Third, the position of 
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micro-transplanted neurons was mostly in the upper layers, so the bias toward corticofugal 
neurons cannot be explained by fusion with neurons at the transplantation location. Fourth, 
when transplanting Tau::GFP neurons into a Rosa26::tdTomato mouse, no transplanted 
neurons expressed tdTomato; this does not exclude rare fusion events, but such events cannot 
account for the observed axonal projections. 
The absence of Ctip2 expression in micro-transplanted ES-derived neurons is striking 
(Figure 4.6; and data not shown). This expression profile is inconsistent with normal CFuPN 
development. However, there is a substantial precedent for Ctip2-deficient CFuPN-directed 
reprogramming (Chen et al., 2008; Rouaux and Arlotta, 2013; De la Rossa et al., 2013). Given 
simplified media and differentiation conditions, I speculate that ES-derived CFuPN might 
harbor multiple molecular deficits. It remains to be explored what other molecular distinctions 
exist between ES-derived CFuPN and the corresponding types and subtypes of CFuPN in vivo.  
Overall, these findings indicate that the delineation of distinct transcriptional cascades 
in CFuPN development permits a rational approach to directed differentiation of mouse ES-
derived neurons to CFuPN. Sequentially expressing transient developmental programs might 
be essential for the optimal specification of neuronal subtypes that continue to post-mitotically 
refine their identity over an extended period, which is theoretically necessary for precise 
neocortical development. By providing critical transcriptional cues, and allowing endogenous 
responses to execute cell fate specification, this modRNA-based approach helps ensure the 
proper development of ES-derived CFuPN. Further refinements to this protocol (e.g., 
epigenetic priming, Chapter 3; or modified dosing or composition of specific transcription 
factors) might enable the specification of more precisely defined projection neuron subtypes, 
including the clinically important population of corticospinal motor neurons. This modRNA-
based approach to directed neocortical subtype differentiation might be easily and safely 
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applied to directed differentiation of human pluripotent cell types.  
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4.5 Experimental Procedures 
 
Cell culture and differentiation 
 Murine embryonic stem cells: Feeder-free E14Tg2a (Baygenomics) mouse ES cells 
were propagated using standard procedures (Ying et al., 2003) on gelatin-coated (0.1% gelatin, 
StemCell Technologies) cell culture treated plastic dishes. Tau-GFP knock-in ES cells (gift of 
Kerry Tucker, University of Heidelberg) were routinely propagated on mitotically inactivated 
mouse embryonic fibroblasts (Millipore) on gelatin-coated cell culture treated plastic dishes. 
 Mouse embryonic stem cell media is GMEM (Invitrogen) supplemented with 10% ESC-
certified fetal bovine serum (vol/vol, Invitrogen), 0.1 mM nonessential amino acids (Invitrogen), 
1mM sodium pyruvate (Invitrogen), 0.1mM β-mercaptoethanol (Sigma), 50 U/mL 
penicillin/streptomycin and 1000 U/mL leukemia inhibitor factor (ESGRO).  
 For differentiation, ES cells were plated at low density (5,000 cells/cm2) on gelatin-
coated plastic dishes in ES cell medium, and cultured as described (Gaspard et al., 2009). 
Briefly, ESCs were trypsinized, dissociated, and plated on gelatin-coated cell culture plates. 
Medium was changed to DDM after one day.  
 DDM consists of DMEM/F12 (Invitrogen-Gibco) supplemented with N2 supplement (N2 
supplement consists of 8.61uM insulin, 1mM transferrin, 2uM progesterone, 10mM putrescine 
and 3uM selenite; Invitrogen-Gibco), 2mM glutamine, 0.1 mM nonessential amino acids, 1mM 
sodium pyruvate, 0.5 mg/ml bovine serum albumin fraction V (all from Invitrogen-Gibco), and 
0.1mM β-mercaptoethanol (Sigma).  
 Cyclopamine (Calbiochem) was added from day 2 to day 10 in the differentiation 
medium at a final concentration of 1uM. After 10 to 14 days of differentiation, cells were 
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trypsinized, dissociated and plated on poly-lysine/laminin (Becton-Dickinson) coated glass 
coverslips and allowed to grow for 4–14 days in N2B27 medium.  
 N2B27 medium consists of a 1:1 mixture of DDM and Neurobasal that is supplemented 
with B27 (without vitamin A; Invitrogen-Gibco) and 2 mM glutamine. 
 
Visualization and Analysis 
 Wide-field image acquisition was performed using a Nikon 90i epifluorescence 
microscope with a Clara DR-328G cooled CCD digital camera (Andor Technology, Belfast, 
Northern Ireland). Confocal imaging was performed with a BioRad Radiance 2100 Rainbow 
laser-scanning confocal microscope based on a Nikon E800 microscope. Images were 
assembled in Adobe Photoshop and Illustrator (CS3, CS5), with adjustments for contrast, 
brightness, and color balance to obtain optimal visual reproduction of data. 
 
RNA synthesis and transfection 
 modRNA was generated as per (Warren et al., 2010). Briefly, RNA was synthesized with 
the MEGAscript T7 kit (Ambion, Austin, TX). A custom ribonucleoside blend was used 
comprising 6 mM 5’ cap analog (New England Biolabs), 7.5 mM adenosine triphosphate and 
1.5 mM guanosine triphosphate (USB, Cleveland, OH), 7.5 mM 5-methylcytidine triphosphate 
and 7.5 mM pseudo-uridine triphosphate (TriLink Biotechnologies, San Diego, CA). Reactions 
were incubated 3–6 hr at 37C and DNase treated as directed by the manufacturer. RNA was 
purified with Ambion MEGAclear spin columns, then treated with Antarctic Phosphatase (New 
England Biolabs) for 30 min at 37C to remove residual 5’ triphosphates. Treated RNA was 
repurified, quantitated by Nano-drop (Thermo), and adjusted to 100ng/mL working 
 136 
concentration by addition of Tris-EDTA (pH 7.0). modRNA transfections were carried out with 
RNAiMAX (Invitrogen), as per manufacturer’s instructions. To minimize the toxicity of repeat 
transfection, the lipofectamine-containing media was replaced with DDM after 4-5hrs. 
 
Mice 
 All mice used in these experiments were handled according to guidelines of the 
National Institutes of Health (NIH), and all procedures were conducted with approval of the 
Institutional Animal Care and Use Committee (IACUC) of Harvard University. The date of 
vaginal plug detection was designated E0.5, and the day of birth as P0. Rosa26::tdTomato 
mice were acquired from Jackson Laboratories. Wild-type CD1 mice were used in all other 
experiments (Charles River Laboratories). 
 
Transplantation into early postnatal neocortex 
 ES-derived cells were concentrated to a density of approximately 100 million cells per 
mL. P0-P1 mice were deeply anesthetized on ice for 3-4 minutes. A small incision in the skull 
was made with a needle. Cells were delivered using a digitally controlled nanoinjection system 
(Nanoject Variable, Drummond) via a glass micropipette with an outer diameter of 80-100 µm. 
Approximately 5-6 single injections of 4.6nL volume (total: 20-30nL; ~2,000 cells) were placed 
at multiple depths in a single tract, no deeper than 100um below the pial surface, positioned 
1mm lateral and 1mm rostral to bregma. Only sample brains that did not have white matter 
injections were included in the analyses.  
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Immunocytochemistry 
 Mice were deeply anesthetized with a lethal dose of anesthetic (Avertin) or hypothermia, 
and perfused trans-cardially with phosphate-buffered saline (PBS), followed by 4% 
paraformaldehyde. Brains were removed, post-fixed overnight in 4% paraformaldehyde, rinsed 
with PBS, and sectioned coronally with 50µm thickness on a vibrating microtome (Leica). 
Sections were blocked in 1% BSA (Sigma), and 0.3% Triton X-100 (Sigma) for 1hr at room 
temperature before incubation with primary antibodies overnight at 4°C.  Cells were fixed in 
4% paraformaldehyde (wt/vol) for 30 min and washed three times in phosphate-buffered saline 
(PBS) before incubation with blocking reagent and primary antibodies for 1hr. Primary 
antibodies and dilutions used were: rat antibody to Ctip2 (1:500, Abcam), mouse antibody to 
Satb2 (1:200, Abcam), rabbit antibody to Ctip1 (1:500, Abcam), rabbit antibody to GFP (1:500, 
Invitrogen), rabbit antibody to Ki67 (1:500, Abcam), chicken antibody to Nestin (1:500, Novus 
Biologicals), mouse antibody to TuJ (1:500, Covance), mouse antibody to Map2 (1:500, Sigma), 
and mouse antibody to NeuN (1:250, Millipore). Alexa fluorophore conjugated secondary 
antibodies from Invitrogen were used at a dilution of 1:1000. Hoechst 33342 counterstain was 
used to visualize nuclei (1:3,000, Invitrogen). 
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Chapter 5 
 
Discussion
 140 
5.1 Overview 
 
During neocortical development, diverse projection neuron classes, types, and 
subtypes are generated under temporal and spatial regulation of cell-extrinsic and cell-intrinsic 
molecular controls (Molyneaux et al., 2007; Fame et al., 2011; Woodworth et al., 2012; 
MacDonald et al., in press; Custo Greig et al., in editorial revision, 2013). Neocortical projection 
neurons can be broadly classified into two groups: corticofugal projection neurons (CFuPN) 
and commissural projection neurons, which primarily include callosal projection neurons (CPN). 
CFuPN are the primary output neuron population of the neocortex, and their axons innervate 
sub-cortical targets including thalamus, striatum, brainstem, and spinal cord. In contrast, the 
axons of CPN comprise the corpus callosum, which bridges the two cerebral hemispheres. 
Together, CFuPN and CPN account for the vast majority of neocortical projection neurons; 
included within each of these distinct classes of neurons are potentially hundreds of neuronal 
subtypes intermixed in distinct neocortical layers and areas, with distinct axonal targets.  
In this dissertation, I introduce multiple approaches that apply an emerging 
understanding of neocortical development both to evaluate and direct mouse embryonic stem 
(ES) cell differentiation to CFuPN, the primary output neurons of the neocortex. Although ES 
cells are theoretically competent to generate CFuPN in vitro, existing ES cell differentiation 
protocols are not directed toward specific classes, types, or subtypes of neocortical projection 
neurons and instead rely on the spontaneous generation of neurons with neocortical-like 
characteristics. In Chapter 2, after successfully replicating these established protocols, I 
present experimental results indicating that these spontaneously-generated ES-derived 
neocortical-like neurons are heterogeneous, immature, and “stalled” at a stage roughly 
equivalent to mid-embryonic differentiation in vivo. In Chapter 3, I build on this foundation to 
promote CFuPN-specific differentiation among these “stalled” neocortical-like neurons, using a 
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combination of recently developed synthetic modified mRNA (modRNA) and high-content 
chemical screening technologies. Finally, in Chapter 4, I direct differentiation of ES cells to 
CFuPN by sequentially and transiently expressing critical forebrain, neocortex, and CFuPN-
specific transcription factors. When micro-transplanted into neonatal neocortex, these ES-
derived neurons appropriately innervate corticofugal targets in the thalamus and midbrain. 
Overall, using these biological and technical approaches, I rigorously characterize and then 
successfully enhance the directed differentiation of ES cells into CFuPN. 
In this final chapter of my dissertation, I critically review my experimental findings and 
discuss topics of directed differentiation that have broad relevance to the field, including: 1) 
commonalities of maturation defects in many in vitro protocols of directed differentiation, 
potentially owing to “confusion” of molecular identity; 2) potential mechanisms causing 
immature or “confused” in vitro differentiation; and 3) strategies for directed differentiation of 
clinically important subtypes (e.g. CSMN) within the broad class of CFuPN. Together, these 
topics delineate the broader challenges and long-term applications of my work for in vitro 
neurodegenerative disease modeling, particularly toward developing new treatments for 
amyotrophic lateral sclerosis (ALS) and spinal cord injury (SCI). 
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5.2. Maturation deficits in protocols of ES cell directed differentiation 
 
 Neocortical projection neuron classes, types, and subtypes undergo distinct molecular 
refinements under the sequential control of transcriptional regulators at progenitor and post-
mitotic stages of development (Woodworth et al., 2012; Custo Greig et al., in editorial revision, 
2013). In the absence of transcriptional regulators that control this refinement, precise 
molecular identity, laminar/areal positioning, and/or projection patterns of neocortical 
projection neuron subtypes are disrupted in vivo. Critical transcriptional controls, therefore, are 
promising candidates for both rigorous characterization of in vitro ES-derived neocortical-like 
neurons and for CFuPN-directed differentiation. Recent advances in the largely spontaneous 
differentiation of ES cells recapitulate some, but not all, aspects of corticogenesis. These 
protocols are largely based on the sequential expression of single genes characteristic of 
neocortical neurons (Hansen et al., 2011).  
 My experiments in Chapter 2 and Chapter 3 are the first to systematically assess 
multiple stage-specific characteristics of neocortical differentiation in vitro, and my findings 
identify distinct deficits of these ES-derived pallial-like progenitors and neocortical-like 
neurons. These conclusions are based on the results of four inter-related experiments. First, 
ES-derived pallial-like progenitors are more heterogeneous than their in vivo counterparts and 
seemingly include many incorrectly specified progenitors (e.g., heterogeneous expression of 
pallial and forebrain transcriptional regulators Pax6, Sox6, and Otx2; Figure 2.2). Second, ES-
derived neurons are not uniformly or completely mature, but some display crucial hallmarks of 
early maturation (e.g., TuJ1, Map2, NeuN), roughly equivalent to neocortical neurons in vivo at 
E16.5-E18.5 (Figure 2.4). Third, these immature neocortical-like neurons co-express multiple 
critical transcription regulators (e.g., Tbr1, Ctip2, Satb2, Ctip1), consistent with the broad co-
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expression of these genes by immature neocortical projection neurons at an equivalent in vivo 
stage of mid-corticogenesis (Figure 2.3; Figure 2.5). Fourth, these “stalled” neocortical-like 
neurons appropriately co-express some, but not all, post-mitotic controls over area-specific 
differentiation (e.g., CoupTF1, Bhlhb5, Ctip1), which potentially indicates deficits in area-
specific neocortical differentiation (Figure 2.6). My findings support the conclusion that ES-
derived neocortical-like neurons generated by an established monolayer protocol most closely 
resemble in vivo neocortical neurons stalled at mid-corticogenesis and display features of 
incomplete neocortical specification.  
One of the more striking implications of incomplete neocortical neuronal specification is 
that the molecular context of ES-derived neocortical-like neurons is not sufficiently permissive 
for SCPN specification by transient modRNA-based Fezf2 expression (Figure 3.3). In contrast, 
the molecular context of in vivo pallial progenitors is sufficiently permissive for SCPN 
specification by transient modRNA-based expression of Fezf2 at E12.5 (Figure 3.1E-I). These 
data presented in my dissertation (Chapter 3) and in the existing literature (Wang et al., 2011) 
strongly indicate that a sufficiently permissive molecular context of differentiation is critical to 
enable Fezf2-directed CFuPN differentiation in vitro and further highlight the insufficient 
specification and maturation of these populations of heterogeneous ES-derived neocortical-like 
neurons. 
 
Specification and maturation defects are broadly reported in the field of directed differentiation 
Deficits in the differentiation ES cells to mature neuronal populations are commonly 
observed in the broader field of directed differentiation. These maturation deficits are 
hypothetically due to simplified media conditions and to a potentially common biology of 
neuronal specification. For example, neocortical projection neurons are not the only neuronal 
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population that displays increasingly restricted expression of subtype-specific transcription 
factors during maturation in vivo; indeed, spinal motor neurons (SMN) follow a similar process 
of refinement and diversity generation (Jessell, 2000; Dasen and Jessell, 2009; Alaynick et al., 
2011). Initially, early post-mitotic SMN express the transcription factors Hb9, Islet1, and Lhx3 
(Sharma et al., 1998). With continued maturation and position-dependent differentiation 
(Sürmeli et al., 2011), expression of each transcription factor becomes progressively restricted 
to distinct SMN subtype identities, including medial, lateral, and hypaxial motor column 
subtypes. However, in vitro subtype-specific molecular refinements by heterogeneous ES-
derived SMN are not distinct at early, immature stages of differentiation (Wichterle et al., 2002; 
Soundararajan et al., 2006; reviewed in Peljto and Wichterle, 2011).  
 More broadly, incomplete neuronal differentiation has been documented in protocols of 
largely spontaneous ES cell differentiation into retinal tissue and spinal cord nociceptors 
(Eiraku et al., 2011; Nakano et al., 2012; Chambers et al., 2012). The remarkable differentiation 
of ES cells into self-organizing optic cup and retinal tissue recapitulates most aspects of retinal 
differentiation; however, photoreceptors within the spontaneously differentiated retina do not 
form the external rod segment and are not functional (Eiraku et al., 2011; Nakano et al., 2012). 
Similarly, human ES-derived nociceptors recapitulate multiple in vivo molecular and 
physiological characteristics, but the vast majority of these neurons in vitro are not responsive 
to capsaicin (Chambers et al., 2012), a hallmark of mature nociceptors. Maturation deficits are 
also observed after directed differentiation of non-neuronal cell types; for example, established 
protocols for the directed differentiation of pancreatic islet beta cells generate endocrine cells 
that co-express glucagon and insulin, resembling immature precursors in vivo (Rezania et al., 
2012). 
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Remarkably, distinct features of neuronal maturation that are temporally correlated in 
vivo appear to be dissociable and independently regulated in vitro. For example, ES-derived 
SMN that are immature with regard to their expression of multiple subtype markers are, 
paradoxically, sufficiently mature to target their axons to the ventral spinal nerve root and form 
synapses at neuromuscular junctions (Wichterle et al., 2002; Peljto and Wichterle, 2011). 
Similarly, in ES-derived nociceptors, relatively mature physiology in the absence of capsaicin 
response reflects potentially uncoordinated maturation that is not normally observed in vivo 
(Chambers et al., 2012). In light of these data, the simultaneous expression of CoupTF1 and 
Ctip1, and the absence of Bhlhb5 in ES-derived neocortical-like neurons (Figure 2.6) could 
alternatively be interpreted as a relatively mature area-specific phenotype, entirely dissociable 
from early-stage maturation deficits indicated by other metrics. 
Together, these examples suggest that distinct aspects of neuronal maturation might 
be independently regulated, posing additional challenges for the refinement of these protocols 
and the interpretation of results. Moreover, these examples reflect the increasingly 
substantiated view that in vitro environments pose multiple challenges for ensuring the 
appropriate maturation of ES-derived neurons. Though these deficits are a potentially major 
barrier to the directed differentiation of distinct neuronal subtypes, their identification might 
guide future refinements of these protocols. 
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5.3. Maturation-stalled neurons are potentially “confused” 
 
Judging from the typically exceptional specificity of neuronal subtype involvement in 
specific neurodegenerative diseases, particularly ALS (e.g., CSMN/SCPN in the brain, along 
with SMN in the spinal cord), the utility of directed differentiation for studying pathologic 
mechanisms and potential therapies hinges on its close approximation to in vivo development. 
Similarly compelling arguments maintain that directed differentiation to near-biological 
equivalents of neocortical neurons is critical to sufficiently model the basic biology of 
corticogenesis in vitro (Gaspard and Vanderhaeghen, 2010; Tiberi et al., 2012). 
Therefore, a major unanswered question, broadly relevant in the field, is whether or not 
there exist in vivo equivalents to some of these heterogeneous, maturation-stalled, ES-derived 
neocortical-like neurons. If not, the possibility remains that these ES-derived neurons, rather 
than “stalling” an appropriate developmental trajectory of maturation, are somehow “confused” 
with regard to molecular and functional identity and therefore might not be useful for 
neocortical neuronal subtype-specific disease modeling.  
Increasingly, characterizations of ES cell directed differentiation protocols, exemplified 
by my findings and related findings by other groups, are consistent with the interpretation that 
neuronal identities can be potentially “confused” during spontaneous in vitro ES cell 
differentiation in culture. To help understand the nature of such developmental defects, it is 
useful to consider a popular model for differentiation in the field, called Waddington’s 
‘epigenetic landscape’ model, based on the work of C.H. Waddington (1957) (reviewed in 
Hochedlinger and Plath, 2009). In the Waddington model, a ball rolling down a hilly landscape 
represents the trajectory and progressive restriction of cell fate determination; the landscape 
encompasses a complex mix of stochastic and directed mechanisms of sequential cell fate 
 147 
determination. Theoretically, this landscape could be altered, as might occur during the 
absence or mis-expression of specific transcriptional regulators, ultimately leading neurons 
down alternative developmental trajectories that would never occur in vivo and therefore 
appear “confused.”  
Questions about the fidelity of neocortical neuronal identity acquisition are increasingly 
relevant to the recent field of “direct reprogramming” to induced neuronal (iN) cells (reviewed in 
Vierbuchen and Wernig, 2011; Yang et al., 2011). These iN cells can be generated by 
reprogramming non-neural mitotic cells, including heterogeneous embryonic tissue 
(Vierbuchen et al., 2010), albumin-expressing liver cells (Marro et al., 2011), or human 
fibroblasts (Pang et al., 2011), using constitutive high expression of normally transiently 
expressed pro-neural transcription factors (see also: Son et al., 2011; Caiazzo et al., 2011). Not 
surprisingly, terminal differentiation is often incomplete, owing to residual epigenetic marks 
from the original cell type (Marro et al., 2011; Vierbuchen and Wernig, 2011; Caiazzo et al., 
2011; Sadegh, unpublished data, 2012). Therefore, iN cells are likely “confused,” seemingly 
lacking in vivo equivalents.  
The possibility of in vitro ES-derived neuronal identity “confusion” is further supported 
in vivo by the identification of mixed neocortical neuronal molecular identities in vivo following 
the disruption of critical transcriptional regulators. For example, Sox5 is a post-mitotic 
determinant of the timing of CFuPN subtype acquisition; in its absence, normally early-born 
subplate neurons and CThPN shift their axonal projection patterns to resemble later-born 
SCPN, while maintaining “hybrid” expression of layer-specific markers (Lai et al., 2008; Kwan 
et al., 2008). Similarly, in the absence of Ctip1, Foxg1 or CoupTF1, the timing of neuronal entry 
into the cortical plate can be stalled, with late-arriving neurons adopting mixed laminar and 
subtype identities (Miyoshi and Fishell, 2012; Alfano et al., 2011; Woodworth et al., 
unpublished data, 2013). Finally, as discussed in Chapter 3, the overexpression of Fezf2 in 
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alternate neuron populations in vivo does not completely specify SCPN fate; these “hybrid” 
SCPN-like neurons do not activate the expression of Ctip2, nor fully repress the expression of 
Satb2 (Rouaux and Arlotta, 2010; Rouaux and Arlotta, 2013; De la Rossa et al., 2013). While 
the relevance of “hybrid” neocortical neuronal differentiation in disease modeling is unclear, it 
seems reasonable to question the present utility of potentially “confused” neurons and instead 
focus on developing refined protocols of differentiation. 
Alternately, if ES-derived neocortical-like neurons closely resemble equivalent type(s) of 
neurons in vivo, one might speculate that in vitro differentiation conditions somehow bias 
neuronal differentiation toward theoretically transient or unknown subpopulations of 
neocortical neurons. This argument has been previously invoked to explain discrepancies 
between the differentiation of human retinal development and ectopic photoreceptor 
progenitors in human ES-derived retinal tissue (Nakano et al., 2012). Importantly, there are 
precedents in neocortical biology for transient neuronal populations expressing characteristic 
markers of multiple neocortical subtypes, including subplate neurons (Hoerder-Suabedissen et 
al., 2009; Ayoub and Kostovic, 2009) and Cajal-Retzius cells. Cajal-Retzius cells, in particular, 
are marked by the expression of Reelin and Tbr1, are generated in the periphery of the pallium, 
migrate within the neocortex, and occupy layer I until their apoptosis by the end of the first 
postnatal week (Soriano and Del Rio, 2005). Ultimately, it is difficult to argue in support of the 
hypothesis that seemingly “confused” ES-derived neocortical-like neurons represent a rare or 
transient in vivo equivalent neuronal population, in the absence of a comprehensive molecular 
taxonomy of neocortical neuronal subtypes. Moreover, the usefulness of these hypothetically 
transient or rare neuronal populations for subtype-specific biological and disease modeling 
would still be in question.  
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5.4. Potentially aberrant mechanisms of cell-intrinsic and cell-extrinsic CFuPN 
differentiation 
 
Chromatin remodeling in ES-derived neocortical subtype refinement 
During the sequential and progressive generation of neocortical projection neuron 
classes, types, and subtypes, the refinement and maturation of neocortical progenitors and 
post-mitotic neurons are progressively shaped by multiple epigenetic changes, including 
histone remodeling, histone methylation, DNA methylation, and regulation by non-coding RNA 
(reviewed in MacDonald and Roskams, 2009; Shimomura and Hashino, 2013). The roles of 
histone deacetylases have been identified in multiple forebrain cell types, including retinal 
subtypes (Chen and Cepko, 2007), and in neocortical neurons (Kishi and Macklis, 2004; 
MacDonald and Roskams, 2008). As discussed in Chapter 3, a number of neocortical subtype-
specific transcriptional regulators (e.g., Ctip2, Satb2, Ski) can directly interact with chromatin 
remodeling enzymes, implicating epigenetic mechanisms for neocortical subtype specification.  
Taking advantage of the concept of “epigenetic priming” (reviewed in Papp and Plath, 
2013) as an approach to generate a more permissive molecular context prior to Fezf2-directed 
differentiation, I screened a small library of compounds that modulate chromatin remodeling 
enzymes. I identify Sirt1 as the first chromatin-remodeling enzyme that is differentially 
expressed by two neocortical projection neuron subtypes in vivo: low in subcerebral projection 
neurons (SCPN), and high in inter-hemispheric callosal projection neurons (CPN) (Chapter 3). 
Moreover, Sirt1 is functional in the differential molecular refinement of neocortical SCPN and 
CPN subtype identity (Figure 3.8, Figure 3.9) and can enhance Fezf2-mediated SCPN directed 
differentiation of ES cells (Figure 3.5). My findings suggest that directed chromatin remodeling 
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potentially bypasses some of the deficits of ES-derived neocortical-like differentiation identified 
in Chapter 2 and discussed in Section 5.3.  
 
Aberrant chromatin modifications might hinder CFuPN specification 
A growing understanding of chromatin remodeling mechanisms enables a potential 
mechanistic understanding for the sequential and “nested” differentiation of forebrain, 
neocortical, and CFuPN progenitors (Woodworth et al., 2012; Custo Greig et al., in editorial 
revision, 2013; Chapter 4). In ES cell differentiation, promoters of transcriptional regulators 
important for neocortical development are marked with “bivalent domains,” which consist of 
hybrid (mix of active and repressive) histone modifications that are “poised” for activation; 
these bivalent domains ultimately resolve their histone modifications to an either completely 
active or completely repressed state (Bernstein et al., 2006; Azuara et al., 2006). The nested 
differentiation of CFuPN might be explained by the important role of “pioneer” transcription 
factors, which can occupy promoters harboring bivalent domains and maintain the poised 
state until these loci are fully activated during later stages of differentiation (e.g., in 
hematopoietic differentiation, Oguro et al., 2010; reviewed in Zaret and Carroll, 2011). These 
mechanisms of poised histone modifications might enable the maturation of neocortical 
subtypes. 
To address whether bivalent domains are involved in the differentiation of mouse ES 
cells to neural fates, Bernstein, Lander, and colleagues at the Broad Institute confirmed the 
resolution of such bivalent domains in the neural differentiation of mouse ES cells (Mikkelsen et 
al., 2007), using an embryoid body protocol that spontaneously generates Nestin/Pax6 co-
expressing, non-telencephalic progenitors under the maintenance of EGF/FGF (Conti et al., 
2005). When ES cells are differentiated to neural precursor cells, multiple highly methylated 
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promoter regions (e.g., including Sox2, Lhx2, Pax6, Sox6, CoupTF1) transition from having 
bivalent, “poised,” domains to fully active sites; other promoter regions (e.g., Ctip2, Satb2) are 
partially-active sites; lastly, some promoter regions (e.g. Fezf2, Ctip1, Bhlhb5, Otx1, Emx1) 
transition from bivalent domain to repressed sites. These changes are accompanied by 
proportional changes in the dose of gene expression (Mikkelsen et al., 2007, Supplementary 
Figure 5). Although these findings are consistent with my findings of incomplete neocortical 
specification by ES cells (Chapter 2, Chapter 3), because these data were acquired in a non-
telencephalic protocol of differentiation, the interpretations cannot be fully extended to 
neocortical development. However, recent evidence suggests that similar bivalent domains 
exist at the stage of E11.5 neocortical progenitors, specifically in the regulation of Ngn1 
expression (Onoguchi et al., 2012), raising the possibility that these mechanisms are indeed 
acting in neocortical development and potentially responsible for deficits in protocols of 
directed differentiation. 
I speculate that during the directed differentiation of ES cells into maturation-stalled 
neocortical-like neurons, many of these “poised” histone modifications might not resolve to 
active sites. Importantly, deficits in these mechanisms are useful to understand why ES-
derived cells, following spontaneous differentiation, might not have a sufficiently permissive 
molecular context for directed differentiation. In this dissertation, I have demonstrated that 
broad, non-specific manipulation of chromatin remodeling in ES cell differentiation (e.g., 
valproic acid; Juliandi et al., 2012) might potentially be replaced by more focal chromatin 
remodeling strategies (e.g. SCPN-specific Sirt1 inhibition; Chapter 3). In the future, further 
refinements to this approach might identify critical “pioneer” transcription factors that can 
recruit poised transcriptional domains and direct differentiation of neocortical neuronal 
subtypes (e.g., by expression of CFuPN transcriptional regulators; Chapter 4). 
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Absence of critical factors and post-translational modifications might hinder CFuPN 
differentiation 
As a consequence of deficits in ES-derived neocortical-like neuronal molecular context 
and chromatin remodeling (Chapter 3), I speculate that Fezf2-specific cofactors are absent 
following monolayer ES cell telencephalic differentiation. The most striking evidence for Fezf2 
context dependence is the requirement of Sox11 and Sox4 for the neocortex-specific 
expression of Fezf2 (Shim et al., 2012). Borrowing from examples in neocortical development, 
multiple cofactors might be required to form complexes that enable specific transcriptional 
activity. For example, the absence of either component of the transcriptional repressor 
complex containing Bhlhb5 and Prdm8 remarkably results in similar corticospinal tract defects 
(Joshi et al., 2008; Ross et al., 2012). In the absence of a full complement of transcriptional 
cofactors, one might bypass this requirement by “engineering” the ability of a single 
transcription factor to directly activate or repress its transcriptional targets in the absence of 
cofactors. Such a strategy, involving the fusion of direct activator or repressor domains, has 
been previously used to dissect Ngn2 functions (Kovach et al., 2012). Hypothetically, if Fezf2 
induces SCPN identity by cofactor-dependent repression of Fezf2 downstream targets, the 
“direct” repression of its targets might enable cofactor-independent induction of SCPN. 
However, preliminary data for the in utero mis-expression of chimeric Fezf2 proteins, fused to 
direct activator or repressor domains, suggests that the role of Fezf2 in promoting SCPN 
identity is neither completely based on repression or activation and likely requires distinct 
cofactors (Sadegh, unpublished data, 2011). 
In addition, post-translational modifications (e.g. phosphorylation, SUMOylation) of 
critical transcription factors might be important for the regulation of subtype specification, and 
possibly for directed CFuPN differentiation. For example, Ngn2 has multiple phosphorylation 
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sites, the regulation of which determines its role in morphology or neuronal specification (Hand 
et al., 2005; Ma et al., 2008). Moreover, the SUMOylation of Ctip2, shown in hippocampal 
neurons (Tirard et al., 2012), and Satb2, in non-neocortical cells (Dobreva et al., 2003), might 
be important for regulating precise subtype specification in the neocortex. Thus, these post-
translational modifications of critical transcriptional regulators are potentially useful for the 
assessment of appropriate neocortical neuronal specification from ES cells. 
 
Extrinsic factors important in neocortical subtype differentiation  
 Given the incomplete progenitor specification, neuronal maturation, and subtype-
specific neocortical differentiation from spontaneous ES cell differentiation by an established 
monolayer protocol (Chapter 2), multiple deficiencies might account for faulty differentiation. 
Numerous cell-extrinsic factors are required for neocortical development in vivo (reviewed in 
Tiberi et al., 2012). Among these factors, a number of them are subtype-specific. First, the 
well-studied endo-cannabinoid signaling pathway has been recently identified to be critical for 
the maintenance of Ctip2 expression in layer V; CB1 receptor null mice resemble the Ctip2 null 
mice, with loss of expression and defasciculation of CSMN, whereas mice lacking a major 
cannabinoid-degrading enzyme display increased expression of Ctip2 in deep neocortical 
layers (Diaz-Alonso et al., 2012). Second, IGF-1 is specifically required for extension, but not 
branching, of CSMN axons (Ozdinler and Macklis, 2006); moreover, multiple other factors, 
including IGF-2 and BDNF, enhance the survival of cultured CSMN (Dugas et al., 2008). Finally, 
mutant mice lacking choroid plexus have a reduction in Ctip2-expressing layer V neurons 
(Johansson et al., 2013). This phenotype is striking because it suggests that one or more of 
multiple growth factors secreted in the CSF (e.g. IGF-1, IGF-2; Lehtinen et al., 2011) are 
critically important for the molecular refinement of CFuPN identity. 
 154 
 Multiple other extrinsic factors that are not subtype-specific might still be involved in 
the molecular refinement of CFuPN identity, particularly toward rostral motor cortex identity. 
First, mature cortical area pattern is organized during development by a finely tuned Fgf8 
signaling gradient; the focal overexpression of Fgf8 by E11.5 neocortical progenitors can 
pattern rostral neocortical areas (Fukuchi-Shimogori and Grove, 2001; Assimacopoulos et al., 
2012). Importantly, Fgf8 was successfully applied to induce characteristics of rostral 
neocortical areas in an established embryoid body protocol of telencephalic differentiation 
(Eiraku et al., 2008). Second, retinoids have been shown to promote neurogenesis in the 
mouse cerebral cortex (Siegenthaler et al., 2009). Significantly, retinoids have been 
successfully applied to multiple protocols of directed differentiation to glutamatergic neurons 
from mouse ES cells (Bibel et al., 2004) and to neocortical-like neurons from human pluripotent 
stem cells (Shi et al., 2012), despite an early role of retinoids in caudal patterning of the neural 
tube. Differences in the timing and dosage of retinoid expression might be critical for 
establishing an appropriate molecular context of neocortical differentiation. 
Though an established monolayer protocol of mouse ES cell differentiation (Gaspard et 
al., 2009) offers advantages for detailed in vitro characterizations and potential mechanistic and 
therapeutic screening, the absence of three-dimensional cell-cell interactions in monolayer 
culture might impede subtype-specific refinements. Consistent with this hypothesis, an 
established embryoid body protocol of telencephalic differentiation generates neurons with 
seemingly reduced co-expression of distinct neocortical subtype markers (Eiraku et al., 2008; 
Nasu et al., 2012). Despite the apparent benefits of embryoid body culture, distinct deficits in 
ES-derived neuronal laminar organization indicate that cell-cell contacts are either incompletely 
replicated or insufficient in embryoid body culture without additional factors.  
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Notch signaling is one of the best-studied mechanisms of cell-cell signaling in the 
neocortex and is particularly relevant to directed differentiation given its longstanding roles in 
delineating distinct identities in related cell types (Greenwald and Rubin, 1992), including spinal 
cord motor neurons in zebrafish (Appel et al., 2001). Notch signaling has emerged to be 
important for neocortical migration (Hashimoto-Torii et al., 2008; Rodriguez et al., 2012), 
neocortical neurogenesis (Mizutani and Saito, 2005), and asymmetric cell division in the 
neocortex (Rasin et al., 2007; Bultje et al., 2009). Notch expression oscillates in the neocortex, 
correlated with the timing of interkinetic nuclear migration (Kageyama et al., 2008). Given the 
many roles of Notch signaling, it is important to note the molecular context of its regulation and 
the potentially varied distributions of its pathway components in different cell populations. This 
is more critical given that Notch signaling has at least two mechanisms, including lateral 
inhibition (Chitnis, 1995; Bray, 1998) and lateral induction (Ross and Kadesch, 2004). 
 Overall, multiple cell-intrinsic and cell-extrinsic processes, including focal chromatin 
remodeling, post-translational modifications of transcriptional regulators, paracrine molecular 
signaling, and cell-cell contacts, regulate the stepwise generation of CFuPN and diverse 
corticofugal types and subtypes in vivo. Importantly, deficits in some of these more specific 
mechanisms of differentiation might limit the in vitro capacity of ES cells to generate CFuPN. 
Therefore, identification of mechanistic deficits in differentiation protocols might indicate 
further directions for the generation of CFuPN and corticofugal subtypes. 
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5.5 Future directions: directed differentiation of clinically important CFuPN subtypes 
 
As the primary population of output neurons in the neocortex, CFuPN enable direct 
communication to other regions of the central nervous system, including clinically important 
spinal cord networks of motor control. One corticofugal subtype, corticospinal motor neurons 
(CSMN), project long-distance axons to the spinal cord to control motor function (Stanfield, 
1992). CSMN, and related sub-cerebral projection neurons (SCPN), selectively degenerate in 
the brains of both patients and mouse models (Zang and Cheema, 2002; Ozdinler et al., 2011) 
of amyotrophic lateral sclerosis (ALS). After spinal cord injury (SCI), CSMN axonal damage is 
central to ensuing loss of motor function. Importantly, production of significantly large numbers 
of CFuPN / SCPN / CSMN will contribute to in vitro models of the strikingly specific 
neurodegeneration of CSMN during the extended pathogenesis of ALS.  
To model human CFuPN degeneration in ALS in vitro, approaches of mouse ES cell 
directed differentiation would need to be adapted to other sources of pluripotent stem cells, 
including patient-derived induced pluripotent stem (iPS) cells. Since the first derivation of iPS 
from mouse (Takahashi and Yamanaka, 2006), and human fibroblasts (Takahashi et al., 2007; 
Yu et al., 2007), numerous protocol refinements and comparative epigenetics studies have 
indicated that ES and iPS cells are roughly equivalent pluripotent populations (Yamanaka, 
2012). Moreover, an established monolayer protocol of pallial differentiation from mouse ES 
cells (Gaspard et al., 2009) has been successfully adapted to human ES and iPS cells (Espuny-
Camacho et al., 2013; Shi et al., 2012). 
Using human iPS cells, large quantities of ALS patient-derived CSMN / CFuPN could be 
used for: 1) basic studies of mechanisms of neurodegeneration; 2) pharmacologic screening of 
small molecules and other bioactive compounds that might slow or reduce the neocortical 
component of ALS neurodegeneration; and 3) cellular replacement strategies using autologous 
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patient iPS-derived CSMN. First, recent in vitro studies have dissected mechanisms of ALS-
specific neurodegeneration in spinal motor neurons (SMN), which are the “lower” motor 
neurons that selectively degenerate in the spinal cords of ALS patients and mouse models. 
These in vitro studies successfully recapitulate some, but not all, aspects of ALS pathogenesis 
by primary SMN (Nagai et al., 2007) and by ES-derived SMN (Di Giorgio et al., 2007; Di Giorgio 
et al., 2008; Dimos et al., 2008). Second, using these foundation data, hypothesis-driven 
approaches to drug screening are possible. Pharmacologic screening strategies are already 
being successfully applied to the development of potential treatments targeted toward 
disease-specific SMN. Work by the Inoue and Yamanaka labs identified a histone acetyl-
transferase inhibitor that, in the context of increased metabolic stress, blocks degeneration of 
SMN derived from ALS patient-specific human iPS cells (Egawa et al., 2012). In a 
complementary approach, Lee Rubin and colleagues conducted a high-content chemical 
screen and identified a kinase inhibitor that promotes the survival of SMN derived from ALS 
patient-specific human iPS cells (Yang et al., 2013; see also Makhortova et al., 2011). In a 
similar manner, large quantities of human iPS-derived CFuPN / SCPN / CSMN might also be 
used for high-content screening to identify small molecules or bioactive compounds that can 
reduce or slow the progression of CSMN-specific dysfunction in ALS. Third, the seemingly 
remote idea that ES cell-derived CSMN might be used for cellular replacement is supported by 
recent evidence that the generation, insertion, and functional integration of new neurons is 
possible in both neurogenic and non-neurogenic regions under specific conditions of the adult 
mammalian brain (Emsley et al., 2004; Sohur et al., 2006; Czupryn et al., 2011; Wuttke and 
Macklis, unpublished data, 2013). Because of the focal localization of CSMN in primary motor 
cortex and positioning on the convexity of the cerebral cortex, transplantation of a single 
population of human ES- or iPS-derived CSMN might be especially feasible. 
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Several hypothetical approaches for in vitro directed differentiation of human ES- or 
iPS-derived CSMN are based on more closely mimicking an emerging molecular “logic” of in 
vivo CSMN development (Custo Greig et al., in editorial revision, 2013). Because CSMN 
development follows a sequential and highly context-dependent process, hypothetical 
approaches include further refinements of progenitor-stage cell-extrinsic signaling and three-
dimensional cell-cell contacts, and are complemented by the recapitulation of focal epigenetic 
processes and “nested” transcriptional regulation. By more closely applying in vivo 
developmental mechanisms, these in vitro approaches might avoid the generation of hybrid 
neuronal identity and maximally ensure the near biological-equivalency of ES- and iPS-derived 
CSMN based on molecular markers. Further characterization of ES-derived neuron physiology 
(e.g. channelrhodopsin and glutamate uncaging experiments in slice culture) would be 
essential to determine functional CSMN subtype maturation and specificity.  
Importantly, because these hypothetical approaches would additionally generate 
numerous other neuronal subtypes, particularly given the asynchronous and heterochronic 
progression of ES cell differentiation, complimentary approaches for the prospective 
identification and isolation of CSMN would be an essential component of future protocols. 
Without a known context-independent CSMN-specific marker, prospective isolation of CSMN 
might be based on intersectional fate mapping technologies (Dymecki et al., 2010) using 
multiple CSMN-specific markers (Arlotta et al., 2005). Prior to the prospective isolation of 
CSMN, ES cells lines that report the expression of Fezf2 or Cux2 (Franco et al., 2012; Custo 
Greig et al., in editorial revision, 2013) might be employed to positively select precursors of 
CFuPN or CPN, respectively; such efforts are currently underway by other laboratories (Ruby 
and Zheng, 2009; Kmet et al., 2013). These hypothetical strategies are supported by my 
approaches of CFuPN-directed differentiation in this dissertation and from work more broadly 
in the field. 
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In this dissertation, I introduced distinct approaches to direct CFuPN differentiation 
from mouse ES cells, applying an emerging “logic” of stage-specific transcriptional regulation 
that is “nested” within neocortical classes, types, and subtypes. Although CSMN-specific 
differentiation remains elusive, findings presented in this dissertation indicate the feasibility of 
promoting CFuPN class, SCPN type, and potential CSMN subtype differentiation. Moreover, 
ongoing work and future insights regarding CFuPN development (Woodworth et al., 
unpublished data, 2013; Custo Greig et al., unpublished data, 2013; Sahni and Macklis, 
unpublished data, 2013; Galazo and Macklis, unpublished data, 2013) will help refine these 
protocols of directed differentiation. Overall, the biological and technical approaches presented 
in this dissertation both rigorously characterize ES-derived neuronal identity and identify novel 
strategies to promote CFuPN differentiation. This work will enable further advances in the 
broader field of in vitro neurodegenerative disease modeling, and, in particular, toward 
potentially developing new treatments for ALS and SCI.  
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